
<html lang="en"     class="pb-page"  data-request-id="908cedcd-ae22-4214-a4e2-5fde01ae27d3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.8b02007;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-6;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Development of Gleevec Analogues for Reducing Production of β-Amyloid Peptides through Shifting β-Cleavage of Amyloid Precursor Proteins" /></meta><meta name="dc.Creator" content="Weilin  Sun" /></meta><meta name="dc.Creator" content="William J.  Netzer" /></meta><meta name="dc.Creator" content="Anjana  Sinha" /></meta><meta name="dc.Creator" content="Katherina  Gindinova" /></meta><meta name="dc.Creator" content="Emily  Chang" /></meta><meta name="dc.Creator" content="Subhash C.  Sinha" /></meta><meta name="dc.Description" content="Imatinib mesylate, 1a, inhibits production of β-amyloid (Aβ) peptides both in cells and in animal models. It reduces both the β-secretase and γ-secretase cleavages of the amyloid precursor protein ..." /></meta><meta name="Description" content="Imatinib mesylate, 1a, inhibits production of β-amyloid (Aβ) peptides both in cells and in animal models. It reduces both the β-secretase and γ-secretase cleavages of the amyloid precursor protein ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 15, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b02007" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b02007" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b02007" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b02007" /></link>
        
    
    

<title>Development of Gleevec Analogues for Reducing Production of β-Amyloid Peptides through Shifting β-Cleavage of Amyloid Precursor Proteins | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b02007" /></meta><meta property="og:title" content="Development of Gleevec Analogues for Reducing Production of β-Amyloid Peptides through Shifting β-Cleavage of Amyloid Precursor Proteins" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0010.jpeg" /></meta><meta property="og:description" content="Imatinib mesylate, 1a, inhibits production of β-amyloid (Aβ) peptides both in cells and in animal models. It reduces both the β-secretase and γ-secretase cleavages of the amyloid precursor protein (APP) and mediates a synergistic effect, when combined with a β-secretase inhibitor, BACE IV. Toward developing more potent brain-permeable leads, we have synthesized and evaluated over 75 1a-analogues. Several compounds, including 2a–b and 3a–c, inhibited production of Aβ peptides with improved activity in cells. These compounds affected β-secretase cleavage of APP similarly to 1a. Compound 2a significantly reduced production of the Aβ42 peptide, when administered (100 mg/kg, twice daily by oral gavage) to 5 months old female mice for 5 days. A combination of compound 2a with BACE IV also reduced Aβ levels in cells, more than the additive effect of the two compounds. These results open a new avenue for developing treatments for Alzheimer’s disease using 1a-analogues." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b02007"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b02007">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b02007&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b02007&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b02007&amp;href=/doi/10.1021/acs.jmedchem.8b02007" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 3122-3134</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01996" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00069" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of Gleevec Analogues for Reducing Production of β-Amyloid Peptides through Shifting β-Cleavage of Amyloid Precursor Proteins</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Weilin Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weilin Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weilin++Sun">Weilin Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William J. Netzer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William J. Netzer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William+J.++Netzer">William J. Netzer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anjana Sinha</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anjana Sinha</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anjana++Sinha">Anjana Sinha</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katherina Gindinova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katherina Gindinova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katherina++Gindinova">Katherina Gindinova</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emily Chang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emily Chang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emily++Chang">Emily Chang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Subhash C. Sinha</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Subhash C. Sinha</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#b3c0c0dadddbd2f3c1dcd0d8d6d5d6dfdfd6c19dd6d7c6"><span class="__cf_email__" data-cfemail="5c2f2f3532343d1c2e333f37393a393030392e72393829">[email protected]</span></a>. Phone: (212)327-8121.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Subhash+C.++Sinha">Subhash C. Sinha</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8916-5677" title="Orcid link">http://orcid.org/0000-0001-8916-5677</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b02007&amp;href=/doi/10.1021%2Facs.jmedchem.8b02007" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 3122–3134</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 15, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 December 2018</li><li><span class="item_label"><b>Published</b> online</span>15 March 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 March 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b02007" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b02007</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3122%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWeilin%2BSun%252C%2BWilliam%2BJ.%2BNetzer%252C%2BAnjana%2BSinha%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D6%26contentID%3Dacs.jmedchem.8b02007%26title%3DDevelopment%2Bof%2BGleevec%2BAnalogues%2Bfor%2BReducing%2BProduction%2Bof%2B%25CE%25B2-Amyloid%2BPeptides%2Bthrough%2BShifting%2B%25CE%25B2-Cleavage%2Bof%2BAmyloid%2BPrecursor%2BProteins%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3134%26publicationDate%3DMarch%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b02007"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1507</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b02007" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of Gleevec Analogues for Reducing Production of β-Amyloid Peptides through Shifting β-Cleavage of Amyloid Precursor Proteins&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Weilin&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;J. Netzer&quot;},{&quot;first_name&quot;:&quot;Anjana&quot;,&quot;last_name&quot;:&quot;Sinha&quot;},{&quot;first_name&quot;:&quot;Katherina&quot;,&quot;last_name&quot;:&quot;Gindinova&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Subhash&quot;,&quot;last_name&quot;:&quot;C. Sinha&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;3122-3134&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b02007&quot;},&quot;abstract&quot;:&quot;Imatinib mesylate, 1a, inhibits production of β-amyloid (Aβ) peptides both in cells and in animal models. It reduces both the β-secretase and γ-secretase cleavages of the amyloid precursor protein (APP) and mediates a synergistic effect, when combined with a β-secretase inhibitor, BACE IV. Toward developing more potent brain-permeable leads, we have synthesized and evaluated over 75 1a-analogues. Several compounds, including 2a–b and 3a–c, inhibited production of Aβ peptides with improved activity in cells. These compounds affected β-secretase cleavage of APP similarly to 1a. Compound 2a significantly reduced production of the Aβ42 peptide, when administered (100 mg/kg, twice daily by oral gavage) to 5 months old female mice for 5 days. A combination of compound 2a with BACE IV also reduced Aβ levels in cells, more than the additive effect of the two compounds. These results open a new avenue for developing treatments for Alzheimer’s disease using 1a-analogues.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b02007&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02007" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b02007&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02007" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b02007&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02007" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b02007&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02007&amp;href=/doi/10.1021/acs.jmedchem.8b02007" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b02007" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b02007" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b02007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b02007%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DSun%26date%3D2019%26atitle%3DDevelopment%2Bof%2BGleevec%2BAnalogues%2Bfor%2BReducing%2BProduction%2Bof%2B%25CE%25B2-Amyloid%2BPeptides%2Bthrough%2BShifting%2B%25CE%25B2-Cleavage%2Bof%2BAmyloid%2BPrecursor%2BProteins%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D6%26spage%3D3122%26epage%3D3134%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/jmcmar.2019.62.issue-6/20190328/jmcmar.2019.62.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Imatinib mesylate, <b>1a</b>, inhibits production of β-amyloid (Aβ) peptides both in cells and in animal models. It reduces both the β-secretase and γ-secretase cleavages of the amyloid precursor protein (APP) and mediates a synergistic effect, when combined with a β-secretase inhibitor, BACE IV. Toward developing more potent brain-permeable leads, we have synthesized and evaluated over 75 <b>1a</b>-analogues. Several compounds, including <b>2a–b</b> and <b>3a–c</b>, inhibited production of Aβ peptides with improved activity in cells. These compounds affected β-secretase cleavage of APP similarly to <b>1a</b>. Compound <b>2a</b> significantly reduced production of the Aβ42 peptide, when administered (100 mg/kg, twice daily by oral gavage) to 5 months old female mice for 5 days. A combination of compound <b>2a</b> with BACE IV also reduced Aβ levels in cells, more than the additive effect of the two compounds. These results open a new avenue for developing treatments for Alzheimer’s disease using <b>1a</b>-analogues.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Neurotoxic forms of β-amyloid (Aβ) peptides that have been implicated for Alzheimer’s disease (AD)<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> are produced by sequential cleavages of the amyloid precursor protein (APP) by β-secretase (BACE1) followed by γ-secretase (GS).<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> N- and C-terminal fragments, soluble APPβ (sAPPβ)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and β-C terminal fragment (βCTF),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> are two other potentially neurotoxic entities produced by cleavage of APP by BACE1.<a onclick="showRef(event, 'ref5 ref9'); return false;" href="javascript:void(0);" class="ref ref5 ref9">(5,9)</a> We have previously shown that imatinib mesylate (Gleevec), <b>1a</b>, which is a potent bcr-Abl kinase inhibitor,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and also an FDA-approved drug for the treatment of chronic myelogenous leukemia<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and gastrointestinal stromal tumor,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> reduces levels of Aβ peptide in cultured cells and in guinea pigs.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Compound <b>1a</b> lowers Aβ levels by selective, indirect reduction of both BACE and GS cleavages of full-length APP and its metabolite, APP-βCTF, respectively.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> This dual targeting and secretase selectivity set <b>1a</b> apart from typical BACE and GS inhibitors (BACEi and GSi) that have failed in clinical trials.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15−18)</a> Besides, a combination of <b>1a</b> and the potent BACEi, BACE IV, in N2a695 cells acts in a synergistic manner to lower Aβ production.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In a clinical setting, such a combination could reduce the side-effects of a BACEi<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> by minimizing inhibitor dosage. However, the p-glycoprotein (pGP) present at the blood–brain barrier (BBB) rapidly pumps out <b>1a</b> from the brain, thus preventing <b>1a</b> from achieving therapeutic concentration in the central nervous system.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> This together with the fact that <b>1a</b> is a relatively less explored molecular entity in terms of APP metabolism prompted us to develop more potent and brain-permeable <b>1a</b>-analogues. Initially, we have prepared straight <b>1a</b>-analogues by performing simple modifications of <b>1a</b> and determined and compared their effects on Aβ production in cellular assays. We obtained dozens of compounds that show some improvement in their activities. We focused on five potent <b>1a</b>-analogues, <b>2a</b>–<b>b</b> and <b>3a</b>–<b>c</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), that also accumulated moderately in wild-type mouse brain. Here, we describe the results of our studies with these compounds showing that: (1) compounds <b>2a–b</b> and <b>3a–c</b> reduce Aβ production similarly to <b>1a</b> by shifting β-cleavage of APP<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and (2) compound <b>2a</b> reduces Aβ42 levels in 5 months old 2xTg female AD mice significantly when administered 100 mg/kg twice daily for 5 days.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of imatinib mesylate, <b>1a</b>, and selected potent analogues for evaluation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our study started with the simple modification of <b>1a</b> for identifying the molecular motifs that are required for reducing the production of secreted Aβ peptides. We prepared truncated compounds <b>4</b> and <b>5</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) containing three or four rings, and their analogs (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">Figure S1</a>). Compounds <b>5</b> was previously shown to lower Aβ level more potently than <b>1a</b> in an assay performed in drosophila.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Because of the low molecular size and less number of hydrogen donor and acceptor atoms (N, O), such compounds could also possess greater brain permeability and retention. However, we found that all truncated <b>1a</b>-analogues, including <b>5</b>, were inactive or had lost substantial activity (see: <a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">Figure S2A</a>). The results led us to focus on <b>1a</b>-analogues that possess all five rings of the parent compound. Thus, we made step-wise modifications in one or more rings of <b>1a</b> and prepared compounds of series <b>1–3</b> that possess ABC rings identical to the parent compound, <b>1a</b>. Compounds of series <b>2</b> and <b>3</b> were developed by making sequential changes in connection sites between the C/D or D/E rings in <b>1a</b>, as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, via <b>6a</b> → <b>7a</b> → <b>2a</b> → <b>3c</b> →<b>3b</b> →<b>3a</b> and via <b>3a</b> → <b>3b</b> → <b>3c</b> → <b>2a</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Development of Active <b>1a</b>-analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Fragmentation of <b>1a</b> across “a” and “b” can afford compounds <b>4</b> and <b>5</b>. Compound <b>2a</b> can be obtained from <b>1a</b> via <b>6a</b> and <b>7a</b>, involving steps c–e or via compounds <b>3a–c</b> (steps f–h). Compound <b>1a</b> can also be modified to <b>8a</b>, which is a truncated analog of <b>2a</b>, and to <b>9a</b> and <b>9r</b>. Compound <b>9a</b> possesses an A ring modified, whereas <b>9r</b> has both A and E ring modified. Additional analogues of <b>9a</b> have one or more rings modified from A, B, and/or C ring(s), and a few of those also have an E ring modified (see: <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>)</p></p></figure><div class="NLM_p">We further modified <b>1a</b> to compounds of the <b>8</b> and <b>9</b> series, such as <b>8a</b> and <b>9a</b> or <b>9r</b> in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>8a</b> closely resembles <b>2a</b>, whereas compound <b>9a</b> possesses a modified A ring. Other analogues of <b>9a</b> can have one or more of ABC rings modified, and some analogues, such as <b>9r</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) also have an E ring modified (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Because the primary goal of this study was to identify modules that could enhance activity, majority of compounds, especially those possessing a piperazine ring in <b>1–2</b>, <b>5–6</b>, and in the <b>9</b> series can still possess pGP activity. Conversely, the parent compounds or some analogues: (1) lacking a piperazine ring in series <b>1</b> or a donor/acceptor “N”/”O” atom(s) in series <b>2</b> and <b>3</b> or (2) having less freedom of rotation across D/E rings in series <b>3</b> and <b>7</b> are likely to have lower pGP activity. Several <b>8</b>- and <b>9</b>-series compounds possessing smaller molecular size and lacking one or more donor/acceptor “N” atom could also possess lower pGP activity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">We prepared compounds <b>2a–b</b>, <b>3a–f</b>, <b>6a–b</b>, and <b>7a–b</b> by modifying the known syntheses of compound <b>1a</b>,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> using amine <b>4</b> and acid <b>10a–h</b> or acid chloride <b>14a</b> in 1–4 steps (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Thus, HATU coupling of <b>4</b> with <b>10a–h</b> or the usual amide coupling with <b>14a</b> in the presence of diisopropylethylamine (DIEA) afforded intermediates <b>11a–b</b>, <b>12a</b>, <b>3d</b>-Boc, <b>3e</b>-Boc, <b>3f</b>-Boc, and <b>7b</b>-Boc, or the target compounds <b>3a–b</b>. Homobenzyl and benzyl chloride intermediates, <b>11a</b> and <b>11b</b> were substituted with dimethylamine, <i>N</i>-methylpiperazine and piperidine to yield compounds <b>2a</b> and <b>6a–b</b>. Intermediate <b>12a</b> was converted to compound <b>2b</b> by performing Suzuki coupling<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> with <i>trans</i>-2-ethoxyethenyl-1-boronic acid pinacol ester,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> followed by trifluoroacetic acid (TFA)-deprotection of the resulting vinyl ether, <b>13a</b>, to afford aldehyde and reductive amination of the latter product with dimethylamine. Boc intermediates, <b>3d</b>-Boc, <b>3e</b>-Boc, <b>3f</b>-Boc, and <b>7b</b>-Boc, were acid-deprotected to yield the target compounds, <b>3d–f</b> and <b>7b</b>. Finally, compounds <b>3c</b> and <b>7a</b> were obtained by reductive amination of <b>3f</b> and <b>7b</b> using paraformaldehyde, (CH<sub>2</sub>O)<sub>n</sub>. All <b>1a</b>-analogues, including compounds <b>1c–l</b>, <b>2c–j</b>, <b>3g–i</b>, and <b>6c–g</b>, were prepared similarly or by modifying one or more steps. We also designed and prepared compounds, <b>8a–q</b> and <b>9a–u</b>. Compounds of series <b>8</b> are nor homologs of <b>2a</b> and analogues, whereas compounds <b>9a–u</b> possess one or more rings of ABC that are different from the parent compound, <b>1a</b>, and <b>9r</b>-<b>u</b> also have an E ring modified. Structures of all compounds from series <b>1–3</b> and <b>6–9</b> can be found in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of <b>1a</b>-Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Key: MW, microwave; (a) HATU, DIEA, DMF, RT, 16 h; (b) aq Me<sub>2</sub>NH (40%, pressure bottle), 120 °C, 16 h; (c) MW, Pd(PPh<sub>3</sub>)<sub>4</sub>, aq Cs<sub>2</sub>CO<sub>3</sub> (2 M), dioxane, 100 °C, 45 min; (d) (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, RT, 16 h, (ii) Me<sub>2</sub>NH (2 M, THF), NaCNBH<sub>3</sub>, 0 °C-RT, 16 h; (e) 4 N HCl, dioxane-EtOAc, RT, 16 h; (f) (CH<sub>2</sub>O)<sub><i>n</i></sub>, NaCNBH<sub>3</sub>, 0 °C-RT, 16 h; (g) DIEA, THF, RT, 1 h; (h) MW, 100 °C, K<sub>2</sub>CO<sub>3</sub>, MeCN, 30 min.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure of <b>1a</b>-Analogues (Series <b>1–3</b> and <b>6</b>) Possessing Modified DE Rings</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0008.gif" alt="" id="gr8" /></img><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure of <b>1a</b>-Analogues: Series <b>8</b> Possessing Modified DE Rings, and Series <b>9</b> Possessing One or More of ABC Rings Different from <b>1a</b> with/without Modification in the E Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0009.gif" alt="" id="gr9" /></img><div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.1.  Screening of <b>1a</b>-Analogues Identified Dozens of Compounds Inhibiting Production of the Aβ Peptide in N2a695 Cells Similarly or Greater than the Parent Compound <b>1a</b></h3><div class="NLM_p">We examined all compounds using mouse neuroblastoma N2a695 cells overexpressing human APP695.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> N2a695 cells secrete sufficient quantities of Aβ40 and Aβ42 peptides into cell culture media in 5 h to determine their concentration with high accuracy using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Under these conditions, Aβ40 levels were generally reduced by 35–45% when cells were treated with 10 μM <b>1a</b> compared to a negative dimethylsulphoxide (DMSO) control. Occasionally, Aβ40 levels were found to be greater than 45% or lower than 35% under similar conditions using 10 μM <b>1a</b>, and readings for the test compounds also varied similarly. These differences may have resulted from testing cell cultures in different growth phases (i.e., logarithmic growth vs Contact-inhibited cells). The screening results for all compounds showing their effects on Aβ40 levels are shown in Figure S2. We have found as many as 44 additional compounds, in addition to compounds, <b>2a–b</b> and <b>3a–c</b>, which reduced Aβ levels by 40–70% or more. Thus, by comparing the structures of all 75 compounds (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">Figure S1</a>) and the results of Aβ production, we have made the following conclusions:</div><div class="NLM_p last">First, all four ABCD rings of <b>1a</b> and an alkyl or cyclic amine are required to maintain the Aβ-lowering activity of the parent compound. This is evident from the fact that none of the compounds among <b>4a</b>-<b>h</b> and <b>5</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">Figure S1</a>) reduced Aβ levels by more than 10–20% (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">Figure S2A</a>). Second, the pyridine “N” in ring “A” of <b>1a</b>-analogues, which is required in <b>1a</b> for kinase binding, is not essential for inhibiting Aβ secretion. In fact, several compounds having phenyl and substituted-phenyl, instead of the pyridine “A” ring, were equally or more active than <b>1a</b>. These include compounds <b>9a–b</b>, <b>9e</b>, <b>9g–h</b>, and <b>9j–u</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">Figure S2B,C</a>). Third, a guanidine-type connection between the “B” and “C” rings may not be required, as compound <b>9e</b> that is lacking such function was also found to be quite active (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">Figure S2C</a>). Fourth, modification of the “C”-phenyl ring as a pyridine ring, as in compound <b>9l</b> or <b>9n–p</b>, had little effect on the activity. Fifth, substitution of “D” ring with F, CF<sub>3</sub>, or OMe, as in compounds <b>1c–d</b> and <b>2j</b>, reduced the activity. However, there was little effect when the “D–E” ring connection was moved from the “1,4” to “1,3” position, as shown by comparing compounds <b>1a</b> versus <b>6a</b> (<a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Finally, compounds possessing an alkyl amine or cyclic amine instead of the piperazine (E) ring were equally as active as the parent compound. At least one amine “N” was required in the “E” ring, where the position of “N” was also important. For example, compound <b>1k</b> is active, whereas the positional isomer <b>1g</b> and compound <b>1j</b> that are lacking “N” are inactive.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.2.  <b>1a-</b>Analogues, <b>2a–b</b> and <b>3a–c</b> Inhibited Production of Aβ Peptide in N2a695 Cells Potently and Accumulated in Mouse Brain</h3><div class="NLM_p">We focused on five hit compounds, <b>2a–b</b> and <b>3a–c</b>, and examined their effects on both Aβ40 and Aβ42 levels at 2.5–10 μM concentrations. All compounds reduced both Aβ40 and Aβ42 significantly in N2a695 cells at 5 and 10 μM concentrations, with an apparent IC50 less than 10 μM and greater than 5 μM. All five compounds have shown cell viability comparable to the DMSO control confirming that the effect on Aβ levels was not due to toxicity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro and in vivo evaluations of <b>1a</b>-analogues. (A) Compounds <b>2a–b</b> and <b>3a–c</b> reduced production of Aβ40 and Aβ42 peptides in N2a695 cells with an apparent IC50 between 10 and 5μM. DMSO and <b>1a</b> were used as the negative and positive controls, respectively. Results presented in (A) are the average of two or three experiments. (B) Compounds <b>1a</b> and <b>3a–3c</b> are nontoxic to N2a cells at 10 μM concentration, whereas <b>2a–2b</b> slightly increased cell density in the 5 h assay. (C) Brain and serum concentration of <b>1a</b>-analogues as determined in brain and serum extracts (<i>n</i> = 3 or 4) using liquid chromatography (LC)–mass spectrometry (MS)/MS. Statistical significance (<i>P</i>): *, <0.05%; **, <0.01%; and ***, <0.001%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We determined the brain permeability and retention of compounds <b>2a–b</b> and <b>3a–c</b>, as compared to <b>1a</b>, in 8 weeks old C57BL/6J male mice by administering compounds i.p. (50–150 mg/kg), collecting both mouse brain and plasma 4 h post injection, and extracting with ethanol or acetonitrile as described (see: General Methods). <b>1a</b> is known to not accumulate efficiently in brain because of rapid efflux by the BBB,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and this is reflected in the low brain concentrations of <b>1a</b> detected 4 h post administration (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). In contrast, the new tested analogues accumulated in the brain at relatively high concentrations (between 21 and 127 pg/g, when administered at a dose of 50 mg/kg) and were found in plasma at higher concentrations (1.0–11.6 μM).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.3.  <b>1a</b> and Its Analogues Reduce Aβ Production in a Similar Manner</h3><div class="NLM_p">Next, we determined whether <b>1a</b>-analogues lower Aβ levels by affecting β-cleavage of APP similarly to <b>1a</b>. For this, we performed western blotting (WB) experiments with the cell lysates obtained from the compound treatments and probed the blots using antibody RU369 that recognizes APP-CTFs.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B, cell lysates from <b>1a</b> and all its analog-treated samples reveal intense bands for APP CTFs compared to those from the control DMSO-treated samples. In addition, there are multiple APP CTFs, including 16 kDa CTF-141, comprising 141 amino acid residues and the 10 kDa CTF (weak band), in cell lysates from <b>1a</b> and all its analogues tested. It should be noted that the 10 kDa-CTF migrating near βCTF is not a product of BACE cleavage, and that the CTF-141 and other long APP CTFs in <b>1a</b>-treated samples fractionate with the lysosome.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Compounds <b>2a</b> and <b>3a</b> produced significantly higher levels of the 16 kDa CTF-141 than compounds <b>1a</b>, <b>2b</b>, <b>3b</b>, or <b>3c</b>, as observed in WB experiments (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B). Interestingly, a 16 kDa CTF is also produced from cells transfected with the APP A673T mutant.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The latter is a protective mutation found in Icelandic populations.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> However, the significance of 16 kDa CTF-141 from APP-WT or with AD mutations remains to be understood.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of <b>1a</b>-analogues on APP metabolism modeled in N2a695 cells and in N2a cells transiently expressing human APP full length (APP-FL) or APP-C99. Shown are: WB analysis of N2a695 cell lysates post compound treatment shows formation of the 16 kDa (CTF-141) and 10 kDa CTF and αCTF in [(A) the labels are not in chronological order] and quantification of CTF-141 and the 10 kDa CTF bands produced in (B). Note that the 10 kDa CTF band runs just below the βCTF (12 kDa). Shown in (C and D) are: Aβ40, sAPPα, and sAPPβ levels in media from cells, transfected with plasmids for APP-FL or APP-C99 and treated with <b>1a</b> or its analogues (10 μM), BACEi (BACE IV, 2 μM), or GSi (DAPT, 1 μM). The Aβ40, Aβ42 (data shown in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">Figure S3A</a>), sAPPα, and sAPPβ levels were measured using the MSD ELISA. Results presented here are the representatives of two or three independent experiments. Statistical significance (<i>P</i>): *, <0.05%; **, <0.01%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we examined the effects of <b>1a</b>-analogues on β- and γ-cleavages of APP by transfecting N2a cells with plasmids expressing FL APP695 (APP-FL) and β-CTF (APP-C99) and incubating with analogues <b>2a</b>, <b>2b</b>, <b>3a</b>, and <b>3c</b>. For a comparison, we also used a BACEi (BACE IV) or a GSi (DAPT) and determined both Aβ40 and Aβ42 peptides as well as sAPPα and sAPPβ by measuring them using MSD ELISA. The results are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C,D and <a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">S3A</a>. As expected, BACE IV and DAPT reduced the Aβ levels in cells expressing APP-FL, and DAPT also reduced Aβ in cells expressing APP-C99 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Compound <b>1a</b> and its analogues also reduced the Aβ levels in cells transfected with APP-FL, but not as much in cells transfected with APP-C99. However, there is a clear trend of Aβ reduction in the latter case also, where compounds <b>2b</b> had shown a ∼25% reduction of Aβ40 or of both Aβ40 and Aβ42 in APP-C99—transfected cells. Because neither <b>1a</b> nor its five analogues affected BACE1 activity, in vitro, at 10 μM concentration (Figure S3B), the reduced β-cleavage of APP could be due to an increase in alternative cleavages of APP that produce larger CTFs, including CTF-141 or could be the result of increased trafficking of APP to lysosomes, thereby reducing APP exposure to secretases.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Production of the large CTFs might also account for the observed reduction of both sAPPβ (by 40–75%) and sAPPα (by 20–45%) levels (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). An increase in APP αCTF levels in <b>1a</b> and analogue-treated samples suggests that the larger CTFs preferentially undergo α-cleavage, possibly because of a reduction in the competing BACE cleavage. An increase in the APP level (with compound <b>3c</b>) could be due to a decrease in APP metabolism.</div><div class="NLM_p last">We selected compound <b>2a</b> to carry out a pilot in vivo study for several reasons. First, compounds <b>2a</b> and <b>3a</b> had shown that they produced the 16 kDa CTF-141 significantly higher than <b>1a</b> and the other three compounds, <b>2b</b> and <b>3b–c</b>. Second, both compounds <b>2a</b> and <b>3a</b> accumulated in mouse brain in similar quantity, but the former had a significantly higher serum concentration than the latter. Third, when we fed WT mice with an increasing amount, up to 150 mg of compound <b>2a</b> orally (gavage) for five days, we did not notice any toxicity. In fact, all mice appeared more active. Additionally, we were able to design and achieve a multigram synthesis of compound <b>2a</b> using relatively cheap starting materials without any chromatographic separation.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.4.  Compound <b>2a</b> Possessed Metabolic Stability Comparable to the Parent Compound, <b>1a</b></h3><div class="NLM_p">We determined and compared the metabolic stabilities of <b>1a</b> and <b>2a</b> by adding these to mouse or human liver microsomes and measuring the remaining unmodified <b>1a</b> and <b>2a</b> in reaction mixtures.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In brief, <b>1a</b> and <b>2a</b> were incubated at two different concentrations, 1 and 10 μM, with either mouse or human liver microsomes, and the remaining amounts of <b>1a</b> and <b>2a</b> were determined after 30 and 60 min by high-pressure liquid chromatography (HPLC)–MS/MS analysis.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The results shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A corroborated the prior report that compound <b>1a</b> metabolizes more readily in mice than in humans.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> We have now found that compound <b>2a</b> also metabolizes more readily in mice than in humans. Moreover, both compounds <b>1a</b> and <b>2a</b> possess comparable metabolic stability, and compound <b>2a</b> is suitable for studies in humans, if found to effectively reduce Aβ levels in an AD mouse model.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vitro and in vivo evaluation of compound <b>2a</b>. (A) Microsomal stability of <b>1a</b> and its analog <b>2a</b>, measured by incubating these compounds with mouse and human liver microsomes, and determining the remaining compounds periodically using LC–MS/MS. (B) Analog <b>2a</b> reduced Aβ40 and 42 levels in 2xTg AD mice. Effects of <b>2a</b> on insoluble Aβ40/42 were determined in 5-month old 2xTg AD mice (<i>n</i> = 6 or 7). (C) Metabolic demethylation of <b>2a</b> affords <b>2c</b> via <b>2d</b>. (D) Metabolite <b>2d</b> is detected in the brain and plasma extracts of AD mice by performing LC–MS/MS analysis at the end of the 5-day in vivo study, and (E) compounds <b>2c</b> and <b>2d</b> reduce Aβ40 and/or Aβ42 weakly in N2a695 cells. Statistical significance (<i>P</i>): *, <0.05%; **, <0.01%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.5.  Compound <b>2a</b> Reduced Aβ Levels in 2xTg AD Mouse Brain</h3><div class="NLM_p">To determine the effects of <b>2a</b> on Aβ production/secretion, we performed a pilot study using the 2xTg AD mouse model. The latter harbors the APP Swedish and PS1ΔE9 mutations, and begins to form amyloid plaques in the brain by 6 months of age with abundant plaques present at 9 months.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> We first determined the dosing requirements by administering <b>2a</b> to wild-type mice and measuring its accumulation in the brain and plasma over a 24 h period. Compound <b>2a</b> (50 mg/kg as a mesylate salt solution in water containing 0.1% methylcellulose) was administered by gavage, and its concentration measured in the brain and plasma extracts, as described previously using LC–MS/MS, 2, 4, 8, 12, and 24 h post gavage. As shown in Figure S4, <b>2a</b> was detected in nearly steady amounts during the first 6 h in the brain and 12 h in plasma, but it was completely washed out at the 24-h time point. Because compound <b>2a</b> had shown no toxicity when it was administered orally (gavage), 150 mg/kg once a day for 5 days, we chose to administer <b>2a</b>-mesylate as aqueous solution to AD female mice (<i>n</i> = 7) at an elevated dose, 100 mg/kg twice daily with at least 8 h between the two administrations for 4 days and once on day 5. We obtained TBS-soluble and formic acid (FA)-soluble Aβ by performing extraction of brain tissue using 1% Triton-x100 TBS buffer (pH 7.4) and 70% FA, respectively, as described,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and determined the Aβ levels using ELISA. We found that TBS-soluble Aβ levels were too low to measure without large errors. In contrast, there were sufficient amounts of FA-soluble Aβ40 and Aβ42, which could be measured with great accuracy. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B, there were large reductions in both Aβ40 and Aβ42 levels in the drug-treated mice compared to the control mice, but only Aβ42 was significantly reduced (<i>p</i> < 0.01).</div><div class="NLM_p last">We anticipated that compound <b>2a</b> could undergo metabolic oxidative demethylation and didemethylation to produce demethylated and didemethylated products, <b>2d</b> and <b>2c</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C), similarly to <b>1a</b> that affords demethylated-<b>1a</b> besides other metabolites.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Therefore, we performed LC–MS/MS analysis of the extracts of brain homogenates and plasma samples from <b>2a</b>-treated AD mice to determine the levels of both <b>2a</b> and the potential metabolites, <b>2d</b> and <b>2c</b>. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D, we found that approximately 15–20% of the drug in both brain and plasma consisted of metabolite <b>2d</b>. We did not examine the amounts of <b>2c</b> in these samples. To examine whether these metabolites retain Aβ-lowering activity, we prepared these compounds and evaluated them at 10 μM concentration in N2a695 cells. Indeed, both metabolites, <b>2d</b> and <b>2c</b>, reduced the levels of secreted Aβ42 peptide significantly (<i>p</i> < 0.05), whereas compound <b>2c</b> also reduced the levels of Aβ40 peptide (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>E). Thus, the observed activity of compound <b>2a</b> in AD mouse model, in vivo, could still be the combined effects of all three compounds, that is, the parent drug, <b>2a</b>, and its metabolites, <b>2c–d</b>.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.6.  Perspective</h3><div class="NLM_p">Accumulation of two key neurotoxic agents, Aβ peptides and hyperphosphorylated tau (pTau) protein, in an AD brain starts decades ahead of when the actual sign of the disease becomes evident and is followed by neuronal loss and dementia.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Although aging is a major causative factor of AD,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> the Aβ peptides and pTau protein levels increase with age both in AD patients and in non-AD people.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39−41)</a> It can be argued that reducing the production of Aβ peptides and pTau protein starting early on in life could improve cognition and dementia of both AD patients and of non-AD individuals. Earlier, compound <b>1a</b> has been shown to prevent Abl-dependent tau phosphorylation<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and Aβ fibrils-induced apoptosis in rat models.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> We anticipate that the <b>1a</b>-analogues, <b>2a–b</b> and <b>3a–c</b>, which inhibit Abl kinase potently (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A), could also reduce Abl-dependent tau phosphorylation. Separately, Netzer, et al., have shown that <b>1a</b> reduces production of Aβ peptides independent of Abl kinase inhibition.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> By analogy, we argue that compounds <b>2a–b</b> and <b>3a–c</b> could also be inhibiting production of Aβ peptides independent of Abl kinase inhibition. Nevertheless, a direct measurement of these compounds and any future <b>1a</b>-analogues in Abl knockout cells may be desirable to confirm that the effects of <b>1a</b>-analogues on Aβ production are indeed Abl independent.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of (A) <b>1a</b>-analogues on Abl kinase inhibition (performed by an outsourced company: Luceome Biotechnologies, Tucson, AZ), and (B) <b>2a</b> on Aβ40 and Aβ42 production in combination with BACE IV and Abl and ic-Kit kinase inhibition. N2a695 cells were pretreated with BACE IV for 1 h before treatment with <b>1a</b> or <b>2a</b> (and BACE IV) for 5 h. Aβ40 and Aβ42 levels were measured using commercially available ELISA kits for human Aβ40 and Aβ42. Statistical significance (<i>P</i>): *, <0.05%; **, <0.01%, ***, <0.001%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Another key feature of <b>1a</b> is that it can be combined with a BACEi to reduce production of Aβ peptides by lessening the BACEi-related toxicity. BACE1 inhibition is considered a highly desirable strategy for treating or preventing AD, which is evident from the fact that multiple clinical trials with small molecule BACEi’s are in progress.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> However, no BACEi has yet been successful in clinical trials, as BACE1 has many cellular substrates and by inhibiting processing of all or most of these substrates, nonselective BACE1 inhibitors cause serious side effects.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> We have previously shown that a combination of <b>1a</b> and a BACEi, BACE IV, reduces Aβ levels in N2a695 cells in a synergistic manner.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> We have now found that a combination of compound <b>2a</b> with BACE IV caused greater reduction in the production of the Aβ peptide, than using compound <b>2a</b> alone, similarly to the <b>1a</b>-BACE IV combination.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> We will continue screening <b>1a</b>-analog/BACEi combinations in our future studies to identify those that mediate synergistic effects at low BACEi concentration.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">3.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, we have developed chemical analogues of <b>1a</b> that possess comparable activities. The new analogues also function similarly to the parent compound and reduce Aβ levels in N2a695 cells primarily through reducing the β-cleavage of APP and shifting APP metabolism toward a nonamyloidogenic pathway. By performing an in vivo study in 5 months old 2xTg female AD mice, compound <b>2a</b> was found to have significantly reduced brain Aβ42 levels, when given at 100 mg/kg twice daily for 4.5 days. The observed effect of compound <b>2a</b> on Aβ production could indeed be the effect of both the parent drug, <b>2a</b>, and its metabolites, <b>2c</b> and <b>2d</b>. This in vivo study provides a basis to further examine compound <b>2a</b> or other analogues in larger studies for treating AD and for studies for prevention. The second, a combination therapy using compound <b>2a</b> and a BACEi could provide maximum therapeutic benefit, while reducing the effective dose of both BACEi and <b>2a</b> (or its analogues). This approach would require a potent brain-permeable BACEi. Future development of <b>1a</b>-analogues will avoid functionalities known to possess pGP activity, and include assays to determine pGP activity of such compounds and Aβ levels in Abl knock-out cells.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41582" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41582" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">4.1.  General Methods</h3><div class="NLM_p last">All commercial chemicals and solvents were reagent grade and used without further purification. All air-sensitive reactions were performed under argon protection. Microwave reactions were performed on a Biotage Initiator. Column chromatography was performed using CombiFlash or Biotage instruments and silica gel SNAP columns. Analytical thin layer chromatography was performed on Merck 250 μM silica gel F<sub>254</sub> plates, and preparative thin layer chromatography (PTLC) on Merck 1000 μM silica gel F<sub>254</sub> plates obtained from EMD Millipore corporation. Purity of final compounds was checked using Agilent 1260 Infinity Series II preparative HPLC equipped with a 1260 Infinity II Multiple wavelength detector and Gemini 5 μm C18 110 Å LC column (100 × 4.6 mm), mobile phase: acetonitrile and water (0.1% TFA), 80:20 isocratic. All final compounds were found ≥95% pure. The identity of each product was determined using MS (MS: Thermo Scientific LTQ XL; LC: Thermo Scientific Dionex UltiMate 3000) and NMR (Bruker 400 or 600 MHz instrument) using CDCl<sub>3</sub> as the solvent unless otherwise mentioned. Chemical shifts are reported in δ values in ppm downfield from TMS as the internal standard. <sup>1</sup>H data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constant (Hz), integration.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">4.2.  Synthesis and Characterization of Compounds</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">4.2.1.  4-(2-(Dimethylamino)ethyl)-<i>N</i>-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-benzamide, <b>2a</b></h4><div class="NLM_p last">DIEA (3.5 mL, 20 mmol) was added to a mixture of amine <b>4</b> (2.77 g, 10 mmol), acid <b>10a</b> (1.85 g, 10 mmol), and HATU (4.94 g, 13 mmol) in anhydrous dimethylformamide (DMF, 25 mL), and the mixture was stirred overnight at room temperature (RT). The reaction mixture was diluted with water, and the resulting solid <b>11a</b> was collected by filtration (3.15 g, 70%). A mixture of crude <b>11a</b> and Me<sub>2</sub>NH (30 mL, 40% in water) in a pressure bottle was heated at 120 °C overnight. The reaction mixture was cooled and filtered, and the resulting white solid was washed with water. The solid was dissolved in MeOH, coevaporated with toluene, and triturated with MeOH to afford <b>2a</b> (2.60 g 59% yield) upon filtration. <sup>1</sup>H NMR (600 MHz) of <b>2a</b>: δ 9.27 (s, 1H), 8.73 (d, <i>J</i> = 3.6 Hz, 1H), 8.61 (s, 1H), 8.55 (d, <i>J</i> = 4.2 Hz, 2H), 7.84 (d, <i>J</i> = 6.0 Hz, 2H), 7.45 (t, <i>J</i> = 6.60 Hz, 1H), 7.35 (d, <i>J</i> = 7.80 Hz, 2H), 7.32 (d, <i>J</i> = 7.80 Hz, 1H), 7.24–7.21 (m, 2H), 7.05 (s, 1H), 2.90 (t, <i>J</i> = 7.80 Hz, 2H), 2.62 (t, <i>J</i> = 7.80 Hz, 2H), 2.38 (s, 3H), and 2.36 (s, 6H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.78, 162.07, 161.66, 159.94, 151.85, 148.67, 144.92, 138.26, 137.72, 134.89, 133.17, 132.69, 130.48, 129.04, 128.04, 124.25, 117.66, 117.18, 107.97, 60.88, 45.22, 33.56, and 18.11. HRMS (ESI), <i>m</i>/<i>z</i>: 453.2398 [M + H]<sup>+</sup>. Purity (HPLC): >98%.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">4.2.2.  4-(2-(Dimethylamino)ethyl)-<i>N</i>-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-2-(trifluoromethyl)benzamide, <b>2b</b></h4><div class="NLM_p">Acid <b>10b</b> (1.10, 4.0 mmol) was coupled to <b>4</b> (1.10, mmol) similarly as described above for <b>11a</b>, using HATU (1.82 g, 4.8 mmol) and <i>i</i>Pr<sub>2</sub>EtN (1.5 mL, 8 mmol) in DMF (12 mL) to afford intermediate <b>12a</b> (1.6 g, 75%). <sup>1</sup>H NMR (600 MHz) of <b>12a</b>: δ 9.19, (s, 1H), 8.65 (d, <i>J</i> = 6.0 Hz, 1H), 8.50 (d, <i>J</i> = 6.0 Hz, 1H), 8.49 (d, <i>J</i> = 6.0 Hz, 1H), 8.44 (s, 1H), 7.88 (s, 1H), 7.78 (d, <i>J</i> = 6.0 Hz, 1H), 7.54 (d, <i>J</i> = 12.0 Hz, 1H), 7.44 (dd, <i>J</i> = 6.0, 6.0 Hz, 1H), 7.30 (d, <i>J</i> = 6.0 Hz, 1H), 7.22 (d, <i>J</i> = 12.0 Hz, 1H), 7.19 (d, <i>J</i> = 6.0 Hz, 1H), and 2.35 (s, 3H). MS, <i>m</i>/<i>z</i>: 528.0 [M + H]<sup>+</sup>.</div><div class="NLM_p">To a degassed mixture of intermediate <b>12a</b> (528 mg, 1.0 mmol), (E)-1-ethoxyethane-2-boronic acid pinacol ester (257 mg, 1.30 mmol), and Cs<sub>2</sub>CO<sub>3</sub> 2 M solution (1 mL) in 1,4-dioxane (3 mL/mmol) in a microwave vial was added Pd(PPh<sub>3</sub>)<sub>4</sub> (55 mg, 5 mol %). After the reaction mixture was heated at 100 °C for 45 min using a microwave, it was diluted with water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was adsorbed over silica gel and chromatographed affording the ethoxyvinyl-coupled product, <b>13a</b> (450 mg, 85%). MS: <i>m</i>/<i>z</i> 520.4 [M + H]<sup>+</sup>.</div><div class="NLM_p">TFA (1.0 mL) in DCM (20 mL) was added to the above-described intermediate, and the mixture was stirred overnight at RT. Volatile materials were removed under reduced pressure, and the resulting aldehyde was taken to next step without further purification. MS: <i>m</i>/<i>z</i> 492.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Me<sub>2</sub>NH (10 mL, 4 M in THF) was added to a solution of the above-described aldehyde intermediate in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) in a pressure bottle. After the mixture was stirred for 1 h at RT, it was cooled and NaCNBH<sub>3</sub> (130 mg, 2 mmol) was added, and stirring was continued overnight. Solvents were removed, and the residues were suspended in CH<sub>2</sub>Cl<sub>2</sub> and washed with brine. Combined organic layers were dried over anhydrous MgSO<sub>4</sub>, inorganic materials were separated by filtration, organic layers were concentrated under reduced pressure, and the residue was chromatographed over SiO<sub>2</sub> gel using CH<sub>2</sub>Cl<sub>2</sub>–MeOH–aq NH<sub>3</sub> to afford compound <b>2b</b> (235 mg, 45% based on <b>13a</b>). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) of <b>2b</b>: δ 9.13 (s, 1H),  8.60 (d, <i>J</i> = 3.3 Hz, 1H), 8.53 (d, <i>J</i> = 7.9 Hz, 1H), 8.45 (d, <i>J</i> = 2.0 Hz, 2H), 8.37 (s, 1H), 7.59 (s, 1H), 7.56 (d, <i>J</i> = 7.8 Hz, 1H), 7.53 (d, <i>J</i> = 7.6 Hz, 1H), 7.46 (dd, <i>J</i> = 7.8, 4.9 Hz, 1H), 7.35 (s, 1H), 7.26 (d, <i>J</i> = 7.8 Hz, 1H), 7.19 (d, <i>J</i> = 8.2 Hz, 1H), 7.18 (d, <i>J</i> = 5.2 Hz, 1H), 3.00 (br s, 4H), 2.62 (s, 6H), and 2.31 (s, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.99, 162.03, 161.58, 159.97, 151.85, 148.65, 143.43, 138.36, 137.47, 134.88, 134.55, 133.07, 132.71, 130.62, 128.25, 126.79, 126.31, 125.24, 124.20, 123.42, 116.89, 116.45, 60.41, 45.40, 32.86, and 18.13. HRMS (ESI), <i>m</i>/<i>z</i>: 521.2264 [M + H]<sup>+</sup>. Purity (HPLC): >98%.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">4.2.3.  <i>N</i>-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-phenyl)-4-(4-methylpiperazin-1-yl)benzamide, <b>3a</b></h4><div class="NLM_p last">Amine <b>4</b> (1.39, 5.0 mmol) was coupled with acid <b>10c</b> (1.10 g, 5.0 mmol) similarly as described above for <b>11a</b>, using HATU (2.25 g, 6.0 mmol) in anhydrous DMF (mL) and iPr<sub>2</sub>EtN (1.75 mL, 10 mmol) at 60 °C (2 h) than at RT overnight to afford <b>3a</b> (1.20 g, 50%) after the usual work-up and chromatographic separation using CombiFlash (CH<sub>2</sub>Cl<sub>2</sub>–MeOH, 15%). <sup>1</sup>H NMR (400 MHz) of <b>3a</b>: δ 9.19 (br s, 1H), 8.64 (d, <i>J</i> = 4.0 Hz, 1H), 8.50–8.46 (m, 2H), 8.42 (br s, 1H), 7.79 (t, <i>J</i> = 8.0 Hz, 3H), 7.62 (d, <i>J</i> = 8.0 Hz, 1H), 7.42 (t, <i>J</i> = 8.0 Hz, 1H), 7.31 (m, 1H), 7.17 (dd, <i>J</i> = 8.0, 4.0 Hz, 2H), 6.90 (d, <i>J</i> = 8.0 Hz, 1H), 3.39 (br s, 4H), 2.80 (br s, 4H), and 2.49 and 2.32 (s, 3H each). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.30, 162.06, 161.70, 159.93, 153.43, 151.84, 148.66, 138.18, 138.02, 134.89, 132.70, 130.39, 129.47, 129.47, 127.64, 124.24, 117.67, 117.17, 113.96, 107.91, 54.82, 47.40, 46.18, and 18.09. HRMS (ESI), <i>m</i>/<i>z</i>: 480.2496 [M + H]<sup>+</sup>. Purity (HPLC): 96%.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">4.2.4.  <i>N</i>-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(1-methylpiperidin-4-yl)benzamide, <b>3b</b></h4><div class="NLM_p last">Amine <b>4</b> (277 mg, 1.0 mmol) was coupled with acid <b>10e</b> (220 mg, 1.0 mmol) using HATU (494 mg, 1.3 mmol) and DIEA (0.350 mL, 1.3 mmol) in anhydrous DMF (3.0 mL) as described above for <b>11a</b> to afford <b>3b</b> (200 mg, 42%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) of <b>3b</b>: δ 10.10 (s, 1H), 9.25 (s, 1H), 8.94 (s, 1H), 8.66 (d, <i>J</i> = 6.0 Hz, 1H), 8.48 (d, <i>J</i> = 6.0 Hz, 1H), 8.45 (d, <i>J</i> = 6.0 Hz, 1H), 8.05 (s, 1H), 7.86 (d, <i>J</i> = 6.0 Hz, 1H), 7.50 (td, <i>J</i> = 6.0 Hz, 1H), 7.46 (d, <i>J</i> = 6.0 Hz, 1H), 7.40 (d, <i>J</i> = 6.0 Hz, 1H), 7.37 (d, <i>J</i> = 6.0 Hz, 1H), 7.18 (d, <i>J</i> = 12.0 Hz, 1H), 2.91 (br, 2H), 2.55 (m, 1H), 2.23 and 2.20 (s, 3H each), 2.04 (br, 2H), and 1.76–1.68 (m, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.75, 162.07, 161.66, 159.94, 151.85, 150.23, 148.67, 138.26, 137.72, 134.89, 133.48, 132.69, 130.48, 124.24, 128.02, 127.17, 124.25, 117.64, 167.15, 107.98, 55.97, 46.33, 41.25, 32.97, and 18.11. HRMS (ESI), <i>m</i>/<i>z</i>: 479.2550 [M + H]<sup>+</sup>. Purity (HPLC): >98%.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">4.2.5.  <i>N</i>-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(1-methylpiperidin-3-yl)benzamide, <b>3c</b></h4><div class="NLM_p">Amine <b>4</b> (106.0 mg, 0.382 mmol) was coupled with acid <b>10g</b> (128.0 mg, 0.42 mmol) using HATU (172.0 mg, 0.42 mmol) and DIEA (0.097 mL, 0.76 mmol) in anhydrous DMF (3.0 mL) as described above for <b>11a</b> to afford the Boc-protected precursor (80 mg, 37%) of <b>3f</b>. The latter was deprotected using 4 M HCl in dioxane (0.500 mL) as above to afford <b>3f</b> (50 mg, 60%) as a HCl salt. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) of <b>3f</b>: δ 9.26 (s, 1H), 8.61 (d, <i>J</i> = 3.7 Hz, 1H), 8.57 (d, <i>J</i> = 7.8 Hz, 1H), 8.45 (d, <i>J</i> = 4.9 Hz, 1H), 8.22 (s, 1H), 7.90 (d, <i>J</i> = 7.8 Hz, 2H), 7.52 (m, 1H), 7.39 (m, 3H), 7.33 (d, <i>J</i> = 5 Hz, 1H), 7.24 (d, <i>J</i> = 8.1 Hz, 1H), 3.18 (d, <i>J</i> = 10.8 Hz, 2H), 2.73–2.88 (m, 3H), 2.31 (s, 3H), 2.00 (m, 1H), 1.89 (m, 1H), and 1.73 (m, 2H). MS: <i>m</i>/<i>z</i> 465.3 [M + H]<sup>+</sup>. Purity (HPLC): >98%.</div><div class="NLM_p last">Amine <b>3f</b> (40 mg, 0.107 mmol) was methylated using paraformaldehyde (10 mg, 0.300 mmol) and NaCNBH<sub>3</sub> (20 mg, 0.30 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) in a tightly-capped bottle to afford <b>3c</b> (10 mg, 20%) after the usual work-up and silica gel PTLC using CH<sub>2</sub>Cl<sub>2</sub>–MeOH–aq NH<sub>3</sub> as the mobile phase. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d<sub>6</sub></i>) of <b>3c</b>: δ 10.18 (s, 1H), 9.28 (s, 1H), 8.98 (s, 1H), 8.68 (dd, <i>J</i> = 4.8, 1.2 Hz, 1H), 8.52 (d, <i>J</i> = 5.4 Hz, 1H), 8.48 (d, <i>J</i> = 8.4 Hz, 1H), 8.08 (s, 1H), 7.96 (d, <i>J</i> = 8.4 Hz, 2H), 7.52 (m, 1H), 7.48 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.44 (m, 1H), 7.22 (d, <i>J</i> = 8.4 Hz, 1H),  3.50 (d, <i>J</i> = 10.8 Hz, 1H), 3.45 (d, <i>J</i> = 11.4 Hz, 1H), 3.14 (t, <i>J</i> = 11.4 Hz, 1H), 3.06 (m, 1H), 2.95 (m, 1H), 2.81 (s, 1H), 2.23 (s, 3H), 1.97 (d, <i>J</i> = 12.0 Hz, 1H), 1.92 (d, <i>J</i> = 12.0 Hz, 1H), 1.80 (m, 1H), and 1.66 (m, 1H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.42, 162.07, 161.65, 159.96, 151.84, 148.67, 145.14, 138.29, 137.56, 134.89, 134.45, 132.68, 130.53, 128.55, 128.17, 127.57, 124.25, 117.70, 117.22, 108.11, 57.92, 53.70, 43.52, 29.07, 23.01, and 18.12. HRMS (ESI), <i>m</i>/<i>z</i>: 479.2547 [M + H<sup>+</sup>]. Purity (HPLC): >98%.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">4.3.  Evaluation of Compounds in Cells</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">4.3.1.  Screening and Evaluation of <b>1a</b>-Analogues</h4><div class="NLM_p">N2a695 cells were used to screen all <b>1a</b>-analogues and in the follow-up studies with compounds found active in the preliminary screen. Cells were cultured in 1:1 Opti-MEM Reduced Serum Media (Life Technologies): Dulbecco’s modified Eagle medium ([+] 4.5 g/L <span class="smallcaps smallerCapital">d</span>-glucose; [+] <span class="smallcaps smallerCapital">l</span>-glutamine; [-] sodium pyruvate (Life Technologies) supplemented with 5% fetal bovine serum, 0.4% penstrep, and 0.4% geneticin and incubated at 37 °C in 5% CO<sub>2</sub>.</div><div class="NLM_p last">In a typical experiment, 6-well tissue culture plates (Corning) were seeded at 4.0 × 10<sup>5</sup> to 4.5 × 10<sup>5</sup> N2a695 cells/mL, 2 mL/well for overnight incubation. Media were carefully removed and fresh media containing 10 μM solution of compounds (prepared from 10 mM solution in DMSO) were gently layered onto adherent cells (>95% confluent). Appropriate dilution of compounds was performed in DMSO before adding to media. After cells were incubated with compounds for 5 h at 37 °C in 5% CO<sub>2</sub>, culture media were collected. To measure soluble Aβ concentrations in the culture media, these were transferred to strips of a 96-well ELISA plate for human Aβ40 peptide or to a 96-well V-PLEX Plus MSD (Mesoscale Discovery) plate for Aβ Peptide Panel 1 (6E10) Kit (Catalog number K15200G) and processed as per manufacturer instructions. Signals for Aβ were measured using a PerkinElmer EnVision and SQ120 MSD ELISA reader. Follow-up studies with N2a695 cells were performed similarly.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">4.3.2.  In Vitro Metabolic Stability of <b>1a</b>-Analogues</h4><div class="NLM_p last">Compound <b>1a</b> and analogues (1 and 10 μM) were incubated with human or CD-1 mouse liver microsomes (0.5 mg protein/mL) and appropriate cofactors (2.5 mM NADPH and 3.3 mM MgCl<sub>2</sub>) in 100 mM phosphate buffer, pH 7.4, at 37 °C. The incubation contained a final organic solvent concentration of 0.1% DMSO. Reactions were started with the addition of an NADPH/MgCl<sub>2</sub> mix and stopped by removing 100 μL aliquots at selected time points (0, 30, and 60 min) and mixing with 200 μL of acetonitrile. Following brief vortexing and centrifugation, an aliquot of the supernatant was transferred to a tube and further diluted 2-fold (for 1 μM, using 10% acetonitrile containing internal standards) or 20-fold (for 10 μM, using 37% acetonitrile containing internal standards). Subsequently, amounts of unmodified <b>1a</b> or analogues in the quenched reactions were determined using LC-MS/MS analysis.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">4.3.3.  Effects of <b>1a</b>-Analogues on APP Metabolism</h4><div class="NLM_p">N2a695 cells were treated with compounds for 5 h as described above, and media were aspirated out (or collected for determination of Aβ levels). Cells were scraped in cold Dulbecco’s phosphate-buffered saline (PBS) buffer (1 mL) containing mini ethylenediaminetetraacetic acid-free protease inhibitor (Roche) and centrifuged for 1 min at 13 000 rpm at 4 °C to form a cell pellet. The buffer was aspirated, and the cell pellets were lysed in 3% SDS by sonication for two rounds of 20 s on a low setting. Protein concentrations were measured using the Pierce BCA Protein Assay (Thermo Fisher) Kit in accordance with the manufacturer’s instructions.</div><div class="NLM_p">To perform WBs, N2a695 cell lysates from <b>1a</b> and analogue-treated samples were run on a 16.5% Tris-Tricine gel (Criterion) and electrotransferred to PVDF membranes (EMD Millipore) overnight at 30 V. The PVDF membranes were incubated in PBS containing 0.25% glutaraldehyde (Sigma) for 30 min after electrotransference, blocked for 30 min in milk PBST, incubated with primary antibody RU369 for 1 h at RT followed by washing and incubation with an HRP-linked secondary antibody, and detected with enhanced chemiluminescence ECL reagents. WB images were analyzed using ImageJ to quantify the prominent bands.</div><div class="NLM_p last">To determine effects of the compounds on BACE1 versus GS inhibition, we used N2a cells transfected with FL APP (APP-FL) or with APP99 (APP-βCTF). After 48 h, media were removed and fresh media containing compound <b>1a</b> and analogues were added. Following 5 h of incubation, cell supernatants were collected, and analyzed using MSD-ELISA for Aβ and for sAPPα and β.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">4.4.  Evaluation of Compounds Using Mouse Models, in Vivo</h3><div class="NLM_p">All procedures involving animals were approved by The Rockefeller University Institutional Animal Care and Use Committee and were in accordance with the National Institutes of Health guidelines.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">4.4.1.  In Vivo Brain Permeability and Retention of <b>1a</b> and Analogues</h4><div class="NLM_p">Mesylate salts of <b>1a</b> analogues (1 or 3 mg/mL in water, 125 μL, 50 or 150 mg/kg) were administered intraperitoneally (i.p.) or through oral gavage to 8 weeks old C57BL/6J WT mice. The mice were euthanized 4 h post drug administration, and the brain hemispheres and plasma were harvested and collected in preweighted tubes and snap-frozen in liquid nitrogen. To measure brain and plasma concentrations of the specific compounds, mouse brain tissue was homogenized and extracted using ethanol, and plasma samples were extracted using acetonitrile. Concentration of the drug compounds and metabolites both in brain and in plasma was determined by LC-MS/MS analysis.</div><div id="sec4_4_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29">4.4.1.1.  Drug Extraction from Brain</h5><div class="NLM_p last">After the tubes were weighed to calculate brain weight and thawed to RT, 1 mL of EtOH (200 Proof) was added to the microcentrifuge tubes containing the harvested right brain hemispheres. The internal standard (ABG190, a synthetic analog of <b>1a,</b> 10 μL, 1 μM) was added to each tube, and samples were sonicated to homogeneity (∼2 min). Tubes were shaken at 40 min at RT (1 K rpm) and centrifuged for 8 min at 13 K RPM. The supernatant (0.9 mL) was transferred to a new collection tube, and 0.5 mL EtOH was added to the pellet for a second round of extraction as described above. The supernatant (600 μL) was combined with the first collection before samples were submitted for LC–MS/MS analysis.</div></div><div id="sec4_4_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30">4.4.1.2.  Drug Extraction from Blood</h5><div class="NLM_p last">Acetonitrile (300 μL) was added to the collected blood samples. The internal standard (ABG190, 10 μL, 1 μM) was added to each tube, and the samples were sonicated to homogeneity (∼2 min). The tubes were centrifuged at 13 K RPM for 9 min. The supernatant (300 μL) was collected and combined with 500 μL of 5 mM ammonium formate before the samples were submitted for LCMS-MS analysis.</div></div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">4.4.2.  In Vivo Evaluation of Compound <b>2a</b> in 2xTg AD Mice</h4><div class="NLM_p">Female mice expressing the human FAD mutations APP KM670/671NL (Swedish) and PSEN1 M146V were used in this study. Mice were obtained by performing in vitro fertilization, in house, and those positive for APP Swedish and PS1ΔE9 genes were identified by PCR-based genotyping. The WT C57BL/6J mice (The Jackson Laboratory; stock no. 000664) were used for generating 2xTg mouse pups from in vitro fertilization.</div><div id="sec4_4_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32">4.4.2.1.  Evaluation</h5><div class="NLM_p last">2xTg AD female mice (<i>n</i> = 7 for each group) received 100–125 μL solution (based on mouse weight) via oral administration (gavage) of <b>2a</b>-mesylate (20 mg/mL in water containing 0.1% methylcellulose, 100 mg/kg/mouse) or with vehicle (water containing 0.1% methylcellulose, 100–125 μL) twice a day, 8 h apart in the morning and afternoon, for 4 days and in the morning on day 5. All mice were euthanized 4 h after the last injection. Brain hemispheres and plasma were harvested, collected in preweighted tubes, and the tubes were snap-frozen in liquid nitrogen. On the day of analysis, tubes containing the left-brain hemispheres were weighed after they were defrosted. Brain mass was submerged in 1% Triton-x100 TBS Buffer (pH 7.4) (2 mL), homogenized using a Dounce homogenizer and transferred to ultraclear centrifuge tubes (Beckman Coulter) in which they were ultracentrifuged at 40 000 RPM for 35 min (TLA. 100.3 100 K RPM rotor). Supernatants were collected to measure soluble Aβ peptides. Insoluble Aβ was extracted from the pellets with 70% FA (1 mL) and 20 μL aliquots were neutralized with 200 μL Bis–Tris buffer. Aβ 1–40 and Aβ 1–42 were measured using ELISA (Invitrogen) in accordance with the manufacturer’s instructions.</div></div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">4.4.3.  Statistical Analysis</h4><div class="NLM_p last">The data are presented as means ± SEM. The data were analyzed by Student’s <i>t</i>-test for single comparison and one-way ANOVA for multiple comparisons, and those showing <i>P</i> value < 0.05 were considered significant.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34">4.4.4.  In Vitro Kinase Activity Assay</h4><div class="NLM_p last">The assay was performed by Luceome Biotechnolgies, LLC, using the general methods, as described.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Typically, 10 mM stock solutions of the compounds were diluted in DMSO to a concentration of 250 μM. Before initiating the assay, all test compounds were evaluated for a false positive against split-luciferase. For kinase assays, each Cfluc-Kinase was translated along with Fos-Nfluc using a cell-free system (rabbit reticulocyte lysate) at 30 °C for 90 min. An aliquot (24 μL) of this lysate containing either 1 μL of DMSO (for no-inhibitor control) or compound solution in DMSO (10 μM final concentration) was incubated for 30 min at RT followed by 1 h in the presence of a kinase-specific probe. Luciferin assay reagent (80 μL) was added to each solution, and luminescence was immediately measured on a luminometer. The percent inhibition was calculated using the following equation: % inhibition = (ALU<sub>control</sub> – ALU<sub>sample</sub> × 100)/ALU<sub>control</sub>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35"><a href="/doi/suppl/10.1021/acs.jmedchem.8b02007" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80744" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80744" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b02007" class="ext-link">10.1021/acs.jmedchem.8b02007</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">General synthetic procedures and characterization of synthesized compounds including <sup>1</sup>H NMR spectra and MS data, truncated Gleevec analogues containing 3 or 4 rings, Gleevec analogues containing 4 or 5 rings and ABC rings identical to 1a and different from 1a, and figures showing screening data of all synthetic analogues and evaluation of selected compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES data for compounds <b>1a–l</b>, <b>2a–j</b>, <b>3a–i</b>, <b>4a–h</b>, <b>5</b>, <b>6a–g</b>, <b>7a–b</b>, <b>8a–q</b>, and <b>9a–u</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf">jm8b02007_si_001.pdf (1.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_002.csv">jm8b02007_si_002.csv (7.0 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b02007" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15725" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15725" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Subhash C. Sinha</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Molecular and Cellular
Neuroscience, The Rockefeller University, New York, New York 10065, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8916-5677" title="Orcid link">http://orcid.org/0000-0001-8916-5677</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#80f3f3e9eee8e1c0f2efe3ebe5e6e5ecece5f2aee5e4f5"><span class="__cf_email__" data-cfemail="6211110b0c0a0322100d01090704070e0e07104c070617">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weilin Sun</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Molecular and Cellular
Neuroscience, The Rockefeller University, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William J. Netzer</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Molecular and Cellular
Neuroscience, The Rockefeller University, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anjana Sinha</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Molecular and Cellular
Neuroscience, The Rockefeller University, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherina Gindinova</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Molecular and Cellular
Neuroscience, The Rockefeller University, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily Chang</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Molecular and Cellular
Neuroscience, The Rockefeller University, New York, New York 10065, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are thankful to Dr. Victor Bustos of the Rockefeller University for helpful discussions, and to Mondana H. Ghias for determining Aβ of some compounds in cellular assays early on. Funding support from JPB (#322 and #839 to SCS) is duly acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">β amyloid or amyloid β</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">APP</td><td class="NLM_def"><p class="first last">amyloid precursor protein</p></td></tr><tr><td class="NLM_term">Aq Me<sub>2</sub>NH</td><td class="NLM_def"><p class="first last">aqueous dimethylamine</p></td></tr><tr><td class="NLM_term">BACE1</td><td class="NLM_def"><p class="first last">β-secretase</p></td></tr><tr><td class="NLM_term">BACEi</td><td class="NLM_def"><p class="first last">β-secretase inhibitor</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain-barrier</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last">butoxycarbonyl</p></td></tr><tr><td class="NLM_term">βCTF</td><td class="NLM_def"><p class="first last">β-carboxy terminal fragment</p></td></tr><tr><td class="NLM_term">CH<sub>2</sub>Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">(CH<sub>2</sub>O)<sub><i>n</i></sub></td><td class="NLM_def"><p class="first last">paraformaldehyde</p></td></tr><tr><td class="NLM_term">Cs<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">cesium carbonate</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropyethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsufoxide</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethylacetate</p></td></tr><tr><td class="NLM_term">GS</td><td class="NLM_def"><p class="first last">γ-secretase or gamma secretase</p></td></tr><tr><td class="NLM_term">GS<i>i</i></td><td class="NLM_def"><p class="first last">γ-secretase inhibitor</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">K<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">potassium carbonate</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">microwave</p></td></tr><tr><td class="NLM_term">NaCNBH<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium cyanoborohydride</p></td></tr><tr><td class="NLM_term">Pd(PPh<sub>3</sub>)<sub>4</sub></td><td class="NLM_def"><p class="first last">tetrakis(triphenylphosphine)palladium(0)</p></td></tr><tr><td class="NLM_term">pGP</td><td class="NLM_def"><p class="first last">p-glycoprotein</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61515" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61515" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younkin, S. G.</span></span> <span> </span><span class="NLM_article-title">The role of Aβ42 in Alzheimer’s disease</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/s0928-4257(98)80035-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fs0928-4257%2898%2980035-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=289-292&author=S.+G.+Younkin&title=The+role+of+A%CE%B242+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fs0928-4257%2898%2980035-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Aβ42 in Alzheimer's disease</span></div><div class="casAuthors">Younkin, Steven G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Paris)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">289-292</span>CODEN:
                <span class="NLM_cas:coden">JHYSEM</span>;
        ISSN:<span class="NLM_cas:issn">0928-4257</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review, with 32 refs.  The authors' recent studies of plasma, fibroblasts, transfected cells and transgenic mice show that a fundamental effect of the mutations linked to familial Alzheimer's disease (FAD) is to increase the extracellular concn. of Aβ42.  This effect of the FAD-linked mutations is likely to be directly related to the pathogenesis of Alzheimer's disease (AD) because Aβ42 is deposited early and selectively in the senile plaques that are an invariant feature of all forms of AD.  Thus, the authors' results provide strong evidence that the FAD-linked mutations all cause AD by increasing the extracellular concn. of Aβ42, thereby fostering Aβ deposition, and they support the hypothesis that cerebral Aβ deposition is an essential early event in the pathogenesis of all forms of AD.  Interactions between the basal forebrain cholinergic system and Aβ that could influence AD pathogenesis are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSyp7Jwfo1OrVg90H21EOLACvtfcHk0lhG_0eIFi_mRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ms7s%253D&md5=f65018862a0daa181209286af8c1bcb9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fs0928-4257%2898%2980035-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0928-4257%252898%252980035-1%26sid%3Dliteratum%253Aachs%26aulast%3DYounkin%26aufirst%3DS.%2BG.%26atitle%3DThe%2520role%2520of%2520A%25CE%25B242%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Physiol.%26date%3D1998%26volume%3D92%26spage%3D289%26epage%3D292%26doi%3D10.1016%2Fs0928-4257%2898%2980035-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuperstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broersen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benilova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckheere, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debulpaep, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandersteen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segers-Nolten, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Werf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braeken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callewaert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schymkowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">Neurotoxicity of Alzheimer’s disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3408</span>– <span class="NLM_lpage">3420</span>, <span class="refDoi"> DOI: 10.1038/emboj.2010.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Femboj.2010.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=20818335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSmsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=3408-3420&author=I.+Kupersteinauthor=K.+Broersenauthor=I.+Benilovaauthor=J.+Rozenskiauthor=W.+Jonckheereauthor=M.+Debulpaepauthor=A.+Vandersteenauthor=I.+Segers-Noltenauthor=K.+Van+Der+Werfauthor=V.+Subramaniamauthor=D.+Braekenauthor=G.+Callewaertauthor=C.+Barticauthor=R.+D%E2%80%99Hoogeauthor=I.+C.+Martinsauthor=F.+Rousseauauthor=J.+Schymkowitzauthor=B.+De+Strooper&title=Neurotoxicity+of+Alzheimer%E2%80%99s+disease+A%CE%B2+peptides+is+induced+by+small+changes+in+the+A%CE%B242+to+A%CE%B240+ratio&doi=10.1038%2Femboj.2010.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotoxicity of Alzheimer's disease A peptides is induced by small changes in the A42 to A40 ratio</span></div><div class="casAuthors">Kuperstein, Inna; Broersen, Kerensa; Benilova, Iryna; Rozenski, Jef; Jonckheere, Wim; Debulpaep, Maja; Vandersteen, Annelies; Segers-Nolten, Ine; Van Der Werf, Kees; Subramaniam, Vinod; Braeken, Dries; Callewaert, Geert; Bartic, Carmen; D'Hooge, Rudi; Martins, Ivo Cristiano; Rousseau, Frederic; Schymkowitz, Joost; De Strooper, Bart</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3408-3420</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The amyloid peptides A40 and A42 of Alzheimer's disease are thought to contribute differentially to the disease process.  Although A42 seems more pathogenic than A40, the reason for this is not well understood.  We show here that small alterations in the A42:A40 ratio dramatically affect the biophys. and biol. properties of the A mixts. reflected in their aggregation kinetics, the morphol. of the resulting amyloid fibrils and synaptic function tested in vitro and in vivo.  A minor increase in the A42:A40 ratio stabilizes toxic oligomeric species with intermediate conformations.  The initial toxic impact of these A species is synaptic in nature, but this can spread into the cells leading to neuronal cell death.  The fact that the relative ratio of A peptides is more crucial than the abs. amts. of peptides for the induction of neurotoxic conformations has important implications for anti-amyloid therapy.  Our work also suggests the dynamic nature of the equil. between toxic and non-toxic intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR-22pazffF7Vg90H21EOLACvtfcHk0lhG_0eIFi_mRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSmsbzP&md5=1048db62830cd821652c6337364d067d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Femboj.2010.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2010.211%26sid%3Dliteratum%253Aachs%26aulast%3DKuperstein%26aufirst%3DI.%26aulast%3DBroersen%26aufirst%3DK.%26aulast%3DBenilova%26aufirst%3DI.%26aulast%3DRozenski%26aufirst%3DJ.%26aulast%3DJonckheere%26aufirst%3DW.%26aulast%3DDebulpaep%26aufirst%3DM.%26aulast%3DVandersteen%26aufirst%3DA.%26aulast%3DSegers-Nolten%26aufirst%3DI.%26aulast%3DVan%2BDer%2BWerf%26aufirst%3DK.%26aulast%3DSubramaniam%26aufirst%3DV.%26aulast%3DBraeken%26aufirst%3DD.%26aulast%3DCallewaert%26aufirst%3DG.%26aulast%3DBartic%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DR.%26aulast%3DMartins%26aufirst%3DI.%2BC.%26aulast%3DRousseau%26aufirst%3DF.%26aulast%3DSchymkowitz%26aufirst%3DJ.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DNeurotoxicity%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520A%25CE%25B2%2520peptides%2520is%2520induced%2520by%2520small%2520changes%2520in%2520the%2520A%25CE%25B242%2520to%2520A%25CE%25B240%2520ratio%26jtitle%3DEMBO%2520J.%26date%3D2010%26volume%3D29%26spage%3D3408%26epage%3D3420%26doi%3D10.1038%2Femboj.2010.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1126/science.1072994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1126%2Fscience.1072994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12130773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Cju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2002&pages=353-356&author=J.+Hardyauthor=D.+J.+Selkoe&title=The+amyloid+hypothesis+of+Alzheimer%E2%80%99s+disease%3A+progress+and+problems+on+the+road+to+therapeutics&doi=10.1126%2Fscience.1072994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</span></div><div class="casAuthors">Hardy, John; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">5580</span>),
    <span class="NLM_cas:pages">353-356</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  It has been more than 10 yr since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide (Aβ) in plaques in brain tissue.  According to the amyloid hypothesis, accumulation of Aβ in the brain is the primary influence driving AD pathogenesis.  The rest of the disease process, including formation of neurofibrillary tangles contg. tau protein, is proposed to result from an imbalance between Aβ prodn. and Aβ clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9G5omTHR6cbVg90H21EOLACvtfcHk0lhG_0eIFi_mRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Cju7s%253D&md5=f7b8db1bc6f13e85f887b73f3042e86e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1072994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1072994%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520progress%2520and%2520problems%2520on%2520the%2520road%2520to%2520therapeutics%26jtitle%3DScience%26date%3D2002%26volume%3D297%26spage%3D353%26epage%3D356%26doi%3D10.1126%2Fscience.1072994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golde, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younkin, S. G.</span></span> <span> </span><span class="NLM_article-title">Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1502</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/s0925-4439(00)00043-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fs0925-4439%2800%2900043-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10899442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFSguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1502&publication_year=2000&pages=172-187&author=T.+E.+Goldeauthor=C.+B.+Eckmanauthor=S.+G.+Younkin&title=Biochemical+detection+of+A%CE%B2+isoforms%3A+implications+for+pathogenesis%2C+diagnosis%2C+and+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fs0925-4439%2800%2900043-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease</span></div><div class="casAuthors">Golde, T. E.; Eckman, C. B.; Younkin, S. G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1502</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 108 refs.  Prior to the identification of the various abnormal proteins deposited as fibrillar aggregates in the Alzheimer's disease (AD) brain, there was tremendous controversy over the importance of the various lesions with respect to primacy in the pathol. of AD.  Nevertheless, based on analogy to systemic amyloidosis, many investigators believed that the amyloid deposits in AD played a causal role and that characterization of these deposits would hold the key to understanding this complex disease.  Indeed, in retrospect, it was the initial biochem. purifications of the ∼4 kDa amyloid β-peptide (Aβ) from amyloid deposits in the mid 1980s that launched a new era of AD research.  Subsequent studies of the biol. of Aβ together with genetic studies of AD have all supported the hypothesis that altered Aβ metab. leading to aggregation plays a causal role in AD.  Although there remains controversy as to whether Aβ deposited as classic amyloid or a smaller, aggregated, form causes AD, the relevance of studying the amyloid deposits has certainly been proven.  Despite the significant advances in our understanding of the role of Aβ in AD pathogenesis, many important aspects of Aβ biol. remain a mystery.  This review will highlight those aspects of Aβ biol. that have led to the authors' increased understanding of the pathogenesis of AD as well as areas which warrant addnl. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozbB3CHRVy2LVg90H21EOLACvtfcHk0lg702NADuN1eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFSguro%253D&md5=f5230c98609990d7425afafcbabe5558</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fs0925-4439%2800%2900043-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0925-4439%252800%252900043-0%26sid%3Dliteratum%253Aachs%26aulast%3DGolde%26aufirst%3DT.%2BE.%26aulast%3DEckman%26aufirst%3DC.%2BB.%26aulast%3DYounkin%26aufirst%3DS.%2BG.%26atitle%3DBiochemical%2520detection%2520of%2520A%25CE%25B2%2520isoforms%253A%2520implications%2520for%2520pathogenesis%252C%2520diagnosis%252C%2520and%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2000%26volume%3D1502%26spage%3D172%26epage%3D187%26doi%3D10.1016%2Fs0925-4439%2800%2900043-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haass, C.</span></span> <span> </span><span class="NLM_article-title">Take five-BACE and the γ-secretase quartet conduct Alzheimer’s amyloid β-peptide generation</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7600061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fsj.emboj.7600061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=483-488&author=C.+Haass&title=Take+five-BACE+and+the+%CE%B3-secretase+quartet+conduct+Alzheimer%E2%80%99s+amyloid+%CE%B2-peptide+generation&doi=10.1038%2Fsj.emboj.7600061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600061%26sid%3Dliteratum%253Aachs%26aulast%3DHaass%26aufirst%3DC.%26atitle%3DTake%2520five-BACE%2520and%2520the%2520%25CE%25B3-secretase%2520quartet%2520conduct%2520Alzheimer%25E2%2580%2599s%2520amyloid%2520%25CE%25B2-peptide%2520generation%26jtitle%3DEMBO%2520J.%26date%3D2004%26volume%3D23%26spage%3D483%26epage%3D488%26doi%3D10.1038%2Fsj.emboj.7600061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">A cell biological perspective on Alzheimer’s disease</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.18.020402.142302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1146%2Fannurev.cellbio.18.020402.142302" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=25-51&author=W.+Annaertauthor=B.+De+Strooper&title=A+cell+biological+perspective+on+Alzheimer%E2%80%99s+disease&doi=10.1146%2Fannurev.cellbio.18.020402.142302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.18.020402.142302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.18.020402.142302%26sid%3Dliteratum%253Aachs%26aulast%3DAnnaert%26aufirst%3DW.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DA%2520cell%2520biological%2520perspective%2520on%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D2002%26volume%3D18%26spage%3D25%26epage%3D51%26doi%3D10.1146%2Fannurev.cellbio.18.020402.142302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, D. D.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier-Lavigne, M.</span></span> <span> </span><span class="NLM_article-title">APP binds DR6 to trigger axon pruning and neuron death via distinct caspases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>457</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1038/nature07767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fnature07767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=19225519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitFKlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=457&publication_year=2009&pages=981-989&author=A.+Nikolaevauthor=T.+McLaughlinauthor=D.+D.%0AM.+O%E2%80%99Learyauthor=M.+Tessier-Lavigne&title=APP+binds+DR6+to+trigger+axon+pruning+and+neuron+death+via+distinct+caspases&doi=10.1038%2Fnature07767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">APP binds DR6 to trigger axon pruning and neuron death via distinct caspases</span></div><div class="casAuthors">Nikolaev, Anatoly; McLaughlin, Todd; O'Leary, Dennis D. M.; Tessier-Lavigne, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">457</span>
        (<span class="NLM_cas:issue">7232</span>),
    <span class="NLM_cas:pages">981-989</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Naturally occurring axonal pruning and neuronal cell death help to sculpt neuronal connections during development, but their mechanistic basis remains poorly understood.  Here the authors report that β-amyloid precursor protein (APP) and death receptor 6 (DR6, also known as TNFRSF21) activate a widespread caspase-dependent self-destruction program.  DR6 is broadly expressed by developing neurons, and is required for normal cell body death and axonal pruning both in vivo and after trophic-factor deprivation in vitro.  Unlike neuronal cell body apoptosis, which requires caspase 3, we show that axonal degeneration requires caspase 6, which is activated in a punctate pattern that parallels the pattern of axonal fragmentation.  DR6 is activated locally by an inactive surface ligand(s) that is released in an active form after trophic-factor deprivation, and the authors identify APP as a DR6 ligand.  Trophic-factor deprivation triggers the shedding of surface APP in a β-secretase (BACE)-dependent manner.  Loss- and gain-of-function studies support a model in which a cleaved amino-terminal fragment of APP (N-APP) binds DR6 and triggers degeneration.  Genetic support is provided by a common neuromuscular junction phenotype in mutant mice.  These results indicate that APP and DR6 are components of a neuronal self-destruction pathway, and suggest that an extracellular fragment of APP, acting via DR6 and caspase 6, contributes to Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmuM5crlTWx7Vg90H21EOLACvtfcHk0lg702NADuN1eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitFKlu7k%253D&md5=28ef7ad016a4fec752df35c3ac9a4e0a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature07767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07767%26sid%3Dliteratum%253Aachs%26aulast%3DNikolaev%26aufirst%3DA.%26aulast%3DMcLaughlin%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DD.%2BD.%2BM.%26aulast%3DTessier-Lavigne%26aufirst%3DM.%26atitle%3DAPP%2520binds%2520DR6%2520to%2520trigger%2520axon%2520pruning%2520and%2520neuron%2520death%2520via%2520distinct%2520caspases%26jtitle%3DNature%26date%3D2009%26volume%3D457%26spage%3D981%26epage%3D989%26doi%3D10.1038%2Fnature07767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauritzen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardossi-Piquard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeois, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagnotta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biferi, M.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkats, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checler, F.</span></span> <span> </span><span class="NLM_article-title">Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1007/s00401-016-1577-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1007%2Fs00401-016-1577-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2016&pages=257-276&author=I.+Lauritzenauthor=R.+Pardossi-Piquardauthor=A.+Bourgeoisauthor=S.+Pagnottaauthor=M.-G.+Biferiauthor=M.+Barkatsauthor=P.+Lacorauthor=W.+Kleinauthor=C.+Bauerauthor=F.+Checler&title=Intraneuronal+aggregation+of+the+%CE%B2-CTF+fragment+of+APP+%28C99%29+induces+A%CE%B2-independent+lysosomal-autophagic+pathology&doi=10.1007%2Fs00401-016-1577-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs00401-016-1577-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-016-1577-6%26sid%3Dliteratum%253Aachs%26aulast%3DLauritzen%26aufirst%3DI.%26aulast%3DPardossi-Piquard%26aufirst%3DR.%26aulast%3DBourgeois%26aufirst%3DA.%26aulast%3DPagnotta%26aufirst%3DS.%26aulast%3DBiferi%26aufirst%3DM.-G.%26aulast%3DBarkats%26aufirst%3DM.%26aulast%3DLacor%26aufirst%3DP.%26aulast%3DKlein%26aufirst%3DW.%26aulast%3DBauer%26aufirst%3DC.%26aulast%3DChecler%26aufirst%3DF.%26atitle%3DIntraneuronal%2520aggregation%2520of%2520the%2520%25CE%25B2-CTF%2520fragment%2520of%2520APP%2520%2528C99%2529%2520induces%2520A%25CE%25B2-independent%2520lysosomal-autophagic%2520pathology%26jtitle%3DActa%2520Neuropathol.%26date%3D2016%26volume%3D132%26spage%3D257%26epage%3D276%26doi%3D10.1007%2Fs00401-016-1577-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchelt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span> <span> </span><span class="NLM_article-title">BACE1 is the major β-secretase for generation of Aβ peptides by neurons</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1038/85064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2F85064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=11224536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsF2rtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=233-234&author=H.+Caiauthor=Y.+Wangauthor=D.+McCarthyauthor=H.+Wenauthor=D.+R.+Borcheltauthor=D.+L.+Priceauthor=P.+C.+Wong&title=BACE1+is+the+major+%CE%B2-secretase+for+generation+of+A%CE%B2+peptides+by+neurons&doi=10.1038%2F85064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 is the major β-secretase for generation of Aβ peptides by neurons</span></div><div class="casAuthors">Cai, Huaibin; Wang, Yanshu; McCarthy, Diane; Wen, Hongjin; Borchelt, David R.; Price, Donald L.; Wong, Philip C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-234</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Secretion of Alzheimer's disease (AD) Aβ peptides (Aβ1-40/42 and Aβ11-40) is abolished in cultures of BACE1-deficient cortical neurons; BACE1-deficient is one of the two β-secretases involved in generating AD Aβ peptides.  This study also establishes that BACE1-deficient is the principal neuronal protease required to cleave amyloid precursor protein (APP) at the +1 and +11 sites that generate N-termini of Aβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvJeMWCAU69rVg90H21EOLACvtfcHk0lizTbYEu_HIYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsF2rtbc%253D&md5=fd3d6b77770735ed2b12687281fc511e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2F85064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F85064%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMcCarthy%26aufirst%3DD.%26aulast%3DWen%26aufirst%3DH.%26aulast%3DBorchelt%26aufirst%3DD.%2BR.%26aulast%3DPrice%26aufirst%3DD.%2BL.%26aulast%3DWong%26aufirst%3DP.%2BC.%26atitle%3DBACE1%2520is%2520the%2520major%2520%25CE%25B2-secretase%2520for%2520generation%2520of%2520A%25CE%25B2%2520peptides%2520by%2520neurons%26jtitle%3DNat.%2520Neurosci.%26date%3D2001%26volume%3D4%26spage%3D233%26epage%3D234%26doi%3D10.1038%2F85064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lizTbYEu_HIYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobburu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">U, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staten, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12006504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=935-942&author=M.+H.+Cohenauthor=G.+Williamsauthor=J.+R.+Johnsonauthor=J.+Duanauthor=J.+Gobburuauthor=A.+Rahmanauthor=K.+Bensonauthor=J.+Leightonauthor=S.+K.+Kimauthor=R.+Woodauthor=M.+Rothmannauthor=G.+Chenauthor=K.+M.+Uauthor=A.+M.+Statenauthor=R.+Pazdur&title=Approval+summary+for+imatinib+mesylate+capsules+in+the+treatment+of+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span></div><div class="casAuthors">Cohen, Martin H.; Williams, Grant; Johnson, John R.; Duan, John; Gobburu, Jogarao; Rahman, Atiqur; Benson, Kimberly; Leighton, John; Kim, Sung K.; Wood, Rebecca; Rothmann, Mark; Chen, Gang; Maung U., Khin; Staten, Ann M.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">935-942</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) results from the breakpoint cluster region-Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis.  Imatinib, an orally administered inhibitor of the breakpoint cluster region-Abl tyrosine kinase, is capable of blocking proliferation and inducing apoptosis in CML cell lines.  In this report, we describe the preclin. profile of imatinib and the data submitted in the New Drug Application that led to its marketing approval.  Chem. manufg. and controls, animal toxicol., and biopharmaceutical data are described.  Results of Phase I and Phase II clin. studies in patients with CML in blast crisis (CML-BC), in accelerated phase (CML-AP), and in chronic phase disease-resistant or intolerant to IFN-α (CML-CP) are summarized.  The basis for marketing approval and postmarketing commitments by the pharmaceutical company are discussed.  Toxicol. studies in the rat, dog, and monkey show the hematol., renal, and hepatobiliary toxicity of imatinib.  Pharmacokinetic studies in patients with CML demonstrate 98% imatinib bioavailability.  The elimination half-lives of the parent drug and the major active metabolite, CGP74588, from plasma are approx. 18 and 40 h, resp.  Approx. 81% of the drug is eliminated in 7 days, 68% in the feces and 13% in the urine.  Cytochrome P 450 3A4 is the main enzyme responsible for imatinib metab.  Phase I and II clin. studies were conducted.  The Phase I study, in 83 CML patients, evaluated oral imatinib doses from 25 to 1000 mg/day.  Dose-limiting toxicity was not obsd.  The three Phase II studies, in CML-CP, CML-AP, and CML-BC, enrolled 1027 patients.  CML-CP patients received 400 mg/day imatinib, whereas CML-AP and CML-BC patients generally received 600 mg/day, imatinib.  Primary study endpoints were cytogenetic response rate (CML-CP) and hematol. response rate (CML-AP and CML-BC).  The cytogenetic response rate for CML-CP patients was 49%.  The hematol. response rate of CML-AP and CML-BC patients was 63 and 26%, resp.  The most common imatinib adverse events were nausea, vomiting, myalgia, edema, and diarrhea.  Elevated liver enzymes and/or bilirubin were reported in 27 patients (2.6%).  On May 10, 2001, imatinib mesylate (Gleevec, formerly known as STI-571 and Glivec), manufd. and distributed by Novartis Pharmaceuticals, East Hanover, NJ, was approved by the United States Food and Drug Administration for the treatment of CML in three clin. settings: CML-BC, CML-AP, and CML-CP.  This report summarizes the Food and Drug Administration's review of the New Drug Application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2majxsiqE3LVg90H21EOLACvtfcHk0lizTbYEu_HIYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D&md5=8820d9e1126524a6762242f68262ab86</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DBenson%26aufirst%3DK.%26aulast%3DLeighton%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DWood%26aufirst%3DR.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DU%26aufirst%3DK.%2BM.%26aulast%3DStaten%26aufirst%3DA.%2BM.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%2520for%2520imatinib%2520mesylate%2520capsules%2520in%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D935%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dagher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobburu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griebel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors</span>. <i>Clin Cancer Res</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3034</span>– <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12374669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD38XosFKiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=3034-3038&author=R.+Dagherauthor=M.+Cohenauthor=G.+Williamsauthor=M.+Rothmannauthor=J.+Gobburuauthor=G.+Robbieauthor=A.+Rahmanauthor=G.+Chenauthor=A.+Statenauthor=D.+Griebelauthor=R.+Pazdur&title=Approval+summary%3A+Imatinib+mesylate+in+the+treatment+of+metastatic+and%2For+unresectable+malignant+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors</span></div><div class="casAuthors">Dagher, Ramzi; Cohen, Martin; Williams, Gene; Rothmann, Mark; Gobburu, Jogarao; Robbie, Gabriel; Rahman, Atiqur; Chen, Gang; Staten, Ann; Griebel, Donna; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3034-3038</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Imatinib mesylate (Gleevec; Novartis, East Hanover, NJ) is a receptor tyrosine kinase inhibitor approved previously in 2001 by the United States Food and Drug Administration for the treatment of chronic myelogenous leukemia in blast crisis, accelerated phase, or in chronic phase after failure of IFN-α therapy.  We review herein the clin. profile of this drug and the regulatory review leading to the approval of a supplemental New Drug Application for the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors (GISTs).  We discuss the efficacy and side effects of imatinib mesylate in a Phase II trial of 147 patients with metastatic and/or unresectable malignant GISTs, the basis for marketing approval, and postmarketing commitments by the drug's manufacturer.  Imatinib was assessed in a single, open-label trial involving one European center and three centers in the United States.  Seventy-three patients were randomly allocated to receive 400 mg of imatinib daily, and 74 patients received 600 mg daily.  At the study report cutoff date, an objective response was confirmed in 56 patients; the overall response rate for the combined study arms was 38% (95% confidence interval, 30-46%).  These responses were all partial responses.  There was no statistically significant difference in response rates between the two dose groups.  Adverse events included edema, fluid retention, nausea, vomiting, diarrhea, myalgias, skin rash, bone marrow suppression, bleeding, and elevations in aspartate aminotransferase, alanine aminotransferase, or bilirubin.  Bleeding into the gastrointestinal tract or intratumoral sites occurred in 7 patients (5%) and was not correlated with thrombocytopenia or tumor bulk.  The pharmacokinetics of imatinib in GIST patients were similar to those of chronic myelogenous leukemia patients.  On Feb. 1, 2001, imatinib mesylate was approved by the United States Food and Drug Administration for the treatment of malignant metastatic and/or unresectable GISTs.  The recommended dose is 400 or 600 mg daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ8Oi5tX41LrVg90H21EOLACvtfcHk0ljxn3K-nzhyJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XosFKiu7k%253D&md5=ca5afa0ad6d44775da8e4f137b97fe97</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDagher%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DRobbie%26aufirst%3DG.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DStaten%26aufirst%3DA.%26aulast%3DGriebel%26aufirst%3DD.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%253A%2520Imatinib%2520mesylate%2520in%2520the%2520treatment%2520of%2520metastatic%2520and%252For%2520unresectable%2520malignant%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DClin%2520Cancer%2520Res%26date%3D2002%26volume%3D8%26spage%3D3034%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Netzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span> <span> </span><span class="NLM_article-title">Gleevec inhibits -amyloid production but not Notch cleavage</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">12444</span>– <span class="NLM_lpage">12449</span>, <span class="refDoi"> DOI: 10.1073/pnas.1534745100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1073%2Fpnas.1534745100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12444-12449&author=W.+J.+Netzerauthor=F.+Douauthor=D.+Caiauthor=D.+Veachauthor=S.+Jeanauthor=Y.+Liauthor=W.+G.+Bornmannauthor=B.+Clarksonauthor=H.+Xuauthor=P.+Greengard&title=Gleevec+inhibits+-amyloid+production+but+not+Notch+cleavage&doi=10.1073%2Fpnas.1534745100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1534745100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1534745100%26sid%3Dliteratum%253Aachs%26aulast%3DNetzer%26aufirst%3DW.%2BJ.%26aulast%3DDou%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DJean%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DGreengard%26aufirst%3DP.%26atitle%3DGleevec%2520inhibits%2520-amyloid%2520production%2520but%2520not%2520Notch%2520cleavage%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D12444%26epage%3D12449%26doi%3D10.1073%2Fpnas.1534745100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Netzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flajolet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustos, V.</span></span> <span> </span><span class="NLM_article-title">Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1389</span>– <span class="NLM_lpage">1394</span>, <span class="refDoi"> DOI: 10.1073/pnas.1620963114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1073%2Fpnas.1620963114" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=1389-1394&author=W.+J.+Netzerauthor=K.+Bettayebauthor=S.+C.+Sinhaauthor=M.+Flajoletauthor=P.+Greengardauthor=V.+Bustos&title=Gleevec+shifts+APP+processing+from+a+%CE%B2-cleavage+to+a+nonamyloidogenic+cleavage&doi=10.1073%2Fpnas.1620963114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1620963114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1620963114%26sid%3Dliteratum%253Aachs%26aulast%3DNetzer%26aufirst%3DW.%2BJ.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DSinha%26aufirst%3DS.%2BC.%26aulast%3DFlajolet%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DBustos%26aufirst%3DV.%26atitle%3DGleevec%2520shifts%2520APP%2520processing%2520from%2520a%2520%25CE%25B2-cleavage%2520to%2520a%2520nonamyloidogenic%2520cleavage%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2017%26volume%3D114%26spage%3D1389%26epage%3D1394%26doi%3D10.1073%2Fpnas.1620963114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henley, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundell, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span> <span> </span><span class="NLM_article-title">Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings</span>. <i>Curr. Med. Res. Opin.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2021</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1185/03007995.2014.939167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1185%2F03007995.2014.939167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=24983746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Oktb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2014&pages=2021-2032&author=D.+B.+Henleyauthor=K.+L.+Sundellauthor=G.+Sethuramanauthor=S.+A.+Dowsettauthor=P.+C.+May&title=Safety+profile+of+semagacestat%2C+a+gamma-secretase+inhibitor%3A+IDENTITY+trial+findings&doi=10.1185%2F03007995.2014.939167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings</span></div><div class="casAuthors">Henley, David B.; Sundell, Karen L.; Sethuraman, Gopalan; Dowsett, Sherie A.; May, Patrick C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2021-2032</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Objective: Semagacestat, a γ-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clin. development was halted.  To assist in future development of γ-secretase inhibitors, we report detailed safety findings from the IDENTITY study, with emphasis on those that might be mechanistically linked to γ-secretase inhibition.  Research design and methods: The IDENTITY trial was a double-blind, placebo-controlled trial of semagacestat (100 mg and 140 mg), in which 1537 patients age 55 years and older with probable Alzheimer's disease were randomized.  Treatment-emergent adverse events (TEAEs) are reported by body system along with pertinent lab., vital sign, and ECG findings.  Results: Semagacestat treatment was assocd. with increased reporting of suspected Notch-related adverse events (gastrointestinal, infection, and skin cancer related).  Other relevant safety findings assocd. with semagacestat treatment included cognitive and functional worsening, skin-related TEAEs, renal and hepatic changes, increased QT interval, and wt. loss.  With few exceptions, differences between semagacestat and placebo treatment groups were no longer significant after cessation of treatment with active drug.  Conclusions: Many of these safety findings can be attributed to γ-secretase inhibition, and may be valuable to researchers developing γ-secretase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC2ZGLarufNrVg90H21EOLACvtfcHk0ljxn3K-nzhyJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Oktb3N&md5=7c2d61aafe7bbf26ce9d853d8b5f590a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1185%2F03007995.2014.939167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007995.2014.939167%26sid%3Dliteratum%253Aachs%26aulast%3DHenley%26aufirst%3DD.%2BB.%26aulast%3DSundell%26aufirst%3DK.%2BL.%26aulast%3DSethuraman%26aufirst%3DG.%26aulast%3DDowsett%26aufirst%3DS.%2BA.%26aulast%3DMay%26aufirst%3DP.%2BC.%26atitle%3DSafety%2520profile%2520of%2520semagacestat%252C%2520a%2520gamma-secretase%2520inhibitor%253A%2520IDENTITY%2520trial%2520findings%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2014%26volume%3D30%26spage%3D2021%26epage%3D2032%26doi%3D10.1185%2F03007995.2014.939167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morstorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, K.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease drug-development pipeline: few candidates, frequent failures</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi"> DOI: 10.1186/alzrt269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1186%2Falzrt269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=25024750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BC2cbisFWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=37&author=J.+L.+Cummingsauthor=T.+Morstorfauthor=K.+Zhong&title=Alzheimer%E2%80%99s+disease+drug-development+pipeline%3A+few+candidates%2C+frequent+failures&doi=10.1186%2Falzrt269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease drug-development pipeline: few candidates, frequent failures</span></div><div class="casAuthors">Cummings Jeffrey L; Zhong Kate; Morstorf Travis</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's research & therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">37</span>
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    </div><div class="casAbstract">INTRODUCTION:  Alzheimer's disease (AD) is increasing in frequency as the global population ages.  Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist.  We have an urgent need to find new therapies for AD.  METHODS:  We examined Clinicaltrials.gov, a public website that records ongoing clinical trials.  We examined the decade of 2002 to 2012, to better understand AD-drug development.  We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next.  We also reviewed the current AD therapy pipeline.  RESULTS:  During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials.  Seventy-eight percent were sponsored by pharmaceutical companies.  The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed.  The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%).  The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3.  Trials of disease-modifying agents are larger and longer than those for symptomatic agents.  A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure).  CONCLUSIONS:  The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem.  The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area.  The AD drug-development ecosystem requires support.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT__DMPwHFhGGPgL4LrC-0VfW6udTcc2eYP2ngF50bBUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbisFWjtQ%253D%253D&md5=85b84800ce02d7031a4c1046e837e568</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Falzrt269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Falzrt269%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DMorstorf%26aufirst%3DT.%26aulast%3DZhong%26aufirst%3DK.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520drug-development%2520pipeline%253A%2520few%2520candidates%252C%2520frequent%2520failures%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D37%26doi%3D10.1186%2Falzrt269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. K.</span></span> <span> </span><span class="NLM_article-title">Phase II and phase III failures: 2013-2015</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fnrd.2016.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=27811931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslynsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=817-818&author=R.+K.+Harrison&title=Phase+II+and+phase+III+failures%3A+2013-2015&doi=10.1038%2Fnrd.2016.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II and phase III failures: 2013-2015</span></div><div class="casAuthors">Harrison, Richard K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">817-818</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This article analyses recent data on the reported causes of drug candidate attrition, which indicate that lack of efficacy is the reason for approx. half of all phase II and phase III failures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy7ibspDa6WLVg90H21EOLACvtfcHk0liDTyyhIJxTqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslynsLvN&md5=370ee63ca081ca3e958dc17e5315e140</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.184%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DR.%2BK.%26atitle%3DPhase%2520II%2520and%2520phase%2520III%2520failures%253A%25202013-2015%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D817%26epage%3D818%26doi%3D10.1038%2Fnrd.2016.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Godyń, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jończyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malawska, B.</span></span> <span> </span><span class="NLM_article-title">Therapeutic strategies for Alzheimer’s disease in clinical trials</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.pharep.2015.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fj.pharep.2015.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=26721364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=127-138&author=J.+Gody%C5%84author=J.+Jo%C5%84czykauthor=D.+Panekauthor=B.+Malawska&title=Therapeutic+strategies+for+Alzheimer%E2%80%99s+disease+in+clinical+trials&doi=10.1016%2Fj.pharep.2015.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies for Alzheimer's disease in clinical trials</span></div><div class="casAuthors">Godyn, Justyna; Jonczyk, Jakub; Panek, Dawid; Malawska, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-138</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is considered to be the most common cause of dementia and is an incurable, progressive neurodegenerative disorder.  Current treatment of the disease, essentially symptomatic, is based on three cholinesterase inhibitors and memantine, affecting the glutamatergic system.  Since 2003, no new drugs have been approved for treatment of AD.  This article presents current directions in the search for novel, potentially effective agents for the treatment of AD, as well as selected promising treatment strategies.  These include agents acting upon the beta-amyloid, such as vaccines, antibodies and inhibitors or modulators of γ- and β-secretase; agents directed against the tau protein as well as compds. acting as antagonists of neurotransmitter systems (serotoninergic 5-HT6 and histaminergic H3).  Ongoing clin. trials with Aβ antibodies (solanezumab, gantenerumab, crenezumab) seem to be promising, while vaccines against the tau protein (AADvac1 and ACI-35) are now in early-stage trials.  Interesting results have also been achieved in trials involving small mols. such as inhibitors of β-secretase (MK-8931, E2609), a combination of 5-HT6 antagonist (idalopirdine) with donepezil, inhibition of advanced glycation end product receptors by azeliragon or modulation of the acetylcholine response of α-7 nicotinic acetylcholine receptors by encenicline.  Development of new effective drugs acting upon the central nervous system is usually a difficult and time-consuming process, and in the case of AD to-date clin. trials have had a very high failure rate.  Most phase II clin. trials ending with a pos. outcome do not succeed in phase III, often due to serious adverse effects or lack of therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC2G55auOP27Vg90H21EOLACvtfcHk0liDTyyhIJxTqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKrsb0%253D&md5=e3f4010a5408a836683024db61164ae2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2015.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2015.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DGody%25C5%2584%26aufirst%3DJ.%26aulast%3DJo%25C5%2584czyk%26aufirst%3DJ.%26aulast%3DPanek%26aufirst%3DD.%26aulast%3DMalawska%26aufirst%3DB.%26atitle%3DTherapeutic%2520strategies%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520in%2520clinical%2520trials%26jtitle%3DPharmacol.%2520Rep.%26date%3D2016%26volume%3D68%26spage%3D127%26epage%3D138%26doi%3D10.1016%2Fj.pharep.2015.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brulet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β–secretase inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13042</span>, <span class="refDoi"> DOI: 10.1038/ncomms13042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fncomms13042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=27727204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13042&author=A.+M.+Zuhlauthor=C.+E.+Nolanauthor=M.+A.+Brodneyauthor=S.+Niessenauthor=K.+Atchisonauthor=C.+Houleauthor=D.+A.+Karanianauthor=C.+Ambroiseauthor=J.+W.+Bruletauthor=E.+M.+Beckauthor=S.+D.+Doranauthor=B.+T.+O%E2%80%99Neillauthor=C.+W.+Am+Endeauthor=C.+Changauthor=K.+F.+Geogheganauthor=G.+M.+Westauthor=J.+C.+Judkinsauthor=X.+Houauthor=D.+R.+Riddellauthor=D.+S.+Johnson&title=Chemoproteomic+profiling+reveals+that+cathepsin+D+off-target%C2%A0activity%C2%A0drives+ocular+toxicity+of%C2%A0%CE%B2%E2%80%93secretase+inhibitors&doi=10.1038%2Fncomms13042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span></div><div class="casAuthors">Zuhl, Andrea M.; Nolan, Charles E.; Brodney, Michael A.; Niessen, Sherry; Atchison, Kevin; Houle, Christopher; Karanian, David A.; Ambroise, Claude; Brulet, Jeffrey W.; Beck, Elizabeth M.; Doran, Shawn D.; O'Neill, Brian T.; am Ende, Christopher W.; Chang, Cheng; Geoghegan, Kieran F.; West, Graham M.; Judkins, Joshua C.; Hou, Xinjun; Riddell, David R.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13042</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease.  Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity in animal models, but the target mediating this toxicity has not been identified.  Here we use a clickable photoaffinity probe to identify cathepsin D (CatD) as a principal off-target of BACE1 inhibitors in human cells.  We find that several BACE1 inhibitors blocked CatD activity in cells with much greater potency than that displayed in cell-free assays with purified protein.  Through a series of exploratory toxicol. studies, we show that quantifying CatD target engagement in cells with the probe is predictive of ocular toxicity in vivo.  Taken together, our findings designate off-target inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally underscore the power of chem. proteomics for discerning mechanisms of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-LulGVRdJLVg90H21EOLACvtfcHk0lj91SF_8VVLfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL&md5=5e2c31195f4f03babec561a5824ccb0d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fncomms13042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13042%26sid%3Dliteratum%253Aachs%26aulast%3DZuhl%26aufirst%3DA.%2BM.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKaranian%26aufirst%3DD.%2BA.%26aulast%3DAmbroise%26aufirst%3DC.%26aulast%3DBrulet%26aufirst%3DJ.%2BW.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DAm%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DWest%26aufirst%3DG.%2BM.%26aulast%3DJudkins%26aufirst%3DJ.%2BC.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DChemoproteomic%2520profiling%2520reveals%2520that%2520cathepsin%2520D%2520off-target%25C2%25A0activity%25C2%25A0drives%2520ocular%2520toxicity%2520of%25C2%25A0%25CE%25B2%25E2%2580%2593secretase%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13042%26doi%3D10.1038%2Fncomms13042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F. </span></span> <span> </span><span class="NLM_article-title">Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux</span>. <i>J Pharmacol Exp Ther</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.045260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1124%2Fjpet.102.045260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12604685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1eisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2003&pages=1085-92&author=H.+Daiauthor=P.+Marbachauthor=M.+Lemaireauthor=M.+Hayesauthor=W.%C2%A0F.%C2%A0+Elmquist&title=Distribution+of+STI-571+to+the+brain+is+limited+by+P-glycoprotein-mediated+efflux&doi=10.1124%2Fjpet.102.045260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux</span></div><div class="casAuthors">Dai, Haiqing; Marbach, Peter; Lemaire, Michel; Hayes, Michael; Elmquist, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adequate distribution of STI-571 (Gleevec) to the central nervous system (CNS) is crit. for its effective use in CNS tumors.  P-glycoprotein-mediated efflux in the blood-brain barrier may play a role in the CNS delivery of this drug.  Whether STI-571 is a substrate of P-glycoprotein was detd. by examg. the directional flux of [14C]STI-571 in parental and MDR1-transfected Madin-Darby canine kidney (MDCK) II epithelial cell monolayers.  The basolateral-to-apical flux of STI-571 was 39-fold greater than the apical-to-basolateral flux in the MDR1-transfected cells and 8-fold greater in the parental cell monolayers.  This difference in directional flux was significantly reduced by a specific P-glycoprotein inhibitor (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzo- suber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline trihydrochloride (LY335979).  The role of P-glycoprotein in the CNS distribution of STI-571 was examd. in vivo, using wild-type and mdr1a/b (-/-) knockout mice that were orally administered 25 mg/kg [14C]STI-571.  In the wild-type mice, the brain-to-plasma STI-571 concn. ratio at all time points was low (1-3%); however, there was an 11-fold greater brain partitioning of STI-571 at 1 h postdose in the mdr1a/b (-/-) mice compared with the wild-type mice.  When 12.5 mg/kg STI-571 was given i.v., the brain-to-plasma ratio of STI-571 in the mdr1a/b (-/-) mice was approx. 7-fold greater than that of wild-type mice up to 120 min postdose.  These data indicate that STI-571 is a substrate of P-glycoprotein, and that the inhibition of P-glycoprotein affects the transport of STI-571 across MDCKII monolayers.  Moreover, P-glycoprotein plays an important role in limiting the distribution of STI-571 to the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF6vLgl-LGObVg90H21EOLACvtfcHk0lj91SF_8VVLfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1eisrs%253D&md5=c4f1082f27454e16635d768ce337ce7f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.045260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.045260%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DH.%26aulast%3DMarbach%26aufirst%3DP.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DM.%26aulast%3DElmquist%26aufirst%3DW.%25C2%25A0F.%25C2%25A0%26atitle%3DDistribution%2520of%2520STI-571%2520to%2520the%2520brain%2520is%2520limited%2520by%2520P-glycoprotein-mediated%2520efflux%26jtitle%3DJ%2520Pharmacol%2520Exp%2520Ther%26date%3D2003%26volume%3D304%26spage%3D1085%26epage%3D92%26doi%3D10.1124%2Fjpet.102.045260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wielinga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tellingen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span> <span> </span><span class="NLM_article-title">The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of Imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2577</span>– <span class="NLM_lpage">2582</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-04-2416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1158%2F0008-5472.can-04-2416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=15805252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVeqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=2577-2582&author=P.+Breedveldauthor=D.+Pluimauthor=G.+Ciprianiauthor=P.+Wielingaauthor=O.+van+Tellingenauthor=A.+H.+Schinkelauthor=J.+H.+M.+Schellens&title=The+effect+of+Bcrp1+%28Abcg2%29+on+the+in+vivo+pharmacokinetics+and+brain+penetration+of+Imatinib+mesylate+%28Gleevec%29%3A+Implications+for+the+use+of+breast+cancer+resistance+protein+and+P-glycoprotein+inhibitors+to+enable+the+brain+penetration+of+imatinib+in+patients&doi=10.1158%2F0008-5472.can-04-2416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients</span></div><div class="casAuthors">Breedveld, Pauline; Pluim, Dick; Cipriani, Greta; Wielinga, Peter; Van Tellingen, Olaf; Schinkel, Alfred H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2577-2582</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Imatinib mesylate (signal transduction inhibitor 571, Gleevec) is a potent and selective tyrosine kinase inhibitor, which was shown to effectively inhibit platelet-derived growth factor-induced glioblastoma cell growth preclinically.  However, in patients, a limited penetration of imatinib into the brain has been reported.  Imatinib is transported in vitro and in vivo by P-glycoprotein (P-gp; ABCB1), which thereby limits its distribution into the brain in mice.  Previously, imatinib was shown to potently inhibit human breast cancer resistance protein (BCRP; ABCG2).  Here, the authors show that imatinib is efficiently transported by mouse Bcrp1 in transfected Madin-Darby canine kidney strain II (MDCKII) monolayers.  Furthermore, the authors show that the clearance of i.v. imatinib is significantly decreased 1.6-fold in Bcrp1 knockout mice compared with wild-type mice.  At t=2 h, the brain penetration of i.v. imatinib was significantly 2.5-fold increased in Bcrp1 knockout mice compared with control mice.  The authors tested the hypothesis that P-gp and BCRP inhibitors, such as elacridar and pantoprazole, improve the brain penetration of imatinib.  Firstly, the authors showed in vitro that pantoprazole and elacridar inhibit the Bcrp1-mediated transport of imatinib in MDCKII-Bcrp1 cells.  Secondly, the authors showed that coadministration of pantoprazole or elacridar significantly reduced the clearance of i.v. imatinib in wild-type mice by resp. 1.7-fold and 1.5-fold.  Finally, in wild-type mice treated with pantoprazole or elacridar, the brain penetration of i.v. imatinib significantly increased 1.8-fold and 4.2-fold, resp.  Moreover, the brain penetration of p.o. imatinib increased 5.2-fold when pantoprazole was coadministered in wild-type mice.  Our results suggest that coadministration of BCRP and P-gp inhibitors may improve delivery of imatinib to malignant gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYrfIvN18z9rVg90H21EOLACvtfcHk0lj91SF_8VVLfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVeqs70%253D&md5=8520878a8f3082eb735ea0edd12ed4ad</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-04-2416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-04-2416%26sid%3Dliteratum%253Aachs%26aulast%3DBreedveld%26aufirst%3DP.%26aulast%3DPluim%26aufirst%3DD.%26aulast%3DCipriani%26aufirst%3DG.%26aulast%3DWielinga%26aufirst%3DP.%26aulast%3Dvan%2BTellingen%26aufirst%3DO.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DThe%2520effect%2520of%2520Bcrp1%2520%2528Abcg2%2529%2520on%2520the%2520in%2520vivo%2520pharmacokinetics%2520and%2520brain%2520penetration%2520of%2520Imatinib%2520mesylate%2520%2528Gleevec%2529%253A%2520Implications%2520for%2520the%2520use%2520of%2520breast%2520cancer%2520resistance%2520protein%2520and%2520P-glycoprotein%2520inhibitors%2520to%2520enable%2520the%2520brain%2520penetration%2520of%2520imatinib%2520in%2520patients%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D2577%26epage%3D2582%26doi%3D10.1158%2F0008-5472.can-04-2416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arslanova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augelli-Szafran, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span> <span> </span><span class="NLM_article-title">Phenotypic analysis of images of zebrafish treated with Alzheimer’s gamma-secretase inhibitors</span>. <i>BMC Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/1472-6750-10-24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1186%2F1472-6750-10-24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=20307292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ksl2gtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=24&author=D.+Arslanovaauthor=T.+Yangauthor=X.+Xuauthor=S.+T.+Wongauthor=C.+E.+Augelli-Szafranauthor=W.+Xia&title=Phenotypic+analysis+of+images+of+zebrafish+treated+with+Alzheimer%E2%80%99s+gamma-secretase+inhibitors&doi=10.1186%2F1472-6750-10-24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors</span></div><div class="casAuthors">Arslanova Dilyara; Yang Ting; Xu Xiaoyin; Wong Stephen T; Augelli-Szafran Corinne E; Xia Weiming</div><div class="citationInfo"><span class="NLM_cas:title">BMC biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Several gamma-secretase inhibitors (GSI) are in clinical trials for the treatment of Alzheimer's disease (AD).  This enzyme mediates the proteolytic cleavage of amyloid precursor protein (APP) to generate amyloid beta protein, Abeta, the pathogenic protein in AD.  The gamma-secretase also cleaves Notch to generate Notch Intracellular domain (NICD), the signaling molecule that is implicated in tumorigenesis.  RESULTS:  We have developed a method to examine live zebrafish that were each treated with gamma-secretase inhibitors (GSI), DAPT {N- [N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester}, Gleevec, or fragments of Gleevec.  These compounds were first tested in a cell-based assay and the effective concentrations of these compounds that blocked Abeta generation were quantitated.  The mortality of zebrafish, as a result of exposure to different doses of compound, was assessed, and any apoptotic processes were examined by TUNEL staining.  We then used conventional and automatic microscopes to acquire images of zebrafish and applied algorithms to automate image composition and processing.  Zebrafish were treated in 96- or 384-well plates, and the phenotypes were analyzed at 2, 3 and 5 days post fertilization (dpf).  We identified that AD95, a fragment of Gleevec, effectively blocks Abeta production and causes specific phenotypes that were different from those treated with DAPT.  Finally, we validated the specificity of two Notch phenotypes (pigmentation and the curvature of tail/trunk) induced by DAPT in a dose-dependent manner.  These phenotypes were examined in embryos treated with GSIs or AD95 at increasing concentrations.  The expression levels of Notch target gene her6 were also measured by in situ hybridization and the co-relationship between the levels of Notch inhibition by DAPT and AD95 and the severity of phenotypes were determined.  CONCLUSION:  The results reported here of the effects on zebrafish suggest that this newly developed method may be used to screen novel GSIs and other leads for a variety of therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlZYYPOqVJroIRAdBLKY41fW6udTcc2eap6cVZ9qdl07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ksl2gtQ%253D%253D&md5=5bcf8f13b2f09508aa273257c53ddf00</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1186%2F1472-6750-10-24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6750-10-24%26sid%3Dliteratum%253Aachs%26aulast%3DArslanova%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DS.%2BT.%26aulast%3DAugelli-Szafran%26aufirst%3DC.%2BE.%26aulast%3DXia%26aufirst%3DW.%26atitle%3DPhenotypic%2520analysis%2520of%2520images%2520of%2520zebrafish%2520treated%2520with%2520Alzheimer%25E2%2580%2599s%2520gamma-secretase%2520inhibitors%26jtitle%3DBMC%2520Biotechnol.%26date%3D2010%26volume%3D10%26spage%3D24%26doi%3D10.1186%2F1472-6750-10-24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein recognition of substrates and circumvention through rational drug design</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1021/mp0500871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp0500871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlagu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=3-25&author=T.+J.+Raub&title=P-Glycoprotein+recognition+of+substrates+and+circumvention+through+rational+drug+design&doi=10.1021%2Fmp0500871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">P-Glycoprotein Recognition of Substrates and Circumvention through Rational Drug Design</span></div><div class="casAuthors">Raub, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now well recognized that membrane efflux transporters, esp. P-glycoprotein (P-gp; ABCB1), play a role in detg. the absorption, distribution, metab., excretion, and toxicol. behaviors of some drugs and mols. in development.  An investment in screening structure-activity relation (SAR) is warranted in early discovery when exposure and/or target activity in an in vivo efficacy model is not achieved and P-gp efflux is identified as a rate-limiting factor.  However, the amt. of investment in SAR must be placed into perspective by assessing the risks assocd. with the intended therapeutic target, the potency and margin of safety of the compd., the intended patient population(s), and the market competition.  The task of rationally designing a chem. strategy for circumventing a limiting P-gp interaction can be daunting.  The necessity of retaining biol. potency and metabolic stability places restrictions on what can be done, and the factors for P-gp recognition of substrates are complicated and poorly understood.  The parameters within the assays that affect overall pump efficiency or net efflux, such as passive diffusion, membrane partitioning, and mol. interaction between pump and substrate, should be understood when interpreting data sets assocd. with chem. around a scaffold.  No single, functional group alone is often the cause, but one group can accentuate the recognition points existing within a scaffold.  This can be likened to a rheostat, rather than an on/off switch, where addn. or removal of a key group can increase or decrease the pumping efficiency.  The most practical approach to de-emphasize the limiting effects of P-gp on a particular scaffold is to increase passive diffusion.  Efflux pumping efficiency may be overcome when passive diffusion is fast enough.  Eliminating, or substituting with fewer, groups that solvate in water, or decreasing their hydrogen bonding capacity, and adding halogen groups can increase passive diffusion.  Reducing mol. size, replacing electroneg. atoms, blocking or masking H-bond donors with N-alkylation or bulky flanking groups, introducing constrained conformation, or by promoting intramol. hydrogen bonds are all examples of steps to take.  This review discusses our understanding of how P-gp recognizes and pumps compds. as substrates and describes cases where structural changes were made in a chem. scaffold to circumvent the effects of P-gp interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRbEgPosNnxrVg90H21EOLACvtfcHk0ljL2nq4dGVL6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlagu7%252FP&md5=cc89be920dfa0e32edb994be94626aa5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fmp0500871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0500871%26sid%3Dliteratum%253Aachs%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26atitle%3DP-Glycoprotein%2520recognition%2520of%2520substrates%2520and%2520circumvention%2520through%2520rational%2520drug%2520design%26jtitle%3DMol.%2520Pharm.%26date%3D2006%26volume%3D3%26spage%3D3%26epage%3D25%26doi%3D10.1021%2Fmp0500871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deadman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkin, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxendale, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span> <span> </span><span class="NLM_article-title">The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1766</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1039/c2ob27003j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1039%2Fc2ob27003j" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1766-1800&author=B.+J.+Deadmanauthor=M.+D.+Hopkinauthor=I.+R.+Baxendaleauthor=S.+V.+Ley&title=The+synthesis+of+Bcr-Abl+inhibiting+anticancer+pharmaceutical+agents+imatinib%2C+nilotinib+and+dasatinib&doi=10.1039%2Fc2ob27003j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2Fc2ob27003j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob27003j%26sid%3Dliteratum%253Aachs%26aulast%3DDeadman%26aufirst%3DB.%2BJ.%26aulast%3DHopkin%26aufirst%3DM.%2BD.%26aulast%3DBaxendale%26aufirst%3DI.%2BR.%26aulast%3DLey%26aufirst%3DS.%2BV.%26atitle%3DThe%2520synthesis%2520of%2520Bcr-Abl%2520inhibiting%2520anticancer%2520pharmaceutical%2520agents%2520imatinib%252C%2520nilotinib%2520and%2520dasatinib%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D1766%26epage%3D1800%26doi%3D10.1039%2Fc2ob27003j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lg3IZwY0my6bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed Suzuki–Miyaura cross-coupling reactions employing dialkylbiaryl phosphine ligands</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1461</span>– <span class="NLM_lpage">1473</span>, <span class="refDoi"> DOI: 10.1021/ar800036s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar800036s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVejs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=1461-1473&author=R.+Martinauthor=S.+L.+Buchwald&title=Palladium-catalyzed+Suzuki%E2%80%93Miyaura+cross-coupling+reactions+employing+dialkylbiaryl+phosphine+ligands&doi=10.1021%2Far800036s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Suzuki-Miyaura Cross-Coupling Reactions Employing Dialkylbiaryl Phosphine Ligands</span></div><div class="casAuthors">Martin, Ruben; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1461-1473</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review presents the recent advances in palladium-catalyzed Suzuki-Miyaura cross-coupling reactions using dialkylbiaryl phosphine ligands.  The cores of many types of polymers, ligands, natural products, and pharmaceuticals contain biaryl or substituted arom. structures, and efficient methods of synthesizing these structures are crucial to the work of a broad spectrum of org. chemists.  Recently, Pd-catalyzed carbon-carbon bond-forming processes, particularly the Suzuki-Miyaura cross-coupling reaction (SMC), have risen in popularity for this purpose.  The SMC has many advantages over other methods for constructing these moieties, including mild conditions, high tolerance toward functional groups, the com. availability and stability of its reagents, and the ease of handling and sepg. byproducts from its reaction mixts.Until 1998, most catalysts for the SMC employed triarylphosphine ligands.  More recently, new bulky and electron-rich phosphine ligands, which can dramatically improve the efficiency and selectivity of such cross-coupling reactions, have been introduced.  In the course of our studies on carbon-nitrogen bond-forming reactions, we found that the use of electron-rich and bulky phosphines enhanced the rate of both the oxidative addn. and reductive elimination processes; this was the beginning of our development of a new family of ligands, the dialkylbiarylphosphines.  These ligands can be used for a wide variety of palladium-catalyzed carbon-carbon, carbon-nitrogen, and carbon-oxygen bond-forming processes as well as serving as supporting ligands for a no. of other reactions.  The enhanced reactivity of these catalysts has expanded the scope of cross-coupling partners that can be employed in the SMC.  With use of such dialkylbiarylphosphine ligands, the coupling of unactivated aryl chlorides, aryl tosylates, heteroaryl systems, and very hindered substrate combinations have become routine.  The utility of these ligands has been successfully demonstrated in a wide no. of synthetic applications, including industrially relevant processes.  We discuss our studies on the mechanistic framework of the reaction, which have allowed us to rationally modify the ligand structures in order to tune their properties.  We also describe selected applications in the synthesis of natural products and new materials to illustrate the utility of these dialkylbiarylphosphine ligands in various "real-world" synthetic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2cmzKPXhqBbVg90H21EOLACvtfcHk0lg3IZwY0my6bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVejs7c%253D&md5=91dad4ee8d7e21c5fee36b1f10cf054a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Far800036s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far800036s%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-catalyzed%2520Suzuki%25E2%2580%2593Miyaura%2520cross-coupling%2520reactions%2520employing%2520dialkylbiaryl%2520phosphine%2520ligands%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D1461%26epage%3D1473%26doi%3D10.1021%2Far800036s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whelligan, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelder, S.</span></span> <span> </span><span class="NLM_article-title">Two-step synthesis of aza- and diazaindoles from chloroamino-N-heterocycles using ethoxyvinylborolane</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1021/jo902143f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo902143f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=11-15&author=D.+K.+Whelliganauthor=D.+W.+Thomsonauthor=D.+Taylorauthor=S.+Hoelder&title=Two-step+synthesis+of+aza-+and+diazaindoles+from+chloroamino-N-heterocycles+using+ethoxyvinylborolane&doi=10.1021%2Fjo902143f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjo902143f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo902143f%26sid%3Dliteratum%253Aachs%26aulast%3DWhelligan%26aufirst%3DD.%2BK.%26aulast%3DThomson%26aufirst%3DD.%2BW.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DTwo-step%2520synthesis%2520of%2520aza-%2520and%2520diazaindoles%2520from%2520chloroamino-N-heterocycles%2520using%2520ethoxyvinylborolane%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26spage%3D11%26epage%3D15%26doi%3D10.1021%2Fjo902143f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bihorel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camenisch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrmann, J.-M.</span></span> <span> </span><span class="NLM_article-title">Influence of breast cancer resistance protein (Abcg2) and P-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec ) across the mouse blood-brain barrier</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1749</span>– <span class="NLM_lpage">1757</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2007.04808.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1111%2Fj.1471-4159.2007.04808.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=17696988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyksLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2007&pages=1749-1757&author=S.+Bihorelauthor=G.+Camenischauthor=M.+Lemaireauthor=J.-M.+Scherrmann&title=Influence+of+breast+cancer+resistance+protein+%28Abcg2%29+and+P-glycoprotein+%28Abcb1a%29+on+the+transport+of+imatinib+mesylate+%28Gleevec+%29+across+the+mouse+blood-brain+barrier&doi=10.1111%2Fj.1471-4159.2007.04808.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier</span></div><div class="casAuthors">Bihorel, Sebastien; Camenisch, Gian; Lemaire, Michel; Scherrmann, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1749-1757</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib, a protein tyrosine kinase inhibitor, may prevent the growth of glioblastoma cells.  Unfortunately, its brain distribution is restricted by p-glycoprotein (p-gp or multidrug resistance protein Mdr1a), and probably by breast cancer resistance protein (Bcrp1), two efflux pumps expressed at the blood-brain barrier (BBB).  We have used in situ brain perfusion to investigate the mechanisms of imatinib transport across the mouse BBB.  The brain uptake of imatinib in wild-type mice was limited by saturable efflux processes.  The inhibition of p-gp, by valspodar and zosuquidar, increased imatinib uptake (2.5-fold), as did the deficiency of p-gp in Mdr1a/1b(-/-) mice (5.5-fold).  Perfusing imatinib with the p-gp/Bcrp1 inhibitor, elacridar, enhanced the brain uptake of imatinib in wild-type (4.1-fold) and Mdr1a/1b(-/-) mice (1.2-fold).  However, the brain uptake of imatinib was similar in wild-type and Bcrp1(-/-) mice when it was perfused at a non-satg. concn.  The brain uptake of CGP74588, an active metabolite of imatinib, was low.  It was increased by perfusion with elacridar (twofold), but not with valspodar and zosuquidar.  CGP74588 uptake was 1.5 times greater in Bcrp1(-/-) mice than in wild-type mice.  These data suggest that imatinib transport at the mouse BBB is limited by p-gp and probably by Bcrp1, and that CGP74588 transport is restricted by Bcrp1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBJv07PgbrC7Vg90H21EOLACvtfcHk0lg3IZwY0my6bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyksLbN&md5=b3a6dccbdcb2649ac691e1259f0ab8ee</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2007.04808.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2007.04808.x%26sid%3Dliteratum%253Aachs%26aulast%3DBihorel%26aufirst%3DS.%26aulast%3DCamenisch%26aufirst%3DG.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DScherrmann%26aufirst%3DJ.-M.%26atitle%3DInfluence%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528Abcg2%2529%2520and%2520P-glycoprotein%2520%2528Abcb1a%2529%2520on%2520the%2520transport%2520of%2520imatinib%2520mesylate%2520%2528Gleevec%2520%2529%2520across%2520the%2520mouse%2520blood-brain%2520barrier%26jtitle%3DJ.%2520Neurochem.%26date%3D2007%26volume%3D102%26spage%3D1749%26epage%3D1757%26doi%3D10.1111%2Fj.1471-4159.2007.04808.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Netzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flajolet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span> <span> </span><span class="NLM_article-title">Lowering β-amyloid levels rescues learning and memory in a down syndrome mouse model</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e10943</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0010943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1371%2Fjournal.pone.0010943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=20532168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&author=W.+J.+Netzerauthor=C.+Powellauthor=Y.+Nongauthor=J.+Blundellauthor=L.+Wongauthor=K.+Duffauthor=M.+Flajoletauthor=P.+Greengard&title=Lowering+%CE%B2-amyloid+levels+rescues+learning+and+memory+in+a+down+syndrome+mouse+model&doi=10.1371%2Fjournal.pone.0010943"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0010943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0010943%26sid%3Dliteratum%253Aachs%26aulast%3DNetzer%26aufirst%3DW.%2BJ.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DNong%26aufirst%3DY.%26aulast%3DBlundell%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DDuff%26aufirst%3DK.%26aulast%3DFlajolet%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26atitle%3DLowering%2520%25CE%25B2-amyloid%2520levels%2520rescues%2520learning%2520and%2520memory%2520in%2520a%2520down%2520syndrome%2520mouse%2520model%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26doi%3D10.1371%2Fjournal.pone.0010943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaedal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulem, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudbjartsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhangale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenlocher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palotie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span> <span> </span><span class="NLM_article-title">A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1038/nature11283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fnature11283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=22801501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=96-99&author=T.+Jonssonauthor=J.+K.+Atwalauthor=S.+Steinbergauthor=J.+Snaedalauthor=P.+V.+Jonssonauthor=S.+Bjornssonauthor=H.+Stefanssonauthor=P.+Sulemauthor=D.+Gudbjartssonauthor=J.+Maloneyauthor=K.+Hoyteauthor=A.+Gustafsonauthor=Y.+Liuauthor=Y.+Luauthor=T.+Bhangaleauthor=R.+R.+Grahamauthor=J.+Huttenlocherauthor=G.+Bjornsdottirauthor=O.+A.+Andreassenauthor=E.+G.+J%C3%B6nssonauthor=A.+Palotieauthor=T.+W.+Behrensauthor=O.+T.+Magnussonauthor=A.+Kongauthor=U.+Thorsteinsdottirauthor=R.+J.+Wattsauthor=K.+Stefansson&title=A+mutation+in+APP+protects+against+Alzheimer%E2%80%99s+disease+and+age-related+cognitive+decline&doi=10.1038%2Fnature11283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in APP protects against Alzheimer's disease and age-related cognitive decline</span></div><div class="casAuthors">Jonsson, Thorlakur; Atwal, Jasvinder K.; Steinberg, Stacy; Snaedal, Jon; Jonsson, Palmi V.; Bjornsson, Sigurbjorn; Stefansson, Hreinn; Sulem, Patrick; Gudbjartsson, Daniel; Maloney, Janice; Hoyte, Kwame; Gustafson, Amy; Liu, Yichin; Lu, Yanmei; Bhangale, Tushar; Graham, Robert R.; Huttenlocher, Johanna; Bjornsdottir, Gyda; Andreassen, Ole A.; Joensson, Erik G.; Palotie, Aarno; Behrens, Timothy W.; Magnusson, Olafur T.; Kong, Augustine; Thorsteinsdottir, Unnur; Watts, Ryan J.; Stefansson, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7409</span>),
    <span class="NLM_cas:pages">96-99</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The prevalence of dementia in the Western world in people over the age of 60 has been estd. to be greater than 5%, about two-thirds of which are due to Alzheimer's disease.  The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3).  Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1795 Icelanders.  We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease.  This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approx. 40% redn. in the formation of amyloidogenic peptides in vitro.  The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease.  Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4AFwQCLRQOLVg90H21EOLACvtfcHk0ljNS7bRPzxY-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M&md5=4db9cb2e3842d5a9d4af4ce102249b70</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnature11283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11283%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DT.%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DSnaedal%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DP.%2BV.%26aulast%3DBjornsson%26aufirst%3DS.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSulem%26aufirst%3DP.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DHoyte%26aufirst%3DK.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBhangale%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DR.%2BR.%26aulast%3DHuttenlocher%26aufirst%3DJ.%26aulast%3DBjornsdottir%26aufirst%3DG.%26aulast%3DAndreassen%26aufirst%3DO.%2BA.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DE.%2BG.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DThorsteinsdottir%26aufirst%3DU.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DA%2520mutation%2520in%2520APP%2520protects%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520age-related%2520cognitive%2520decline%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D96%26epage%3D99%26doi%3D10.1038%2Fnature11283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edward, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuewen JoAnn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youping, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, T. C.</span></span> <span> </span><span class="NLM_article-title">Applications of high throughput microsomal stability assay in drug discovery</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.2174/138620708784911429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.2174%2F138620708784911429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=18673274" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=469-476&author=D.+Liauthor=H.+K.+Edwardauthor=M.+Xuewen+JoAnnauthor=H.+Youpingauthor=T.+C.+Guy&title=Applications+of+high+throughput+microsomal+stability+assay+in+drug+discovery&doi=10.2174%2F138620708784911429"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F138620708784911429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620708784911429%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DEdward%26aufirst%3DH.%2BK.%26aulast%3DXuewen%2BJoAnn%26aufirst%3DM.%26aulast%3DYouping%26aufirst%3DH.%26aulast%3DGuy%26aufirst%3DT.%2BC.%26atitle%3DApplications%2520of%2520high%2520throughput%2520microsomal%2520stability%2520assay%2520in%2520drug%2520discovery%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2008%26volume%3D11%26spage%3D469%26epage%3D476%26doi%3D10.2174%2F138620708784911429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, D. A.</span></span> <span> </span><span class="NLM_article-title">Small molecule quantification by liquid chromatography-mass spectrometry for metabolites of drugs and drug candidates</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2355</span>– <span class="NLM_lpage">2360</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1124%2Fdmd.111.040865" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2355-2360&author=U.+P.+Dahalauthor=J.+P.+Jonesauthor=J.+A.+Davisauthor=D.+A.+Rock&title=Small+molecule+quantification+by+liquid+chromatography-mass+spectrometry+for+metabolites+of+drugs+and+drug+candidates&doi=10.1124%2Fdmd.111.040865"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040865%26sid%3Dliteratum%253Aachs%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DJones%26aufirst%3DJ.%2BP.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DRock%26aufirst%3DD.%2BA.%26atitle%3DSmall%2520molecule%2520quantification%2520by%2520liquid%2520chromatography-mass%2520spectrometry%2520for%2520metabolites%2520of%2520drugs%2520and%2520drug%2520candidates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2355%26epage%3D2360%26doi%3D10.1124%2Fdmd.111.040865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paniagua, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomooka, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, W. H.</span></span> <span> </span><span class="NLM_article-title">Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">2633</span>– <span class="NLM_lpage">2642</span>, <span class="refDoi"> DOI: 10.1172/jci28546.</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1172%2Fjci28546." title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=2633-2642&author=R.+T.+Paniaguaauthor=O.+Sharpeauthor=P.+P.+Hoauthor=S.+M.+Chanauthor=A.+Changauthor=J.+P.+Higginsauthor=B.+H.+Tomookaauthor=F.+M.+Thomasauthor=J.+J.+Songauthor=S.+B.+Goodmanauthor=D.+M.+Leeauthor=M.+C.+Genoveseauthor=P.+J.+Utzauthor=L.+Steinmanauthor=W.+H.+Robinson&title=Selective+tyrosine+kinase+inhibition+by+imatinib+mesylate+for+the+treatment+of+autoimmune+arthritis&doi=10.1172%2Fjci28546."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1172%2Fjci28546.&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci28546.%26sid%3Dliteratum%253Aachs%26aulast%3DPaniagua%26aufirst%3DR.%2BT.%26aulast%3DSharpe%26aufirst%3DO.%26aulast%3DHo%26aufirst%3DP.%2BP.%26aulast%3DChan%26aufirst%3DS.%2BM.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DHiggins%26aufirst%3DJ.%2BP.%26aulast%3DTomooka%26aufirst%3DB.%2BH.%26aulast%3DThomas%26aufirst%3DF.%2BM.%26aulast%3DSong%26aufirst%3DJ.%2BJ.%26aulast%3DGoodman%26aufirst%3DS.%2BB.%26aulast%3DLee%26aufirst%3DD.%2BM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DUtz%26aufirst%3DP.%2BJ.%26aulast%3DSteinman%26aufirst%3DL.%26aulast%3DRobinson%26aufirst%3DW.%2BH.%26atitle%3DSelective%2520tyrosine%2520kinase%2520inhibition%2520by%2520imatinib%2520mesylate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D2633%26epage%3D2642%26doi%3D10.1172%2Fjci28546." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Alloza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Nunes, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betensky, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prada, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacskai, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frosch, M. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2006.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fj.nbd.2006.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=17029828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cmt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=516-524&author=M.+Garcia-Allozaauthor=E.+M.+Robbinsauthor=S.+X.+Zhang-Nunesauthor=S.+M.+Purcellauthor=R.+A.+Betenskyauthor=S.+Rajuauthor=C.+Pradaauthor=S.+M.+Greenbergauthor=B.+J.+Bacskaiauthor=M.+P.+Frosch&title=Characterization+of+amyloid+deposition+in+the+APPswe%2FPS1dE9+mouse+model+of+Alzheimer+disease&doi=10.1016%2Fj.nbd.2006.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease</span></div><div class="casAuthors">Garcia-Alloza, Monica; Robbins, Elissa M.; Zhang-Nunes, Sandy X.; Purcell, Susan M.; Betensky, Rebecca A.; Raju, Susan; Prada, Claudia; Greenberg, Steven M.; Bacskai, Brian J.; Frosch, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">516-524</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Transgenic mice carrying disease-linked forms of genes assocd. with Alzheimer disease often demonstrate deposition of the β-amyloid as senile plaques and cerebral amyloid angiopathy.  We have characterized the natural history of β-amyloid deposition in APPswe/PS1dE9 mice, a particularly aggressive transgenic mouse model generated with mutant transgenes for APP (APPswe: KM594/5NL) and PS1 (dE9: deletion of exon 9).  Ex vivo histochem. showed Aβ deposition by 4 mo with a progressive increase in plaque no. up to 12 mo and a similar increase of Aβ levels.  In vivo multiphoton microscopy at weekly intervals showed increasing β-amyloid deposition as CAA and plaques.  Although first appearing at an early age, CAA progressed at a significantly slower rate than in the Tg2576 mice.  The consistent and early onset of β-amyloid accumulation in the APPswe/PS1dE9 model confirms its utility for studies of biochem. and pathol. mechanisms underlying β-amyloid deposition, as well as exploring new therapeutic treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMkcjJYjASbLVg90H21EOLACvtfcHk0lhiDumryh0DDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cmt7rI&md5=14fb7f1d39747a0bb5b132f5f2e90613</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2006.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2006.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Alloza%26aufirst%3DM.%26aulast%3DRobbins%26aufirst%3DE.%2BM.%26aulast%3DZhang-Nunes%26aufirst%3DS.%2BX.%26aulast%3DPurcell%26aufirst%3DS.%2BM.%26aulast%3DBetensky%26aufirst%3DR.%2BA.%26aulast%3DRaju%26aufirst%3DS.%26aulast%3DPrada%26aufirst%3DC.%26aulast%3DGreenberg%26aufirst%3DS.%2BM.%26aulast%3DBacskai%26aufirst%3DB.%2BJ.%26aulast%3DFrosch%26aufirst%3DM.%2BP.%26atitle%3DCharacterization%2520of%2520amyloid%2520deposition%2520in%2520the%2520APPswe%252FPS1dE9%2520mouse%2520model%2520of%2520Alzheimer%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2006%26volume%3D24%26spage%3D516%26epage%3D524%26doi%3D10.1016%2Fj.nbd.2006.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Grijalba, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarasa, M.</span></span> <span> </span><span class="NLM_article-title">Optimized protocol for amyloid-β extraction from the brain</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">839</span>, <span class="refDoi"> DOI: 10.3233/jad-121798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.3233%2Fjad-121798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=23302653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFOhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=835-839&author=M.+Izcoauthor=P.+Pesiniauthor=V.+P%C3%A9rez-Grijalbaauthor=N.+Fandosauthor=M.+Sarasa&title=Optimized+protocol+for+amyloid-%CE%B2+extraction+from+the+brain&doi=10.3233%2Fjad-121798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Protocol for Amyloid-β Extraction from the Brain</span></div><div class="casAuthors">Izco, Maria; Pesini, Pedro; Perez-Grijalba, Virginia; Fandos, Noelia; Sarasa, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">835-839</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Brain levels of amyloid-β (Aβ) are frequently assessed in transgenic mice models of Alzheimer's disease.  The procedure involves tissue sample homogenization using different buffers in a sequential process.  No attempt has been made to assess if these procedures are able to ext. the total amt. of Aβ present in the samples.  Here we present data suggesting that std. protocols can lead to a dramatic underestimation of the Aβ content.  Results show that higher extn. buffer vols. and at least two repetitions of the sol. and membrane-bound extn. steps are necessary for a more accurate estn. of the Aβ content in brain tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_FFoRjzy2kLVg90H21EOLACvtfcHk0lhiDumryh0DDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFOhtrc%253D&md5=d0e3833cd714239f8fcbc72501823c68</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3233%2Fjad-121798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252Fjad-121798%26sid%3Dliteratum%253Aachs%26aulast%3DIzco%26aufirst%3DM.%26aulast%3DPesini%26aufirst%3DP.%26aulast%3DP%25C3%25A9rez-Grijalba%26aufirst%3DV.%26aulast%3DFandos%26aufirst%3DN.%26aulast%3DSarasa%26aufirst%3DM.%26atitle%3DOptimized%2520protocol%2520for%2520amyloid-%25CE%25B2%2520extraction%2520from%2520the%2520brain%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2013%26volume%3D34%26spage%3D835%26epage%3D839%26doi%3D10.3233%2Fjad-121798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nebot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crettol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Esposito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tattam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span> <span> </span><span class="NLM_article-title">Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00946.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1111%2Fj.1476-5381.2010.00946.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=20977456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2ms7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=1059-1069&author=N.+Nebotauthor=S.+Crettolauthor=F.+d%E2%80%99Espositoauthor=B.+Tattamauthor=D.+E.+Hibbsauthor=M.+Murray&title=Participation+of+CYP2C8+and+CYP3A4+in+the+N-demethylation+of+imatinib+in+human+hepatic+microsomes&doi=10.1111%2Fj.1476-5381.2010.00946.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes</span></div><div class="casAuthors">Nebot, Noelia; Crettol, Severine; d'Esposito, Fabrizio; Tattam, Bruce; Hibbs, David E.; Murray, Michael</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1059-1069</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Imatinib is a clin. important inhibitor of tyrosine kinases that are dysregulated in chronic myelogenous leukemia and gastrointestinal stromal tumors.  Inter-individual variation in imatinib pharmacokinetics is extensive, and influences drug safety and efficacy.  Hepatic cytochrome P 450 (CYP) 3A4 was implicated in imatinib N-demethylation, but the clearance of imatinib decreases during prolonged therapy.  CYP3A phenotype correlates with imatinib clearance at the commencement of therapy, but not at steady state.  The present study evaluated the possibility that multiple CYPs may contribute to imatinib oxidn. in liver.  Imatinib biotransformation in human liver microsomes (n = 20) and by cDNA-expressed CYPs was detd. by LC-MS.  Relationships between imatinib N-demethylation and other drug metabolizing CYPs were assessed.  N-desmethylimatinib formation was correlated with microsomal oxidn. of the CYP3A4 substrates testosterone (p = 0.60; P < 0.01) and midazolam (p = 0.46; P < 0.05), and the CYP2C8 substrate paclitaxel (p = 0.58; P < 0.01).  CDNA-derived CYPs 2C8, 3A4, 3A5 and 3A7 supported imatinib N-demethylation, but 10 other CYPs were inactive; in kinetic studies, CYP2C8 was a high-affinity enzyme with a catalytic efficiency ∼15-fold greater than those of CYPs 3A4 and 3A5.  The CYP3A inhibitors ketoconazole and troleandomycin, and the CYP2C8 inhibitors quercetin and paclitaxel decreased imatinib oxidn.  From mol. modeling, the imatinib structure could be superimposed on a pharmacophore for CYP2C8 substrates.  CYP2C8 and CYPs 3A contribute to imatinib N-demethylation in human liver.  The involvement of CYP2C8 may account in part for the wide inter-patient variation in imatinib pharmacokinetics obsd. in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq6dSh2LX9GLVg90H21EOLACvtfcHk0lhIGWwOUJN15Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2ms7jL&md5=af09256169b40b8fb106e790efac719c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00946.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00946.x%26sid%3Dliteratum%253Aachs%26aulast%3DNebot%26aufirst%3DN.%26aulast%3DCrettol%26aufirst%3DS.%26aulast%3Dd%25E2%2580%2599Esposito%26aufirst%3DF.%26aulast%3DTattam%26aufirst%3DB.%26aulast%3DHibbs%26aufirst%3DD.%2BE.%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DParticipation%2520of%2520CYP2C8%2520and%2520CYP3A4%2520in%2520the%2520N-demethylation%2520of%2520imatinib%2520in%2520human%2520hepatic%2520microsomes%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D1059%26epage%3D1069%26doi%3D10.1111%2Fj.1476-5381.2010.00946.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jack, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiste, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigand, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankratz, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span> <span> </span><span class="NLM_article-title">Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1016/s1474-4422(12)70291-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fs1474-4422%2812%2970291-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=23332364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=207-216&author=C.+R.+Jackauthor=D.+S.+Knopmanauthor=W.+J.+Jagustauthor=R.+C.+Petersenauthor=M.+W.+Weinerauthor=P.+S.+Aisenauthor=L.+M.+Shawauthor=P.+Vemuriauthor=H.+J.+Wisteauthor=S.+D.+Weigandauthor=T.+G.+Lesnickauthor=V.+S.+Pankratzauthor=M.+C.+Donohueauthor=J.+Q.+Trojanowski&title=Tracking+pathophysiological+processes+in+Alzheimer%E2%80%99s+disease%3A+an+updated+hypothetical+model+of+dynamic+biomarkers&doi=10.1016%2Fs1474-4422%2812%2970291-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers</span></div><div class="casAuthors">Jack, Clifford R.; Knopman, David S.; Jagust, William J.; Petersen, Ronald C.; Weiner, Michael W.; Aisen, Paul S.; Shaw, Leslie M.; Vemuri, Prashanthi; Wiste, Heather J.; Weigand, Stephen D.; Lesnick, Timothy G.; Pankratz, Vernon S.; Donohue, Michael C.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In 2010, we put forward a hypothetical model of the major biomarkers of Alzheimer's disease (AD).  The model was received with interest because we described the temporal evolution of AD biomarkers in relation to each other and to the onset and progression of clin. symptoms.  Since then, evidence has accumulated that supports the major assumptions of this model.  Evidence has also appeared that challenges some of our assumptions, which has allowed us to modify our original model.  Refinements to our model include indexing of individuals by time rather than clin. symptom severity; incorporation of interindividual variability in cognitive impairment assocd. with progression of AD pathophysiol.; modifications of the specific temporal ordering of some biomarkers; and recognition that the two major proteinopathies underlying AD biomarker changes, amyloid β (Aβ) and tau, might be initiated independently in sporadic AD, in which we hypothesise that an incident Aβ pathophysiol. can accelerate antecedent limbic and brainstem tauopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgH6Mv-cXkY7Vg90H21EOLACvtfcHk0lhIGWwOUJN15Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCht7o%253D&md5=0f7a94ec086d5287fef9f7a6995981df</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fs1474-4422%2812%2970291-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1474-4422%252812%252970291-0%26sid%3Dliteratum%253Aachs%26aulast%3DJack%26aufirst%3DC.%2BR.%26aulast%3DKnopman%26aufirst%3DD.%2BS.%26aulast%3DJagust%26aufirst%3DW.%2BJ.%26aulast%3DPetersen%26aufirst%3DR.%2BC.%26aulast%3DWeiner%26aufirst%3DM.%2BW.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DShaw%26aufirst%3DL.%2BM.%26aulast%3DVemuri%26aufirst%3DP.%26aulast%3DWiste%26aufirst%3DH.%2BJ.%26aulast%3DWeigand%26aufirst%3DS.%2BD.%26aulast%3DLesnick%26aufirst%3DT.%2BG.%26aulast%3DPankratz%26aufirst%3DV.%2BS.%26aulast%3DDonohue%26aufirst%3DM.%2BC.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DTracking%2520pathophysiological%2520processes%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520an%2520updated%2520hypothetical%2520model%2520of%2520dynamic%2520biomarkers%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26spage%3D207%26epage%3D216%26doi%3D10.1016%2Fs1474-4422%2812%2970291-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerreiro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bras, J.</span></span> <span> </span><span class="NLM_article-title">The age factor in Alzheimer’s disease</span>. <i>Genome Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">106</span>, <span class="refDoi"> DOI: 10.1186/s13073-015-0232-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1186%2Fs13073-015-0232-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=26482651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SqtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=106&author=R.+Guerreiroauthor=J.+Bras&title=The+age+factor+in+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs13073-015-0232-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The age factor in Alzheimer's disease</span></div><div class="casAuthors">Guerreiro, Rita; Bras, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Genome Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106/1-106/3</span>CODEN:
                <span class="NLM_cas:coden">GMEECG</span>;
        ISSN:<span class="NLM_cas:issn">1756-994X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease is the most common type of dementia, and it is characterized by a decline in memory or other thinking skills.  The greatest risk factor for Alzheimer's disease is advanced age.  A recent genome-wide study identified a locus on chromosome 17 assocd. with the age at onset, and a specific variant in CCL11 is probably responsible for the assocn.  The assocn. of a protective haplotype with a 10-yr delay in the onset of Alzheimer's disease and the identification of a CCL11 variant with possible functional roles in this assocn. might allow the future development of immunomodulators with the potential to halve disease incidence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCXAQavyzR-7Vg90H21EOLACvtfcHk0lhIGWwOUJN15Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SqtLfP&md5=3e493d3eddbd5edbdb0aaafdc7157e1a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2Fs13073-015-0232-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13073-015-0232-5%26sid%3Dliteratum%253Aachs%26aulast%3DGuerreiro%26aufirst%3DR.%26aulast%3DBras%26aufirst%3DJ.%26atitle%3DThe%2520age%2520factor%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DGenome%2520Med.%26date%3D2015%26volume%3D7%26spage%3D106%26doi%3D10.1186%2Fs13073-015-0232-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigue, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devous, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieck, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebrank, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Arrastia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, D. C.</span></span> <span> </span><span class="NLM_article-title">β-Amyloid burden in healthy aging: Regional distribution and cognitive consequences</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1212/wnl.0b013e318245d295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1212%2Fwnl.0b013e318245d295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=22302550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVSlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2012&pages=387-395&author=K.+M.+Rodrigueauthor=K.+M.+Kennedyauthor=M.+D.+Devousauthor=J.+R.+Rieckauthor=A.+C.+Hebrankauthor=R.+Diaz-Arrastiaauthor=D.+Mathewsauthor=D.+C.+Park&title=%CE%B2-Amyloid+burden+in+healthy+aging%3A+Regional+distribution+and+cognitive+consequences&doi=10.1212%2Fwnl.0b013e318245d295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">β-Amyloid burden in healthy aging: Regional distribution and cognitive consequences</span></div><div class="casAuthors">Rodrigue, K. M.; Kennedy, K. M.; Devous, M. D., Sr.; Rieck, J. R.; Hebrank, A. C.; Diaz-Arrastia, R.; Mathews, D.; Park, D. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-395</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: Several lines of evidence suggest that pathol. changes underlying Alzheimer disease (AD) begin years prior to the clin. expression of the disease, underscoring the need for studies of cognitively healthy adults to capture these early changes.  The overall goal of the current study was to map the cortical distribution of β-amyloid (Aβ) in a healthy adult lifespan sample (aged 30-89), and to assess the relationship between elevated amyloid and cognitive performance across multiple domains.  Methods: A total of 137 well-screened and cognitively normal adults underwent Aβ PET imaging with radiotracer F-florbetapir.  Aβ load was estd. from 8 cortical regions.  Participants were genotyped for APOE and tested for processing speed, working memory, fluid reasoning, episodic memory, and verbal ability.  Results: Aβ deposition is distributed differentially across the cortex and progresses at varying rates with age across cortical brain regions.  A subset of cognitively normal adults aged 60 and over show markedly elevated deposition, and also had a higher rate of APOE ε4 (38%) than nonelevated adults (19%).  Aβ burden was linked to poorer cognitive performance on measures of processing speed, working memory, and reasoning.  Conclusions: Even in a highly selected lifespan sample of adults, Aβ deposition is apparent in some adults and is influenced by APOE status.  Greater amyloid burden was related to deleterious effects on cognition, suggesting that subtle cognitive changes accrue as amyloid progresses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYead0UGiYnrVg90H21EOLACvtfcHk0lgr79C28NshQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVSlurc%253D&md5=aea6e7d3051dd39892fdb758d90940dc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1212%2Fwnl.0b013e318245d295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252Fwnl.0b013e318245d295%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigue%26aufirst%3DK.%2BM.%26aulast%3DKennedy%26aufirst%3DK.%2BM.%26aulast%3DDevous%26aufirst%3DM.%2BD.%26aulast%3DRieck%26aufirst%3DJ.%2BR.%26aulast%3DHebrank%26aufirst%3DA.%2BC.%26aulast%3DDiaz-Arrastia%26aufirst%3DR.%26aulast%3DMathews%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DD.%2BC.%26atitle%3D%25CE%25B2-Amyloid%2520burden%2520in%2520healthy%2520aging%253A%2520Regional%2520distribution%2520and%2520cognitive%2520consequences%26jtitle%3DNeurology%26date%3D2012%26volume%3D78%26spage%3D387%26epage%3D395%26doi%3D10.1212%2Fwnl.0b013e318245d295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wekstein, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markesbery, W. R.</span></span> <span> </span><span class="NLM_article-title">Alzheimer neuropathologic alterations in aged cognitively normal subjects</span>. <i>J. Neuropathol. Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1097/00005072-199904000-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1097%2F00005072-199904000-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10218633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADyaK1M3jtlSjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=376-388&author=D.+G.+Davisauthor=F.+A.+Schmittauthor=D.+R.+Weksteinauthor=W.+R.+Markesbery&title=Alzheimer+neuropathologic+alterations+in+aged+cognitively+normal+subjects&doi=10.1097%2F00005072-199904000-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer neuropathologic alterations in aged cognitively normal subjects</span></div><div class="casAuthors">Davis D G; Schmitt F A; Wekstein D R; Markesbery W R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuropathology and experimental neurology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">376-88</span>
        ISSN:<span class="NLM_cas:issn">0022-3069</span>.
    </div><div class="casAbstract">The histopathologic changes distinguishing early Alzheimer disease (AD) from normal or pathologic aging are not clearly defined.  This report describes the autopsy findings of 59 elderly, well-educated, volunteers.  They were examined longitudinally with mental status testing, some for up to 8 years, as part of our normal aging study.  This study reveals that (1) the brains of many subjects who did not show cognitive impairment on neuropsychologic testing contain abundant senile plaques (SP) and/or neurofibrillary tangles (NFT); (2) 29 subjects met Khachaturian criteria for AD, 15 met CERAD and 7 met National Institute on Aging-Reagan Institute guidelines; (3) Braak and Braak staging method included 9 in stage IV subjects, 4 in stage V, and 1 in stage VI; (4) there was a progression of NFT from entorhinal cortex to hippocampus and amygdala as a function of age; (5) 2 subjects met criteria for a diagnosis of dementia with Lewy bodies but were not demented; (6) cerebral amyloid angiopathy was present in leptomeningeal vessels in 75% of subjects and in parenchymal vessels in 62% of subjects; (7) only 10 of 59 subjects (17%) had no or few degenerative brain changes.  Our study demonstrates that the brains of a large percentage of cognitively normal, relatively well-educated individuals contain numerous degenerative changes and only a small percentage are relatively free of these changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRz4lU9mWZDjhgd2Wuil24tfW6udTcc2eZNFqNHCdnaDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3jtlSjsw%253D%253D&md5=981d6bc8c95e9cd5abc753d55c8b2f98</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2F00005072-199904000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005072-199904000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DD.%2BG.%26aulast%3DSchmitt%26aufirst%3DF.%2BA.%26aulast%3DWekstein%26aufirst%3DD.%2BR.%26aulast%3DMarkesbery%26aufirst%3DW.%2BR.%26atitle%3DAlzheimer%2520neuropathologic%2520alterations%2520in%2520aged%2520cognitively%2520normal%2520subjects%26jtitle%3DJ.%2520Neuropathol.%2520Exp.%2520Neurol.%26date%3D1999%26volume%3D58%26spage%3D376%26epage%3D388%26doi%3D10.1097%2F00005072-199904000-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvanitakis, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. S.</span></span> <span> </span><span class="NLM_article-title">Neuropathology of older persons without cognitive impairment from two community-based studies</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1837</span>– <span class="NLM_lpage">1844</span>, <span class="refDoi"> DOI: 10.1212/01.wnl.0000219668.47116.e6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1212%2F01.wnl.0000219668.47116.e6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=16801647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BD28zosFKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1837-1844&author=D.+A.+Bennettauthor=J.+A.+Schneiderauthor=Z.+Arvanitakisauthor=J.+F.+Kellyauthor=N.+T.+Aggarwalauthor=R.+C.+Shahauthor=R.+S.+Wilson&title=Neuropathology+of+older+persons+without+cognitive+impairment+from+two+community-based+studies&doi=10.1212%2F01.wnl.0000219668.47116.e6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropathology of older persons without cognitive impairment from two community-based studies</span></div><div class="casAuthors">Bennett D A; Schneider J A; Arvanitakis Z; Kelly J F; Aggarwal N T; Shah R C; Wilson R S</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1837-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine the relation of National Institute on Aging-Reagan (NIA-Reagan) neuropathologic criteria of Alzheimer disease (AD) to level of cognitive function in persons without dementia or mild cognitive impairment (MCI).  METHODS:  More than 2,000 persons without dementia participating in the Religious Orders Study or the Memory and Aging Project agreed to annual detailed clinical evaluation and brain donation.  The studies had 19 neuropsychological performance tests in common that assessed five cognitive domains, including episodic memory, semantic memory, working memory, perceptual speed, and visuospatial ability.  A total of 134 persons without cognitive impairment died and underwent brain autopsy and postmortem assessment for AD pathology using NIA-Reagan neuropathologic criteria for AD, cerebral infarctions, and Lewy bodies.  Linear regression was used to examine the relation of AD pathology to level of cognitive function proximate to death.  RESULTS:  Two (1.5%) persons met NIA-Reagan criteria for high likelihood AD, and 48 (35.8%) met criteria for intermediate likelihood; 29 (21.6%) had cerebral infarctions, and 18 (13.4%) had Lewy bodies.  The mean Mini-Mental State Examination score proximate to death was 28.2 for those meeting high or intermediate likelihood AD by NIA-Reagan criteria and 28.4 for those not meeting criteria.  In linear regression models adjusted for age, sex, and education, persons meeting criteria for intermediate or high likelihood AD scored about a quarter standard unit lower on tests of episodic memory (p = 0.01).  There were no significant differences in any other cognitive domain.  CONCLUSIONS:  Alzheimer disease pathology can be found in the brains of older persons without dementia or mild cognitive impairment and is related to subtle changes in episodic memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZrU4dU_XG5BBrI9DTGjC0fW6udTcc2eZNFqNHCdnaDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zosFKjsg%253D%253D&md5=1ddba59fa76644d9e75f4292f626bca3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1212%2F01.wnl.0000219668.47116.e6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252F01.wnl.0000219668.47116.e6%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DD.%2BA.%26aulast%3DSchneider%26aufirst%3DJ.%2BA.%26aulast%3DArvanitakis%26aufirst%3DZ.%26aulast%3DKelly%26aufirst%3DJ.%2BF.%26aulast%3DAggarwal%26aufirst%3DN.%2BT.%26aulast%3DShah%26aufirst%3DR.%2BC.%26aulast%3DWilson%26aufirst%3DR.%2BS.%26atitle%3DNeuropathology%2520of%2520older%2520persons%2520without%2520cognitive%2520impairment%2520from%2520two%2520community-based%2520studies%26jtitle%3DNeurology%26date%3D2006%26volume%3D66%26spage%3D1837%26epage%3D1844%26doi%3D10.1212%2F01.wnl.0000219668.47116.e6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eimerbrink, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chumley, M. J.</span></span> <span> </span><span class="NLM_article-title">Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fj.neuroscience.2016.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=27320209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2016&pages=72-77&author=L.+E.+Gardnerauthor=J.+D.+Whiteauthor=M.+J.+Eimerbrinkauthor=G.+W.+Boehmauthor=M.+J.+Chumley&title=Imatinib+methanesulfonate+reduces+hyperphosphorylation+of+tau+following+repeated+peripheral+exposure+to+lipopolysaccharide&doi=10.1016%2Fj.neuroscience.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide</span></div><div class="casAuthors">Gardner, L. E.; White, J. D.; Eimerbrink, M. J.; Boehm, G. W.; Chumley, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-77</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For years, the prevailing hypothesis for Alzheimer's Disease (AD) has proposed a mechanism by which deposition of amyloid-beta (Aβ) in the brain is independent of tau-pathologies and cognitive decline.  However, despite extensive research on the disease, the mechanisms underlying the etiol. of tau-pathol. remain unknown.  Previous research in our lab has shown that imatinib methanesulfonate (IM) blocks the peripheral prodn. of Aβ in response to LPS, thereby preventing the buildup of Aβ in the hippocampus, and rescuing the cognitive dysfunction that normally follows.  The present study aimed to examine the link between Aβ and tau following inflammation, and to expand our understanding of how IM affects AD pathol.  Specifically, we hypothesized that the IM-mediated inhibition of Aβ prodn. following inflammation would successfully protect against the hyperphosphorylation of tau (ptau).  Here we show that 7 days of LPS treatment in male C57BL/6 J mice, which normally produces elevations in peripheral and central Aβ, also produces hyperphosphorylation of tau.  However, just as pre-treatment and concurrent treatment with IM blocks Aβ prodn., it also blocks the phosphorylation of tau.  In addn., 7 days of LPS-induced inflammation and Aβ prodn. also leads to elevated total tau protein expression.  Our results may provide support for the hypothesis that enhanced expression of tau following LPS administration is a protective measure by hippocampal neurons to compensate for the loss of the microtubule-stabilizing protein due to phosphorylation.  More importantly, our results support the hypothesis that blocking the prodn. of Aβ that follows inflammation also leads to reduced tau phosphorylation, lending credence to a model in which Aβ initiates tau phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnS2iTjJeonbVg90H21EOLACvtfcHk0liWUKUcjXAgsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbvL&md5=b7f91c0d0a2d4aea1772969cfdd54503</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DGardner%26aufirst%3DL.%2BE.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DEimerbrink%26aufirst%3DM.%2BJ.%26aulast%3DBoehm%26aufirst%3DG.%2BW.%26aulast%3DChumley%26aufirst%3DM.%2BJ.%26atitle%3DImatinib%2520methanesulfonate%2520reduces%2520hyperphosphorylation%2520of%2520tau%2520following%2520repeated%2520peripheral%2520exposure%2520to%2520lipopolysaccharide%26jtitle%3DNeuroscience%26date%3D2016%26volume%3D331%26spage%3D72%26epage%3D77%26doi%3D10.1016%2Fj.neuroscience.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cancino, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yévenes, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inestrosa, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A. R.</span></span> <span> </span><span class="NLM_article-title">STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer’s β-amyloid deposits</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2425</span>– <span class="NLM_lpage">2442</span>, <span class="refDoi"> DOI: 10.1093/brain/awn125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1093%2Fbrain%2Fawn125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=18559370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BD1crksVWlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2008&pages=2425-2442&author=G.+I.+Cancinoauthor=E.+M.+Toledoauthor=N.+R.+Lealauthor=D.+E.+Hernandezauthor=L.+F.+Y%C3%A9venesauthor=N.+C.+Inestrosaauthor=A.+R.+Alvarez&title=STI571+prevents+apoptosis%2C+tau+phosphorylation+and+behavioural+impairments+induced+by+Alzheimer%E2%80%99s+%CE%B2-amyloid+deposits&doi=10.1093%2Fbrain%2Fawn125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits</span></div><div class="casAuthors">Cancino Gonzalo I; Toledo Enrique M; Leal Nancy R; Hernandez Diego E; Yevenes L Fernanda; Inestrosa Nibaldo C; Alvarez Alejandra R</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">Pt 9</span>),
    <span class="NLM_cas:pages">2425-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is evidence that amyloid beta-protein (Abeta) deposits or Abeta intermediates trigger pathogenic factors in Alzheimer's disease patients.  We have previously reported that c-Abl kinase activation involved in cell signalling regulates the neuronal death response to Abeta fibrils (Abeta(f)).  In the present study we investigated the therapeutic potential of the selective c-Abl inhibitor STI571 on both the intrahippocampal injection of Abeta(f) and APPsw/PSEN1DeltaE9 transgenic mice Alzheimer's disease models.  Injection of Abeta(f) induced an increase in the numbers of p73 and c-Abl immunoreactive cells in the hippocampal area near to the lesion.  Chronic intraperitoneal administration of STI571 reduced the rat behavioural deficit induced by Abeta(f), as well as apoptosis and tau phosphorylation.  Our in vitro studies suggest that inhibition of the c-Abl/p73 signalling pathway is the mechanism underlying of the effects of STI571 on Abeta-induced apoptosis for the following reasons: (i) Abeta(f) induces p73 phosphorylation, the TAp73 isoform levels increase so as to enhance its proapoptotic function, and all these effects where reduced by STI571; (ii) c-Abl kinase activity is required for neuronal apoptosis and (iii) STI571 prevents the Abeta-induced increase in the expression of apoptotic genes.  Furthermore, in the Abeta-injected area there was a huge increase in phosphorylated p73 and a larger number of TAp73-positive cells, with these changes being prevented by STI571 coinjection.  Moreover, the intraperitoneal administration of STI571 rescued the cognitive decline in APPsw/PSEN1DeltaE9 mice, p73 phosphorylation, tau phosphorylation and caspase-3 activation in neurons around Abeta deposits.  Besides, we observed a decrease in the number and size of Abeta deposits in the APPsw/PSEN1DeltaE9-STI571-treated mice.  These results are consistent with the role of the c-Abl/p73 signalling pathway in Abeta neurodegeneration, and suggest that STI571-like compounds would be effective in therapeutic treatments of Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuTiFgI2X54Hqj_yg7twvpfW6udTcc2eZtjLocS0dA47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crksVWlsA%253D%253D&md5=1fbaf5b5383cddea70d39fd4fcf2796d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawn125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawn125%26sid%3Dliteratum%253Aachs%26aulast%3DCancino%26aufirst%3DG.%2BI.%26aulast%3DToledo%26aufirst%3DE.%2BM.%26aulast%3DLeal%26aufirst%3DN.%2BR.%26aulast%3DHernandez%26aufirst%3DD.%2BE.%26aulast%3DY%25C3%25A9venes%26aufirst%3DL.%2BF.%26aulast%3DInestrosa%26aufirst%3DN.%2BC.%26aulast%3DAlvarez%26aufirst%3DA.%2BR.%26atitle%3DSTI571%2520prevents%2520apoptosis%252C%2520tau%2520phosphorylation%2520and%2520behavioural%2520impairments%2520induced%2520by%2520Alzheimer%25E2%2580%2599s%2520%25CE%25B2-amyloid%2520deposits%26jtitle%3DBrain%26date%3D2008%26volume%3D131%26spage%3D2425%26epage%3D2442%26doi%3D10.1093%2Fbrain%2Fawn125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.1186/s13195-014-0089-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1186%2Fs13195-014-0089-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=25621019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVCqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=89&author=R.+Vassar&title=BACE1+inhibitor+drugs+in+clinical+trials+for+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs13195-014-0089-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 inhibitor drugs in clinical trials for Alzheimer's disease</span></div><div class="casAuthors">Vassar, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">89/1-89/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for the prodn. of the neurotoxic β-amyloid (Aβ) peptide that is widely considered to have a crucial early role in the etiol. of Alzheimer's disease (AD).  As a result, BACE1 has emerged as a prime drug target for reducing the levels of Aβ in the AD brain, and the development of BACE1 inhibitors as therapeutic agents is being vigorously pursued.  It has proven difficult for the pharmaceutical industry to design BACE1 inhibitor drugs that pass the blood-brain barrier, however this challenge has recently been met and BACE1 inhibitors are now in human clin. trials to test for safety and efficacy in AD patients and individuals with pre-symptomatic AD.  Initial results suggest that some of these BACE1 inhibitor drugs are well tolerated, although others have dropped out because of toxicity and it is still too early to know whether any will be effective for the prevention or treatment of AD.  Addnl., based on newly identified BACE1 substrates and phenotypes of mice that lack BACE1, concerns have emerged about potential mechanism-based side effects of BACE1 inhibitor drugs with chronic administration.  It is hoped that a therapeutic window can be achieved that balances safety and efficacy.  This review summarizes the current state of progress in the development of BACE1 inhibitor drugs and the evaluation of their therapeutic potential for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-BPlLZzu7rVg90H21EOLACvtfcHk0liWUKUcjXAgsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVCqtL4%253D&md5=a9ec66c8f0254986406323efa56c6f5a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs13195-014-0089-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-014-0089-7%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DBACE1%2520inhibitor%2520drugs%2520in%2520clinical%2520trials%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D89%26doi%3D10.1186%2Fs13195-014-0089-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span> <span> </span><span class="NLM_article-title">Physiological functions of the beta-site amyloid precursor protein cleaving enzyme 1 and 2</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">97</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2017.00097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.3389%2Ffnmol.2017.00097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=28469554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=97&author=R.+Yan&title=Physiological+functions+of+the+beta-site+amyloid+precursor+protein+cleaving+enzyme+1+and+2&doi=10.3389%2Ffnmol.2017.00097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2</span></div><div class="casAuthors">Yan Riqiang</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in molecular neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97</span>
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    </div><div class="casAbstract">BACE1 was discovered as the β-secretase for initiating the cleavage of amyloid precursor protein (APP) at the β-secretase site, while its close homology BACE2 cleaves APP within the β-amyloid (Aβ) domain region and shows distinct cleavage preferences in vivo.  Inhibition of BACE1 proteolytic activity has been confirmed to decrease Aβ generation and amyloid deposition, and thus specific inhibition of BACE1 by small molecules is a current focus for Alzheimer's disease therapy.  While BACE1 inhibitors are being tested in advanced clinical trials, knowledge regarding the properties and physiological functions of BACE is highly important and this review summarizes advancements in BACE1 research over the past several years.  We and others have shown that BACE1 is not only a critical enzyme for testing the "Amyloid Hypothesis" associated with Alzheimer's pathogenesis, but also important for various functions such as axon growth and pathfinding, astrogenesis, neurogenesis, hyperexcitation, and synaptic plasticity.  BACE2 appears to play different roles such as glucose homeostasis and pigmentation.  This knowledge regarding BACE1 functions is critical for monitoring the safe use of BACE1 inhibitors in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbYoN5Bm7IDcScOqQTSkOffW6udTcc2ebezzuducNgXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D&md5=b8e9ffa2007cebb2ae68c0074b7dea06</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2017.00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2017.00097%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26atitle%3DPhysiological%2520functions%2520of%2520the%2520beta-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520and%25202%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2017%26volume%3D10%26spage%3D97%26doi%3D10.3389%2Ffnmol.2017.00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jester, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, I.</span></span> <span> </span><span class="NLM_article-title">A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">11727</span>– <span class="NLM_lpage">11735</span>, <span class="refDoi"> DOI: 10.1021/ja104491h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja104491h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=11727-11735&author=B.+W.+Jesterauthor=K.+J.+Coxauthor=A.+Gajauthor=C.+D.+Shominauthor=J.+R.+Porterauthor=I.+Ghosh&title=A+coiled-coil+enabled+split-luciferase+three-hybrid+system%3A+applied+toward+profiling+inhibitors+of+protein+kinases&doi=10.1021%2Fja104491h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A Coiled-Coil Enabled Split-Luciferase Three-Hybrid System: Applied Toward Profiling Inhibitors of Protein Kinases</span></div><div class="casAuthors">Jester, Benjamin W.; Cox, Kurt J.; Gaj, Alicia; Shomin, Carolyn D.; Porter, Jason R.; Ghosh, Indraneel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">11727-11735</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 518 protein kinases encoded in the human genome are exquisitely regulated and their aberrant function(s) are often assocd. with human disease.  Thus, to advance therapeutics and to probe signal transduction cascades, there is considerable interest in the development of inhibitors that can selectively target protein kinases.  However, identifying specific compds. against such a large array of protein kinases is difficult to routinely achieve using traditional activity assays, where purified protein kinases are necessary.  Toward a simple, rapid, and practical method for identifying specific inhibitors, the authors describe the development and application of a split-protein methodol. using a coiled-coil-assisted three-hybrid system.  In this approach, a protein kinase of interest is attached to the C-terminal fragment of split-firefly luciferase and the coiled-coil Fos, which is specific for the coiled-coil Jun, is attached to the N-terminal fragment.  Upon addn. of Jun conjugated to a pan-kinase inhibitor such as staurosporine, a three-hybrid complex was established with concomitant reassembly of the split-luciferase enzyme.  An inhibitor can be potentially identified by the commensurate loss in split-luciferase activity by displacement of the modified staurosporine.  This new three-hybrid approach is potentially general by testing protein kinases from the different kinase families.  To interrogate whether this method allows for screening inhibitors, the authors tested six different protein kinases against a library of 80 known protein kinase inhibitors.  Finally, this three-hybrid system can potentially provide a rapid method for structure/function anal. as well as aid in the identification of allosteric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2HlzU6VW-HbVg90H21EOLACvtfcHk0li04xXQjT1_Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtL0%253D&md5=b6b422ada61cbc678e0156eeb07ed9a9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fja104491h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja104491h%26sid%3Dliteratum%253Aachs%26aulast%3DJester%26aufirst%3DB.%2BW.%26aulast%3DCox%26aufirst%3DK.%2BJ.%26aulast%3DGaj%26aufirst%3DA.%26aulast%3DShomin%26aufirst%3DC.%2BD.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DGhosh%26aufirst%3DI.%26atitle%3DA%2520coiled-coil%2520enabled%2520split-luciferase%2520three-hybrid%2520system%253A%2520applied%2520toward%2520profiling%2520inhibitors%2520of%2520protein%2520kinases%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D11727%26epage%3D11735%26doi%3D10.1021%2Fja104491h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Anjana Sinha, Jerry C. Chang, Peng Xu, Katherina Gindinova, Younhee Cho, Weilin Sun, Xianzhong Wu, Yue Ming Li, Paul Greengard, Jeffery W. Kelly, <span class="NLM_string-name hlFld-ContribAuthor">Subhash C. Sinha</span>. </span><span class="cited-content_cbyCitation_article-title">Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1973-1979. <a href="https://doi.org/10.1021/acsmedchemlett.9b00688" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00688</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00688%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBrain%252BPermeable%252BTafamidis%252BAmide%252BAnalogs%252Bfor%252BStabilizing%252BTTR%252Band%252BReducing%252BAPP%252BCleavage%26aulast%3DSinha%26aufirst%3DAnjana%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D31122019%26date%3D02032020%26date%3D12032020%26volume%3D11%26issue%3D10%26spage%3D1973%26epage%3D1979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anjana Sinha, Katherina Gindinova, Emily Mui, William J. Netzer, <span class="NLM_string-name hlFld-ContribAuthor">Subhash C. Sinha</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Kinase Inactive PD173955 Analogues for Reducing Production of Aβ Peptides. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1430-1435. <a href="https://doi.org/10.1021/acsmedchemlett.9b00213" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00213</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00213%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDevelopment%252Bof%252BKinase%252BInactive%252BPD173955%252BAnalogues%252Bfor%252BReducing%252BProduction%252Bof%252BA%2525CE%2525B2%252BPeptides%26aulast%3DSinha%26aufirst%3DAnjana%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D11052019%26date%3D29082019%26date%3D06092019%26volume%3D10%26issue%3D10%26spage%3D1430%26epage%3D1435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raju  Saka</span>, <span class="hlFld-ContribAuthor ">Naveen  Chella</span>, <span class="hlFld-ContribAuthor ">Wahid  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Imatinib Mesylate-Loaded Liposomes for Nose to Brain Delivery: In Vitro and In Vivo Evaluation. </span><span class="cited-content_cbyCitation_journal-name">AAPS PharmSciTech</span><span> <strong>2021,</strong> <em>22 </em>
                                    (5)
                                     <a href="https://doi.org/10.1208/s12249-021-02072-0" title="DOI URL">https://doi.org/10.1208/s12249-021-02072-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12249-021-02072-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12249-021-02072-0%26sid%3Dliteratum%253Aachs%26jtitle%3DAAPS%2520PharmSciTech%26atitle%3DDevelopment%252Bof%252BImatinib%252BMesylate-Loaded%252BLiposomes%252Bfor%252BNose%252Bto%252BBrain%252BDelivery%25253A%252BIn%252BVitro%252Band%252BIn%252BVivo%252BEvaluation%26aulast%3DSaka%26aufirst%3DRaju%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of imatinib mesylate, <b>1a</b>, and selected potent analogues for evaluation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Development of Active <b>1a</b>-analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Fragmentation of <b>1a</b> across “a” and “b” can afford compounds <b>4</b> and <b>5</b>. Compound <b>2a</b> can be obtained from <b>1a</b> via <b>6a</b> and <b>7a</b>, involving steps c–e or via compounds <b>3a–c</b> (steps f–h). Compound <b>1a</b> can also be modified to <b>8a</b>, which is a truncated analog of <b>2a</b>, and to <b>9a</b> and <b>9r</b>. Compound <b>9a</b> possesses an A ring modified, whereas <b>9r</b> has both A and E ring modified. Additional analogues of <b>9a</b> have one or more rings modified from A, B, and/or C ring(s), and a few of those also have an E ring modified (see: <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>)</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of <b>1a</b>-Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Key: MW, microwave; (a) HATU, DIEA, DMF, RT, 16 h; (b) aq Me<sub>2</sub>NH (40%, pressure bottle), 120 °C, 16 h; (c) MW, Pd(PPh<sub>3</sub>)<sub>4</sub>, aq Cs<sub>2</sub>CO<sub>3</sub> (2 M), dioxane, 100 °C, 45 min; (d) (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, RT, 16 h, (ii) Me<sub>2</sub>NH (2 M, THF), NaCNBH<sub>3</sub>, 0 °C-RT, 16 h; (e) 4 N HCl, dioxane-EtOAc, RT, 16 h; (f) (CH<sub>2</sub>O)<sub><i>n</i></sub>, NaCNBH<sub>3</sub>, 0 °C-RT, 16 h; (g) DIEA, THF, RT, 1 h; (h) MW, 100 °C, K<sub>2</sub>CO<sub>3</sub>, MeCN, 30 min.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. In vitro and in vivo evaluations of <b>1a</b>-analogues. (A) Compounds <b>2a–b</b> and <b>3a–c</b> reduced production of Aβ40 and Aβ42 peptides in N2a695 cells with an apparent IC50 between 10 and 5μM. DMSO and <b>1a</b> were used as the negative and positive controls, respectively. Results presented in (A) are the average of two or three experiments. (B) Compounds <b>1a</b> and <b>3a–3c</b> are nontoxic to N2a cells at 10 μM concentration, whereas <b>2a–2b</b> slightly increased cell density in the 5 h assay. (C) Brain and serum concentration of <b>1a</b>-analogues as determined in brain and serum extracts (<i>n</i> = 3 or 4) using liquid chromatography (LC)–mass spectrometry (MS)/MS. Statistical significance (<i>P</i>): *, <0.05%; **, <0.01%; and ***, <0.001%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of <b>1a</b>-analogues on APP metabolism modeled in N2a695 cells and in N2a cells transiently expressing human APP full length (APP-FL) or APP-C99. Shown are: WB analysis of N2a695 cell lysates post compound treatment shows formation of the 16 kDa (CTF-141) and 10 kDa CTF and αCTF in [(A) the labels are not in chronological order] and quantification of CTF-141 and the 10 kDa CTF bands produced in (B). Note that the 10 kDa CTF band runs just below the βCTF (12 kDa). Shown in (C and D) are: Aβ40, sAPPα, and sAPPβ levels in media from cells, transfected with plasmids for APP-FL or APP-C99 and treated with <b>1a</b> or its analogues (10 μM), BACEi (BACE IV, 2 μM), or GSi (DAPT, 1 μM). The Aβ40, Aβ42 (data shown in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf" class="ext-link">Figure S3A</a>), sAPPα, and sAPPβ levels were measured using the MSD ELISA. Results presented here are the representatives of two or three independent experiments. Statistical significance (<i>P</i>): *, <0.05%; **, <0.01%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vitro and in vivo evaluation of compound <b>2a</b>. (A) Microsomal stability of <b>1a</b> and its analog <b>2a</b>, measured by incubating these compounds with mouse and human liver microsomes, and determining the remaining compounds periodically using LC–MS/MS. (B) Analog <b>2a</b> reduced Aβ40 and 42 levels in 2xTg AD mice. Effects of <b>2a</b> on insoluble Aβ40/42 were determined in 5-month old 2xTg AD mice (<i>n</i> = 6 or 7). (C) Metabolic demethylation of <b>2a</b> affords <b>2c</b> via <b>2d</b>. (D) Metabolite <b>2d</b> is detected in the brain and plasma extracts of AD mice by performing LC–MS/MS analysis at the end of the 5-day in vivo study, and (E) compounds <b>2c</b> and <b>2d</b> reduce Aβ40 and/or Aβ42 weakly in N2a695 cells. Statistical significance (<i>P</i>): *, <0.05%; **, <0.01%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/medium/jm-2018-02007a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of (A) <b>1a</b>-analogues on Abl kinase inhibition (performed by an outsourced company: Luceome Biotechnologies, Tucson, AZ), and (B) <b>2a</b> on Aβ40 and Aβ42 production in combination with BACE IV and Abl and ic-Kit kinase inhibition. N2a695 cells were pretreated with BACE IV for 1 h before treatment with <b>1a</b> or <b>2a</b> (and BACE IV) for 5 h. Aβ40 and Aβ42 levels were measured using commercially available ELISA kits for human Aβ40 and Aβ42. Statistical significance (<i>P</i>): *, <0.05%; **, <0.01%, ***, <0.001%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b02007/20190321/images/large/jm-2018-02007a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02007&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42416" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42416" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younkin, S. G.</span></span> <span> </span><span class="NLM_article-title">The role of Aβ42 in Alzheimer’s disease</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/s0928-4257(98)80035-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fs0928-4257%2898%2980035-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=289-292&author=S.+G.+Younkin&title=The+role+of+A%CE%B242+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fs0928-4257%2898%2980035-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Aβ42 in Alzheimer's disease</span></div><div class="casAuthors">Younkin, Steven G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Paris)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">289-292</span>CODEN:
                <span class="NLM_cas:coden">JHYSEM</span>;
        ISSN:<span class="NLM_cas:issn">0928-4257</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review, with 32 refs.  The authors' recent studies of plasma, fibroblasts, transfected cells and transgenic mice show that a fundamental effect of the mutations linked to familial Alzheimer's disease (FAD) is to increase the extracellular concn. of Aβ42.  This effect of the FAD-linked mutations is likely to be directly related to the pathogenesis of Alzheimer's disease (AD) because Aβ42 is deposited early and selectively in the senile plaques that are an invariant feature of all forms of AD.  Thus, the authors' results provide strong evidence that the FAD-linked mutations all cause AD by increasing the extracellular concn. of Aβ42, thereby fostering Aβ deposition, and they support the hypothesis that cerebral Aβ deposition is an essential early event in the pathogenesis of all forms of AD.  Interactions between the basal forebrain cholinergic system and Aβ that could influence AD pathogenesis are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSyp7Jwfo1OrVg90H21EOLACvtfcHk0lgp_U5byrdJzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ms7s%253D&md5=f65018862a0daa181209286af8c1bcb9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fs0928-4257%2898%2980035-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0928-4257%252898%252980035-1%26sid%3Dliteratum%253Aachs%26aulast%3DYounkin%26aufirst%3DS.%2BG.%26atitle%3DThe%2520role%2520of%2520A%25CE%25B242%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Physiol.%26date%3D1998%26volume%3D92%26spage%3D289%26epage%3D292%26doi%3D10.1016%2Fs0928-4257%2898%2980035-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuperstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broersen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benilova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckheere, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debulpaep, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandersteen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segers-Nolten, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Werf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braeken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callewaert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schymkowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">Neurotoxicity of Alzheimer’s disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3408</span>– <span class="NLM_lpage">3420</span>, <span class="refDoi"> DOI: 10.1038/emboj.2010.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Femboj.2010.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=20818335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSmsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=3408-3420&author=I.+Kupersteinauthor=K.+Broersenauthor=I.+Benilovaauthor=J.+Rozenskiauthor=W.+Jonckheereauthor=M.+Debulpaepauthor=A.+Vandersteenauthor=I.+Segers-Noltenauthor=K.+Van+Der+Werfauthor=V.+Subramaniamauthor=D.+Braekenauthor=G.+Callewaertauthor=C.+Barticauthor=R.+D%E2%80%99Hoogeauthor=I.+C.+Martinsauthor=F.+Rousseauauthor=J.+Schymkowitzauthor=B.+De+Strooper&title=Neurotoxicity+of+Alzheimer%E2%80%99s+disease+A%CE%B2+peptides+is+induced+by+small+changes+in+the+A%CE%B242+to+A%CE%B240+ratio&doi=10.1038%2Femboj.2010.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotoxicity of Alzheimer's disease A peptides is induced by small changes in the A42 to A40 ratio</span></div><div class="casAuthors">Kuperstein, Inna; Broersen, Kerensa; Benilova, Iryna; Rozenski, Jef; Jonckheere, Wim; Debulpaep, Maja; Vandersteen, Annelies; Segers-Nolten, Ine; Van Der Werf, Kees; Subramaniam, Vinod; Braeken, Dries; Callewaert, Geert; Bartic, Carmen; D'Hooge, Rudi; Martins, Ivo Cristiano; Rousseau, Frederic; Schymkowitz, Joost; De Strooper, Bart</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3408-3420</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The amyloid peptides A40 and A42 of Alzheimer's disease are thought to contribute differentially to the disease process.  Although A42 seems more pathogenic than A40, the reason for this is not well understood.  We show here that small alterations in the A42:A40 ratio dramatically affect the biophys. and biol. properties of the A mixts. reflected in their aggregation kinetics, the morphol. of the resulting amyloid fibrils and synaptic function tested in vitro and in vivo.  A minor increase in the A42:A40 ratio stabilizes toxic oligomeric species with intermediate conformations.  The initial toxic impact of these A species is synaptic in nature, but this can spread into the cells leading to neuronal cell death.  The fact that the relative ratio of A peptides is more crucial than the abs. amts. of peptides for the induction of neurotoxic conformations has important implications for anti-amyloid therapy.  Our work also suggests the dynamic nature of the equil. between toxic and non-toxic intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR-22pazffF7Vg90H21EOLACvtfcHk0lgp_U5byrdJzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSmsbzP&md5=1048db62830cd821652c6337364d067d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Femboj.2010.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2010.211%26sid%3Dliteratum%253Aachs%26aulast%3DKuperstein%26aufirst%3DI.%26aulast%3DBroersen%26aufirst%3DK.%26aulast%3DBenilova%26aufirst%3DI.%26aulast%3DRozenski%26aufirst%3DJ.%26aulast%3DJonckheere%26aufirst%3DW.%26aulast%3DDebulpaep%26aufirst%3DM.%26aulast%3DVandersteen%26aufirst%3DA.%26aulast%3DSegers-Nolten%26aufirst%3DI.%26aulast%3DVan%2BDer%2BWerf%26aufirst%3DK.%26aulast%3DSubramaniam%26aufirst%3DV.%26aulast%3DBraeken%26aufirst%3DD.%26aulast%3DCallewaert%26aufirst%3DG.%26aulast%3DBartic%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DR.%26aulast%3DMartins%26aufirst%3DI.%2BC.%26aulast%3DRousseau%26aufirst%3DF.%26aulast%3DSchymkowitz%26aufirst%3DJ.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DNeurotoxicity%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520A%25CE%25B2%2520peptides%2520is%2520induced%2520by%2520small%2520changes%2520in%2520the%2520A%25CE%25B242%2520to%2520A%25CE%25B240%2520ratio%26jtitle%3DEMBO%2520J.%26date%3D2010%26volume%3D29%26spage%3D3408%26epage%3D3420%26doi%3D10.1038%2Femboj.2010.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1126/science.1072994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1126%2Fscience.1072994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12130773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Cju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2002&pages=353-356&author=J.+Hardyauthor=D.+J.+Selkoe&title=The+amyloid+hypothesis+of+Alzheimer%E2%80%99s+disease%3A+progress+and+problems+on+the+road+to+therapeutics&doi=10.1126%2Fscience.1072994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</span></div><div class="casAuthors">Hardy, John; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">5580</span>),
    <span class="NLM_cas:pages">353-356</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  It has been more than 10 yr since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide (Aβ) in plaques in brain tissue.  According to the amyloid hypothesis, accumulation of Aβ in the brain is the primary influence driving AD pathogenesis.  The rest of the disease process, including formation of neurofibrillary tangles contg. tau protein, is proposed to result from an imbalance between Aβ prodn. and Aβ clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9G5omTHR6cbVg90H21EOLACvtfcHk0lgp_U5byrdJzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Cju7s%253D&md5=f7b8db1bc6f13e85f887b73f3042e86e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1072994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1072994%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520progress%2520and%2520problems%2520on%2520the%2520road%2520to%2520therapeutics%26jtitle%3DScience%26date%3D2002%26volume%3D297%26spage%3D353%26epage%3D356%26doi%3D10.1126%2Fscience.1072994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golde, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younkin, S. G.</span></span> <span> </span><span class="NLM_article-title">Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1502</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/s0925-4439(00)00043-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fs0925-4439%2800%2900043-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10899442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFSguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1502&publication_year=2000&pages=172-187&author=T.+E.+Goldeauthor=C.+B.+Eckmanauthor=S.+G.+Younkin&title=Biochemical+detection+of+A%CE%B2+isoforms%3A+implications+for+pathogenesis%2C+diagnosis%2C+and+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fs0925-4439%2800%2900043-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease</span></div><div class="casAuthors">Golde, T. E.; Eckman, C. B.; Younkin, S. G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1502</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">172-187</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 108 refs.  Prior to the identification of the various abnormal proteins deposited as fibrillar aggregates in the Alzheimer's disease (AD) brain, there was tremendous controversy over the importance of the various lesions with respect to primacy in the pathol. of AD.  Nevertheless, based on analogy to systemic amyloidosis, many investigators believed that the amyloid deposits in AD played a causal role and that characterization of these deposits would hold the key to understanding this complex disease.  Indeed, in retrospect, it was the initial biochem. purifications of the ∼4 kDa amyloid β-peptide (Aβ) from amyloid deposits in the mid 1980s that launched a new era of AD research.  Subsequent studies of the biol. of Aβ together with genetic studies of AD have all supported the hypothesis that altered Aβ metab. leading to aggregation plays a causal role in AD.  Although there remains controversy as to whether Aβ deposited as classic amyloid or a smaller, aggregated, form causes AD, the relevance of studying the amyloid deposits has certainly been proven.  Despite the significant advances in our understanding of the role of Aβ in AD pathogenesis, many important aspects of Aβ biol. remain a mystery.  This review will highlight those aspects of Aβ biol. that have led to the authors' increased understanding of the pathogenesis of AD as well as areas which warrant addnl. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozbB3CHRVy2LVg90H21EOLACvtfcHk0ljg_eGHWq65vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFSguro%253D&md5=f5230c98609990d7425afafcbabe5558</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fs0925-4439%2800%2900043-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0925-4439%252800%252900043-0%26sid%3Dliteratum%253Aachs%26aulast%3DGolde%26aufirst%3DT.%2BE.%26aulast%3DEckman%26aufirst%3DC.%2BB.%26aulast%3DYounkin%26aufirst%3DS.%2BG.%26atitle%3DBiochemical%2520detection%2520of%2520A%25CE%25B2%2520isoforms%253A%2520implications%2520for%2520pathogenesis%252C%2520diagnosis%252C%2520and%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2000%26volume%3D1502%26spage%3D172%26epage%3D187%26doi%3D10.1016%2Fs0925-4439%2800%2900043-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haass, C.</span></span> <span> </span><span class="NLM_article-title">Take five-BACE and the γ-secretase quartet conduct Alzheimer’s amyloid β-peptide generation</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7600061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fsj.emboj.7600061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=483-488&author=C.+Haass&title=Take+five-BACE+and+the+%CE%B3-secretase+quartet+conduct+Alzheimer%E2%80%99s+amyloid+%CE%B2-peptide+generation&doi=10.1038%2Fsj.emboj.7600061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600061%26sid%3Dliteratum%253Aachs%26aulast%3DHaass%26aufirst%3DC.%26atitle%3DTake%2520five-BACE%2520and%2520the%2520%25CE%25B3-secretase%2520quartet%2520conduct%2520Alzheimer%25E2%2580%2599s%2520amyloid%2520%25CE%25B2-peptide%2520generation%26jtitle%3DEMBO%2520J.%26date%3D2004%26volume%3D23%26spage%3D483%26epage%3D488%26doi%3D10.1038%2Fsj.emboj.7600061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">A cell biological perspective on Alzheimer’s disease</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.18.020402.142302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1146%2Fannurev.cellbio.18.020402.142302" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=25-51&author=W.+Annaertauthor=B.+De+Strooper&title=A+cell+biological+perspective+on+Alzheimer%E2%80%99s+disease&doi=10.1146%2Fannurev.cellbio.18.020402.142302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.18.020402.142302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.18.020402.142302%26sid%3Dliteratum%253Aachs%26aulast%3DAnnaert%26aufirst%3DW.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DA%2520cell%2520biological%2520perspective%2520on%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D2002%26volume%3D18%26spage%3D25%26epage%3D51%26doi%3D10.1146%2Fannurev.cellbio.18.020402.142302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, D. D.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier-Lavigne, M.</span></span> <span> </span><span class="NLM_article-title">APP binds DR6 to trigger axon pruning and neuron death via distinct caspases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>457</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1038/nature07767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fnature07767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=19225519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitFKlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=457&publication_year=2009&pages=981-989&author=A.+Nikolaevauthor=T.+McLaughlinauthor=D.+D.%0AM.+O%E2%80%99Learyauthor=M.+Tessier-Lavigne&title=APP+binds+DR6+to+trigger+axon+pruning+and+neuron+death+via+distinct+caspases&doi=10.1038%2Fnature07767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">APP binds DR6 to trigger axon pruning and neuron death via distinct caspases</span></div><div class="casAuthors">Nikolaev, Anatoly; McLaughlin, Todd; O'Leary, Dennis D. M.; Tessier-Lavigne, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">457</span>
        (<span class="NLM_cas:issue">7232</span>),
    <span class="NLM_cas:pages">981-989</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Naturally occurring axonal pruning and neuronal cell death help to sculpt neuronal connections during development, but their mechanistic basis remains poorly understood.  Here the authors report that β-amyloid precursor protein (APP) and death receptor 6 (DR6, also known as TNFRSF21) activate a widespread caspase-dependent self-destruction program.  DR6 is broadly expressed by developing neurons, and is required for normal cell body death and axonal pruning both in vivo and after trophic-factor deprivation in vitro.  Unlike neuronal cell body apoptosis, which requires caspase 3, we show that axonal degeneration requires caspase 6, which is activated in a punctate pattern that parallels the pattern of axonal fragmentation.  DR6 is activated locally by an inactive surface ligand(s) that is released in an active form after trophic-factor deprivation, and the authors identify APP as a DR6 ligand.  Trophic-factor deprivation triggers the shedding of surface APP in a β-secretase (BACE)-dependent manner.  Loss- and gain-of-function studies support a model in which a cleaved amino-terminal fragment of APP (N-APP) binds DR6 and triggers degeneration.  Genetic support is provided by a common neuromuscular junction phenotype in mutant mice.  These results indicate that APP and DR6 are components of a neuronal self-destruction pathway, and suggest that an extracellular fragment of APP, acting via DR6 and caspase 6, contributes to Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmuM5crlTWx7Vg90H21EOLACvtfcHk0ljg_eGHWq65vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitFKlu7k%253D&md5=28ef7ad016a4fec752df35c3ac9a4e0a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature07767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07767%26sid%3Dliteratum%253Aachs%26aulast%3DNikolaev%26aufirst%3DA.%26aulast%3DMcLaughlin%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DD.%2BD.%2BM.%26aulast%3DTessier-Lavigne%26aufirst%3DM.%26atitle%3DAPP%2520binds%2520DR6%2520to%2520trigger%2520axon%2520pruning%2520and%2520neuron%2520death%2520via%2520distinct%2520caspases%26jtitle%3DNature%26date%3D2009%26volume%3D457%26spage%3D981%26epage%3D989%26doi%3D10.1038%2Fnature07767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauritzen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardossi-Piquard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeois, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagnotta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biferi, M.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkats, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checler, F.</span></span> <span> </span><span class="NLM_article-title">Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1007/s00401-016-1577-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1007%2Fs00401-016-1577-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2016&pages=257-276&author=I.+Lauritzenauthor=R.+Pardossi-Piquardauthor=A.+Bourgeoisauthor=S.+Pagnottaauthor=M.-G.+Biferiauthor=M.+Barkatsauthor=P.+Lacorauthor=W.+Kleinauthor=C.+Bauerauthor=F.+Checler&title=Intraneuronal+aggregation+of+the+%CE%B2-CTF+fragment+of+APP+%28C99%29+induces+A%CE%B2-independent+lysosomal-autophagic+pathology&doi=10.1007%2Fs00401-016-1577-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs00401-016-1577-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-016-1577-6%26sid%3Dliteratum%253Aachs%26aulast%3DLauritzen%26aufirst%3DI.%26aulast%3DPardossi-Piquard%26aufirst%3DR.%26aulast%3DBourgeois%26aufirst%3DA.%26aulast%3DPagnotta%26aufirst%3DS.%26aulast%3DBiferi%26aufirst%3DM.-G.%26aulast%3DBarkats%26aufirst%3DM.%26aulast%3DLacor%26aufirst%3DP.%26aulast%3DKlein%26aufirst%3DW.%26aulast%3DBauer%26aufirst%3DC.%26aulast%3DChecler%26aufirst%3DF.%26atitle%3DIntraneuronal%2520aggregation%2520of%2520the%2520%25CE%25B2-CTF%2520fragment%2520of%2520APP%2520%2528C99%2529%2520induces%2520A%25CE%25B2-independent%2520lysosomal-autophagic%2520pathology%26jtitle%3DActa%2520Neuropathol.%26date%3D2016%26volume%3D132%26spage%3D257%26epage%3D276%26doi%3D10.1007%2Fs00401-016-1577-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchelt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span> <span> </span><span class="NLM_article-title">BACE1 is the major β-secretase for generation of Aβ peptides by neurons</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1038/85064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2F85064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=11224536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsF2rtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=233-234&author=H.+Caiauthor=Y.+Wangauthor=D.+McCarthyauthor=H.+Wenauthor=D.+R.+Borcheltauthor=D.+L.+Priceauthor=P.+C.+Wong&title=BACE1+is+the+major+%CE%B2-secretase+for+generation+of+A%CE%B2+peptides+by+neurons&doi=10.1038%2F85064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 is the major β-secretase for generation of Aβ peptides by neurons</span></div><div class="casAuthors">Cai, Huaibin; Wang, Yanshu; McCarthy, Diane; Wen, Hongjin; Borchelt, David R.; Price, Donald L.; Wong, Philip C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-234</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Secretion of Alzheimer's disease (AD) Aβ peptides (Aβ1-40/42 and Aβ11-40) is abolished in cultures of BACE1-deficient cortical neurons; BACE1-deficient is one of the two β-secretases involved in generating AD Aβ peptides.  This study also establishes that BACE1-deficient is the principal neuronal protease required to cleave amyloid precursor protein (APP) at the +1 and +11 sites that generate N-termini of Aβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvJeMWCAU69rVg90H21EOLACvtfcHk0lj59zLf8mjjcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsF2rtbc%253D&md5=fd3d6b77770735ed2b12687281fc511e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2F85064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F85064%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMcCarthy%26aufirst%3DD.%26aulast%3DWen%26aufirst%3DH.%26aulast%3DBorchelt%26aufirst%3DD.%2BR.%26aulast%3DPrice%26aufirst%3DD.%2BL.%26aulast%3DWong%26aufirst%3DP.%2BC.%26atitle%3DBACE1%2520is%2520the%2520major%2520%25CE%25B2-secretase%2520for%2520generation%2520of%2520A%25CE%25B2%2520peptides%2520by%2520neurons%26jtitle%3DNat.%2520Neurosci.%26date%3D2001%26volume%3D4%26spage%3D233%26epage%3D234%26doi%3D10.1038%2F85064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lj59zLf8mjjcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobburu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">U, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staten, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12006504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=935-942&author=M.+H.+Cohenauthor=G.+Williamsauthor=J.+R.+Johnsonauthor=J.+Duanauthor=J.+Gobburuauthor=A.+Rahmanauthor=K.+Bensonauthor=J.+Leightonauthor=S.+K.+Kimauthor=R.+Woodauthor=M.+Rothmannauthor=G.+Chenauthor=K.+M.+Uauthor=A.+M.+Statenauthor=R.+Pazdur&title=Approval+summary+for+imatinib+mesylate+capsules+in+the+treatment+of+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span></div><div class="casAuthors">Cohen, Martin H.; Williams, Grant; Johnson, John R.; Duan, John; Gobburu, Jogarao; Rahman, Atiqur; Benson, Kimberly; Leighton, John; Kim, Sung K.; Wood, Rebecca; Rothmann, Mark; Chen, Gang; Maung U., Khin; Staten, Ann M.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">935-942</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) results from the breakpoint cluster region-Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis.  Imatinib, an orally administered inhibitor of the breakpoint cluster region-Abl tyrosine kinase, is capable of blocking proliferation and inducing apoptosis in CML cell lines.  In this report, we describe the preclin. profile of imatinib and the data submitted in the New Drug Application that led to its marketing approval.  Chem. manufg. and controls, animal toxicol., and biopharmaceutical data are described.  Results of Phase I and Phase II clin. studies in patients with CML in blast crisis (CML-BC), in accelerated phase (CML-AP), and in chronic phase disease-resistant or intolerant to IFN-α (CML-CP) are summarized.  The basis for marketing approval and postmarketing commitments by the pharmaceutical company are discussed.  Toxicol. studies in the rat, dog, and monkey show the hematol., renal, and hepatobiliary toxicity of imatinib.  Pharmacokinetic studies in patients with CML demonstrate 98% imatinib bioavailability.  The elimination half-lives of the parent drug and the major active metabolite, CGP74588, from plasma are approx. 18 and 40 h, resp.  Approx. 81% of the drug is eliminated in 7 days, 68% in the feces and 13% in the urine.  Cytochrome P 450 3A4 is the main enzyme responsible for imatinib metab.  Phase I and II clin. studies were conducted.  The Phase I study, in 83 CML patients, evaluated oral imatinib doses from 25 to 1000 mg/day.  Dose-limiting toxicity was not obsd.  The three Phase II studies, in CML-CP, CML-AP, and CML-BC, enrolled 1027 patients.  CML-CP patients received 400 mg/day imatinib, whereas CML-AP and CML-BC patients generally received 600 mg/day, imatinib.  Primary study endpoints were cytogenetic response rate (CML-CP) and hematol. response rate (CML-AP and CML-BC).  The cytogenetic response rate for CML-CP patients was 49%.  The hematol. response rate of CML-AP and CML-BC patients was 63 and 26%, resp.  The most common imatinib adverse events were nausea, vomiting, myalgia, edema, and diarrhea.  Elevated liver enzymes and/or bilirubin were reported in 27 patients (2.6%).  On May 10, 2001, imatinib mesylate (Gleevec, formerly known as STI-571 and Glivec), manufd. and distributed by Novartis Pharmaceuticals, East Hanover, NJ, was approved by the United States Food and Drug Administration for the treatment of CML in three clin. settings: CML-BC, CML-AP, and CML-CP.  This report summarizes the Food and Drug Administration's review of the New Drug Application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2majxsiqE3LVg90H21EOLACvtfcHk0liMa3M4dNNYjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D&md5=8820d9e1126524a6762242f68262ab86</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DBenson%26aufirst%3DK.%26aulast%3DLeighton%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DWood%26aufirst%3DR.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DU%26aufirst%3DK.%2BM.%26aulast%3DStaten%26aufirst%3DA.%2BM.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%2520for%2520imatinib%2520mesylate%2520capsules%2520in%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D935%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dagher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobburu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griebel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors</span>. <i>Clin Cancer Res</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3034</span>– <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12374669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD38XosFKiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=3034-3038&author=R.+Dagherauthor=M.+Cohenauthor=G.+Williamsauthor=M.+Rothmannauthor=J.+Gobburuauthor=G.+Robbieauthor=A.+Rahmanauthor=G.+Chenauthor=A.+Statenauthor=D.+Griebelauthor=R.+Pazdur&title=Approval+summary%3A+Imatinib+mesylate+in+the+treatment+of+metastatic+and%2For+unresectable+malignant+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors</span></div><div class="casAuthors">Dagher, Ramzi; Cohen, Martin; Williams, Gene; Rothmann, Mark; Gobburu, Jogarao; Robbie, Gabriel; Rahman, Atiqur; Chen, Gang; Staten, Ann; Griebel, Donna; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3034-3038</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Imatinib mesylate (Gleevec; Novartis, East Hanover, NJ) is a receptor tyrosine kinase inhibitor approved previously in 2001 by the United States Food and Drug Administration for the treatment of chronic myelogenous leukemia in blast crisis, accelerated phase, or in chronic phase after failure of IFN-α therapy.  We review herein the clin. profile of this drug and the regulatory review leading to the approval of a supplemental New Drug Application for the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors (GISTs).  We discuss the efficacy and side effects of imatinib mesylate in a Phase II trial of 147 patients with metastatic and/or unresectable malignant GISTs, the basis for marketing approval, and postmarketing commitments by the drug's manufacturer.  Imatinib was assessed in a single, open-label trial involving one European center and three centers in the United States.  Seventy-three patients were randomly allocated to receive 400 mg of imatinib daily, and 74 patients received 600 mg daily.  At the study report cutoff date, an objective response was confirmed in 56 patients; the overall response rate for the combined study arms was 38% (95% confidence interval, 30-46%).  These responses were all partial responses.  There was no statistically significant difference in response rates between the two dose groups.  Adverse events included edema, fluid retention, nausea, vomiting, diarrhea, myalgias, skin rash, bone marrow suppression, bleeding, and elevations in aspartate aminotransferase, alanine aminotransferase, or bilirubin.  Bleeding into the gastrointestinal tract or intratumoral sites occurred in 7 patients (5%) and was not correlated with thrombocytopenia or tumor bulk.  The pharmacokinetics of imatinib in GIST patients were similar to those of chronic myelogenous leukemia patients.  On Feb. 1, 2001, imatinib mesylate was approved by the United States Food and Drug Administration for the treatment of malignant metastatic and/or unresectable GISTs.  The recommended dose is 400 or 600 mg daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ8Oi5tX41LrVg90H21EOLACvtfcHk0liMa3M4dNNYjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XosFKiu7k%253D&md5=ca5afa0ad6d44775da8e4f137b97fe97</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDagher%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DRobbie%26aufirst%3DG.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DStaten%26aufirst%3DA.%26aulast%3DGriebel%26aufirst%3DD.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%253A%2520Imatinib%2520mesylate%2520in%2520the%2520treatment%2520of%2520metastatic%2520and%252For%2520unresectable%2520malignant%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DClin%2520Cancer%2520Res%26date%3D2002%26volume%3D8%26spage%3D3034%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Netzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span> <span> </span><span class="NLM_article-title">Gleevec inhibits -amyloid production but not Notch cleavage</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">12444</span>– <span class="NLM_lpage">12449</span>, <span class="refDoi"> DOI: 10.1073/pnas.1534745100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1073%2Fpnas.1534745100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12444-12449&author=W.+J.+Netzerauthor=F.+Douauthor=D.+Caiauthor=D.+Veachauthor=S.+Jeanauthor=Y.+Liauthor=W.+G.+Bornmannauthor=B.+Clarksonauthor=H.+Xuauthor=P.+Greengard&title=Gleevec+inhibits+-amyloid+production+but+not+Notch+cleavage&doi=10.1073%2Fpnas.1534745100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1534745100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1534745100%26sid%3Dliteratum%253Aachs%26aulast%3DNetzer%26aufirst%3DW.%2BJ.%26aulast%3DDou%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DJean%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DGreengard%26aufirst%3DP.%26atitle%3DGleevec%2520inhibits%2520-amyloid%2520production%2520but%2520not%2520Notch%2520cleavage%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D12444%26epage%3D12449%26doi%3D10.1073%2Fpnas.1534745100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Netzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flajolet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustos, V.</span></span> <span> </span><span class="NLM_article-title">Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1389</span>– <span class="NLM_lpage">1394</span>, <span class="refDoi"> DOI: 10.1073/pnas.1620963114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1073%2Fpnas.1620963114" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=1389-1394&author=W.+J.+Netzerauthor=K.+Bettayebauthor=S.+C.+Sinhaauthor=M.+Flajoletauthor=P.+Greengardauthor=V.+Bustos&title=Gleevec+shifts+APP+processing+from+a+%CE%B2-cleavage+to+a+nonamyloidogenic+cleavage&doi=10.1073%2Fpnas.1620963114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1620963114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1620963114%26sid%3Dliteratum%253Aachs%26aulast%3DNetzer%26aufirst%3DW.%2BJ.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DSinha%26aufirst%3DS.%2BC.%26aulast%3DFlajolet%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DBustos%26aufirst%3DV.%26atitle%3DGleevec%2520shifts%2520APP%2520processing%2520from%2520a%2520%25CE%25B2-cleavage%2520to%2520a%2520nonamyloidogenic%2520cleavage%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2017%26volume%3D114%26spage%3D1389%26epage%3D1394%26doi%3D10.1073%2Fpnas.1620963114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henley, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundell, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span> <span> </span><span class="NLM_article-title">Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings</span>. <i>Curr. Med. Res. Opin.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2021</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1185/03007995.2014.939167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1185%2F03007995.2014.939167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=24983746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Oktb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2014&pages=2021-2032&author=D.+B.+Henleyauthor=K.+L.+Sundellauthor=G.+Sethuramanauthor=S.+A.+Dowsettauthor=P.+C.+May&title=Safety+profile+of+semagacestat%2C+a+gamma-secretase+inhibitor%3A+IDENTITY+trial+findings&doi=10.1185%2F03007995.2014.939167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings</span></div><div class="casAuthors">Henley, David B.; Sundell, Karen L.; Sethuraman, Gopalan; Dowsett, Sherie A.; May, Patrick C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2021-2032</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Objective: Semagacestat, a γ-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clin. development was halted.  To assist in future development of γ-secretase inhibitors, we report detailed safety findings from the IDENTITY study, with emphasis on those that might be mechanistically linked to γ-secretase inhibition.  Research design and methods: The IDENTITY trial was a double-blind, placebo-controlled trial of semagacestat (100 mg and 140 mg), in which 1537 patients age 55 years and older with probable Alzheimer's disease were randomized.  Treatment-emergent adverse events (TEAEs) are reported by body system along with pertinent lab., vital sign, and ECG findings.  Results: Semagacestat treatment was assocd. with increased reporting of suspected Notch-related adverse events (gastrointestinal, infection, and skin cancer related).  Other relevant safety findings assocd. with semagacestat treatment included cognitive and functional worsening, skin-related TEAEs, renal and hepatic changes, increased QT interval, and wt. loss.  With few exceptions, differences between semagacestat and placebo treatment groups were no longer significant after cessation of treatment with active drug.  Conclusions: Many of these safety findings can be attributed to γ-secretase inhibition, and may be valuable to researchers developing γ-secretase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC2ZGLarufNrVg90H21EOLACvtfcHk0ljX3iAJhHWfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Oktb3N&md5=7c2d61aafe7bbf26ce9d853d8b5f590a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1185%2F03007995.2014.939167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007995.2014.939167%26sid%3Dliteratum%253Aachs%26aulast%3DHenley%26aufirst%3DD.%2BB.%26aulast%3DSundell%26aufirst%3DK.%2BL.%26aulast%3DSethuraman%26aufirst%3DG.%26aulast%3DDowsett%26aufirst%3DS.%2BA.%26aulast%3DMay%26aufirst%3DP.%2BC.%26atitle%3DSafety%2520profile%2520of%2520semagacestat%252C%2520a%2520gamma-secretase%2520inhibitor%253A%2520IDENTITY%2520trial%2520findings%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2014%26volume%3D30%26spage%3D2021%26epage%3D2032%26doi%3D10.1185%2F03007995.2014.939167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morstorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, K.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease drug-development pipeline: few candidates, frequent failures</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi"> DOI: 10.1186/alzrt269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1186%2Falzrt269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=25024750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BC2cbisFWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=37&author=J.+L.+Cummingsauthor=T.+Morstorfauthor=K.+Zhong&title=Alzheimer%E2%80%99s+disease+drug-development+pipeline%3A+few+candidates%2C+frequent+failures&doi=10.1186%2Falzrt269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease drug-development pipeline: few candidates, frequent failures</span></div><div class="casAuthors">Cummings Jeffrey L; Zhong Kate; Morstorf Travis</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's research & therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">37</span>
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    </div><div class="casAbstract">INTRODUCTION:  Alzheimer's disease (AD) is increasing in frequency as the global population ages.  Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist.  We have an urgent need to find new therapies for AD.  METHODS:  We examined Clinicaltrials.gov, a public website that records ongoing clinical trials.  We examined the decade of 2002 to 2012, to better understand AD-drug development.  We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next.  We also reviewed the current AD therapy pipeline.  RESULTS:  During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials.  Seventy-eight percent were sponsored by pharmaceutical companies.  The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed.  The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%).  The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3.  Trials of disease-modifying agents are larger and longer than those for symptomatic agents.  A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure).  CONCLUSIONS:  The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem.  The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area.  The AD drug-development ecosystem requires support.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT__DMPwHFhGGPgL4LrC-0VfW6udTcc2eZJn_TVfGnfd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbisFWjtQ%253D%253D&md5=85b84800ce02d7031a4c1046e837e568</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Falzrt269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Falzrt269%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DMorstorf%26aufirst%3DT.%26aulast%3DZhong%26aufirst%3DK.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520drug-development%2520pipeline%253A%2520few%2520candidates%252C%2520frequent%2520failures%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D37%26doi%3D10.1186%2Falzrt269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. K.</span></span> <span> </span><span class="NLM_article-title">Phase II and phase III failures: 2013-2015</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fnrd.2016.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=27811931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslynsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=817-818&author=R.+K.+Harrison&title=Phase+II+and+phase+III+failures%3A+2013-2015&doi=10.1038%2Fnrd.2016.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II and phase III failures: 2013-2015</span></div><div class="casAuthors">Harrison, Richard K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">817-818</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This article analyses recent data on the reported causes of drug candidate attrition, which indicate that lack of efficacy is the reason for approx. half of all phase II and phase III failures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy7ibspDa6WLVg90H21EOLACvtfcHk0ljX3iAJhHWfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslynsLvN&md5=370ee63ca081ca3e958dc17e5315e140</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.184%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DR.%2BK.%26atitle%3DPhase%2520II%2520and%2520phase%2520III%2520failures%253A%25202013-2015%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D817%26epage%3D818%26doi%3D10.1038%2Fnrd.2016.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Godyń, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jończyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malawska, B.</span></span> <span> </span><span class="NLM_article-title">Therapeutic strategies for Alzheimer’s disease in clinical trials</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.pharep.2015.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fj.pharep.2015.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=26721364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=127-138&author=J.+Gody%C5%84author=J.+Jo%C5%84czykauthor=D.+Panekauthor=B.+Malawska&title=Therapeutic+strategies+for+Alzheimer%E2%80%99s+disease+in+clinical+trials&doi=10.1016%2Fj.pharep.2015.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies for Alzheimer's disease in clinical trials</span></div><div class="casAuthors">Godyn, Justyna; Jonczyk, Jakub; Panek, Dawid; Malawska, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-138</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is considered to be the most common cause of dementia and is an incurable, progressive neurodegenerative disorder.  Current treatment of the disease, essentially symptomatic, is based on three cholinesterase inhibitors and memantine, affecting the glutamatergic system.  Since 2003, no new drugs have been approved for treatment of AD.  This article presents current directions in the search for novel, potentially effective agents for the treatment of AD, as well as selected promising treatment strategies.  These include agents acting upon the beta-amyloid, such as vaccines, antibodies and inhibitors or modulators of γ- and β-secretase; agents directed against the tau protein as well as compds. acting as antagonists of neurotransmitter systems (serotoninergic 5-HT6 and histaminergic H3).  Ongoing clin. trials with Aβ antibodies (solanezumab, gantenerumab, crenezumab) seem to be promising, while vaccines against the tau protein (AADvac1 and ACI-35) are now in early-stage trials.  Interesting results have also been achieved in trials involving small mols. such as inhibitors of β-secretase (MK-8931, E2609), a combination of 5-HT6 antagonist (idalopirdine) with donepezil, inhibition of advanced glycation end product receptors by azeliragon or modulation of the acetylcholine response of α-7 nicotinic acetylcholine receptors by encenicline.  Development of new effective drugs acting upon the central nervous system is usually a difficult and time-consuming process, and in the case of AD to-date clin. trials have had a very high failure rate.  Most phase II clin. trials ending with a pos. outcome do not succeed in phase III, often due to serious adverse effects or lack of therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC2G55auOP27Vg90H21EOLACvtfcHk0ljX3iAJhHWfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKrsb0%253D&md5=e3f4010a5408a836683024db61164ae2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2015.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2015.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DGody%25C5%2584%26aufirst%3DJ.%26aulast%3DJo%25C5%2584czyk%26aufirst%3DJ.%26aulast%3DPanek%26aufirst%3DD.%26aulast%3DMalawska%26aufirst%3DB.%26atitle%3DTherapeutic%2520strategies%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520in%2520clinical%2520trials%26jtitle%3DPharmacol.%2520Rep.%26date%3D2016%26volume%3D68%26spage%3D127%26epage%3D138%26doi%3D10.1016%2Fj.pharep.2015.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brulet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β–secretase inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13042</span>, <span class="refDoi"> DOI: 10.1038/ncomms13042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fncomms13042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=27727204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13042&author=A.+M.+Zuhlauthor=C.+E.+Nolanauthor=M.+A.+Brodneyauthor=S.+Niessenauthor=K.+Atchisonauthor=C.+Houleauthor=D.+A.+Karanianauthor=C.+Ambroiseauthor=J.+W.+Bruletauthor=E.+M.+Beckauthor=S.+D.+Doranauthor=B.+T.+O%E2%80%99Neillauthor=C.+W.+Am+Endeauthor=C.+Changauthor=K.+F.+Geogheganauthor=G.+M.+Westauthor=J.+C.+Judkinsauthor=X.+Houauthor=D.+R.+Riddellauthor=D.+S.+Johnson&title=Chemoproteomic+profiling+reveals+that+cathepsin+D+off-target%C2%A0activity%C2%A0drives+ocular+toxicity+of%C2%A0%CE%B2%E2%80%93secretase+inhibitors&doi=10.1038%2Fncomms13042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span></div><div class="casAuthors">Zuhl, Andrea M.; Nolan, Charles E.; Brodney, Michael A.; Niessen, Sherry; Atchison, Kevin; Houle, Christopher; Karanian, David A.; Ambroise, Claude; Brulet, Jeffrey W.; Beck, Elizabeth M.; Doran, Shawn D.; O'Neill, Brian T.; am Ende, Christopher W.; Chang, Cheng; Geoghegan, Kieran F.; West, Graham M.; Judkins, Joshua C.; Hou, Xinjun; Riddell, David R.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13042</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease.  Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity in animal models, but the target mediating this toxicity has not been identified.  Here we use a clickable photoaffinity probe to identify cathepsin D (CatD) as a principal off-target of BACE1 inhibitors in human cells.  We find that several BACE1 inhibitors blocked CatD activity in cells with much greater potency than that displayed in cell-free assays with purified protein.  Through a series of exploratory toxicol. studies, we show that quantifying CatD target engagement in cells with the probe is predictive of ocular toxicity in vivo.  Taken together, our findings designate off-target inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally underscore the power of chem. proteomics for discerning mechanisms of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-LulGVRdJLVg90H21EOLACvtfcHk0liTrH55zRIw7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL&md5=5e2c31195f4f03babec561a5824ccb0d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fncomms13042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13042%26sid%3Dliteratum%253Aachs%26aulast%3DZuhl%26aufirst%3DA.%2BM.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKaranian%26aufirst%3DD.%2BA.%26aulast%3DAmbroise%26aufirst%3DC.%26aulast%3DBrulet%26aufirst%3DJ.%2BW.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DAm%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DWest%26aufirst%3DG.%2BM.%26aulast%3DJudkins%26aufirst%3DJ.%2BC.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DChemoproteomic%2520profiling%2520reveals%2520that%2520cathepsin%2520D%2520off-target%25C2%25A0activity%25C2%25A0drives%2520ocular%2520toxicity%2520of%25C2%25A0%25CE%25B2%25E2%2580%2593secretase%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13042%26doi%3D10.1038%2Fncomms13042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F. </span></span> <span> </span><span class="NLM_article-title">Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux</span>. <i>J Pharmacol Exp Ther</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.045260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1124%2Fjpet.102.045260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=12604685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1eisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2003&pages=1085-92&author=H.+Daiauthor=P.+Marbachauthor=M.+Lemaireauthor=M.+Hayesauthor=W.%C2%A0F.%C2%A0+Elmquist&title=Distribution+of+STI-571+to+the+brain+is+limited+by+P-glycoprotein-mediated+efflux&doi=10.1124%2Fjpet.102.045260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux</span></div><div class="casAuthors">Dai, Haiqing; Marbach, Peter; Lemaire, Michel; Hayes, Michael; Elmquist, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adequate distribution of STI-571 (Gleevec) to the central nervous system (CNS) is crit. for its effective use in CNS tumors.  P-glycoprotein-mediated efflux in the blood-brain barrier may play a role in the CNS delivery of this drug.  Whether STI-571 is a substrate of P-glycoprotein was detd. by examg. the directional flux of [14C]STI-571 in parental and MDR1-transfected Madin-Darby canine kidney (MDCK) II epithelial cell monolayers.  The basolateral-to-apical flux of STI-571 was 39-fold greater than the apical-to-basolateral flux in the MDR1-transfected cells and 8-fold greater in the parental cell monolayers.  This difference in directional flux was significantly reduced by a specific P-glycoprotein inhibitor (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzo- suber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline trihydrochloride (LY335979).  The role of P-glycoprotein in the CNS distribution of STI-571 was examd. in vivo, using wild-type and mdr1a/b (-/-) knockout mice that were orally administered 25 mg/kg [14C]STI-571.  In the wild-type mice, the brain-to-plasma STI-571 concn. ratio at all time points was low (1-3%); however, there was an 11-fold greater brain partitioning of STI-571 at 1 h postdose in the mdr1a/b (-/-) mice compared with the wild-type mice.  When 12.5 mg/kg STI-571 was given i.v., the brain-to-plasma ratio of STI-571 in the mdr1a/b (-/-) mice was approx. 7-fold greater than that of wild-type mice up to 120 min postdose.  These data indicate that STI-571 is a substrate of P-glycoprotein, and that the inhibition of P-glycoprotein affects the transport of STI-571 across MDCKII monolayers.  Moreover, P-glycoprotein plays an important role in limiting the distribution of STI-571 to the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF6vLgl-LGObVg90H21EOLACvtfcHk0liTrH55zRIw7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1eisrs%253D&md5=c4f1082f27454e16635d768ce337ce7f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.045260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.045260%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DH.%26aulast%3DMarbach%26aufirst%3DP.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DM.%26aulast%3DElmquist%26aufirst%3DW.%25C2%25A0F.%25C2%25A0%26atitle%3DDistribution%2520of%2520STI-571%2520to%2520the%2520brain%2520is%2520limited%2520by%2520P-glycoprotein-mediated%2520efflux%26jtitle%3DJ%2520Pharmacol%2520Exp%2520Ther%26date%3D2003%26volume%3D304%26spage%3D1085%26epage%3D92%26doi%3D10.1124%2Fjpet.102.045260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wielinga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tellingen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span> <span> </span><span class="NLM_article-title">The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of Imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2577</span>– <span class="NLM_lpage">2582</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-04-2416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1158%2F0008-5472.can-04-2416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=15805252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVeqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=2577-2582&author=P.+Breedveldauthor=D.+Pluimauthor=G.+Ciprianiauthor=P.+Wielingaauthor=O.+van+Tellingenauthor=A.+H.+Schinkelauthor=J.+H.+M.+Schellens&title=The+effect+of+Bcrp1+%28Abcg2%29+on+the+in+vivo+pharmacokinetics+and+brain+penetration+of+Imatinib+mesylate+%28Gleevec%29%3A+Implications+for+the+use+of+breast+cancer+resistance+protein+and+P-glycoprotein+inhibitors+to+enable+the+brain+penetration+of+imatinib+in+patients&doi=10.1158%2F0008-5472.can-04-2416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients</span></div><div class="casAuthors">Breedveld, Pauline; Pluim, Dick; Cipriani, Greta; Wielinga, Peter; Van Tellingen, Olaf; Schinkel, Alfred H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2577-2582</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Imatinib mesylate (signal transduction inhibitor 571, Gleevec) is a potent and selective tyrosine kinase inhibitor, which was shown to effectively inhibit platelet-derived growth factor-induced glioblastoma cell growth preclinically.  However, in patients, a limited penetration of imatinib into the brain has been reported.  Imatinib is transported in vitro and in vivo by P-glycoprotein (P-gp; ABCB1), which thereby limits its distribution into the brain in mice.  Previously, imatinib was shown to potently inhibit human breast cancer resistance protein (BCRP; ABCG2).  Here, the authors show that imatinib is efficiently transported by mouse Bcrp1 in transfected Madin-Darby canine kidney strain II (MDCKII) monolayers.  Furthermore, the authors show that the clearance of i.v. imatinib is significantly decreased 1.6-fold in Bcrp1 knockout mice compared with wild-type mice.  At t=2 h, the brain penetration of i.v. imatinib was significantly 2.5-fold increased in Bcrp1 knockout mice compared with control mice.  The authors tested the hypothesis that P-gp and BCRP inhibitors, such as elacridar and pantoprazole, improve the brain penetration of imatinib.  Firstly, the authors showed in vitro that pantoprazole and elacridar inhibit the Bcrp1-mediated transport of imatinib in MDCKII-Bcrp1 cells.  Secondly, the authors showed that coadministration of pantoprazole or elacridar significantly reduced the clearance of i.v. imatinib in wild-type mice by resp. 1.7-fold and 1.5-fold.  Finally, in wild-type mice treated with pantoprazole or elacridar, the brain penetration of i.v. imatinib significantly increased 1.8-fold and 4.2-fold, resp.  Moreover, the brain penetration of p.o. imatinib increased 5.2-fold when pantoprazole was coadministered in wild-type mice.  Our results suggest that coadministration of BCRP and P-gp inhibitors may improve delivery of imatinib to malignant gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYrfIvN18z9rVg90H21EOLACvtfcHk0ljwhN0YNyusWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVeqs70%253D&md5=8520878a8f3082eb735ea0edd12ed4ad</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-04-2416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-04-2416%26sid%3Dliteratum%253Aachs%26aulast%3DBreedveld%26aufirst%3DP.%26aulast%3DPluim%26aufirst%3DD.%26aulast%3DCipriani%26aufirst%3DG.%26aulast%3DWielinga%26aufirst%3DP.%26aulast%3Dvan%2BTellingen%26aufirst%3DO.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DThe%2520effect%2520of%2520Bcrp1%2520%2528Abcg2%2529%2520on%2520the%2520in%2520vivo%2520pharmacokinetics%2520and%2520brain%2520penetration%2520of%2520Imatinib%2520mesylate%2520%2528Gleevec%2529%253A%2520Implications%2520for%2520the%2520use%2520of%2520breast%2520cancer%2520resistance%2520protein%2520and%2520P-glycoprotein%2520inhibitors%2520to%2520enable%2520the%2520brain%2520penetration%2520of%2520imatinib%2520in%2520patients%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D2577%26epage%3D2582%26doi%3D10.1158%2F0008-5472.can-04-2416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arslanova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augelli-Szafran, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span> <span> </span><span class="NLM_article-title">Phenotypic analysis of images of zebrafish treated with Alzheimer’s gamma-secretase inhibitors</span>. <i>BMC Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi"> DOI: 10.1186/1472-6750-10-24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1186%2F1472-6750-10-24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=20307292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ksl2gtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=24&author=D.+Arslanovaauthor=T.+Yangauthor=X.+Xuauthor=S.+T.+Wongauthor=C.+E.+Augelli-Szafranauthor=W.+Xia&title=Phenotypic+analysis+of+images+of+zebrafish+treated+with+Alzheimer%E2%80%99s+gamma-secretase+inhibitors&doi=10.1186%2F1472-6750-10-24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors</span></div><div class="casAuthors">Arslanova Dilyara; Yang Ting; Xu Xiaoyin; Wong Stephen T; Augelli-Szafran Corinne E; Xia Weiming</div><div class="citationInfo"><span class="NLM_cas:title">BMC biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Several gamma-secretase inhibitors (GSI) are in clinical trials for the treatment of Alzheimer's disease (AD).  This enzyme mediates the proteolytic cleavage of amyloid precursor protein (APP) to generate amyloid beta protein, Abeta, the pathogenic protein in AD.  The gamma-secretase also cleaves Notch to generate Notch Intracellular domain (NICD), the signaling molecule that is implicated in tumorigenesis.  RESULTS:  We have developed a method to examine live zebrafish that were each treated with gamma-secretase inhibitors (GSI), DAPT {N- [N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester}, Gleevec, or fragments of Gleevec.  These compounds were first tested in a cell-based assay and the effective concentrations of these compounds that blocked Abeta generation were quantitated.  The mortality of zebrafish, as a result of exposure to different doses of compound, was assessed, and any apoptotic processes were examined by TUNEL staining.  We then used conventional and automatic microscopes to acquire images of zebrafish and applied algorithms to automate image composition and processing.  Zebrafish were treated in 96- or 384-well plates, and the phenotypes were analyzed at 2, 3 and 5 days post fertilization (dpf).  We identified that AD95, a fragment of Gleevec, effectively blocks Abeta production and causes specific phenotypes that were different from those treated with DAPT.  Finally, we validated the specificity of two Notch phenotypes (pigmentation and the curvature of tail/trunk) induced by DAPT in a dose-dependent manner.  These phenotypes were examined in embryos treated with GSIs or AD95 at increasing concentrations.  The expression levels of Notch target gene her6 were also measured by in situ hybridization and the co-relationship between the levels of Notch inhibition by DAPT and AD95 and the severity of phenotypes were determined.  CONCLUSION:  The results reported here of the effects on zebrafish suggest that this newly developed method may be used to screen novel GSIs and other leads for a variety of therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlZYYPOqVJroIRAdBLKY41fW6udTcc2eZY0SNgrI7uw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ksl2gtQ%253D%253D&md5=5bcf8f13b2f09508aa273257c53ddf00</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1186%2F1472-6750-10-24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6750-10-24%26sid%3Dliteratum%253Aachs%26aulast%3DArslanova%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DS.%2BT.%26aulast%3DAugelli-Szafran%26aufirst%3DC.%2BE.%26aulast%3DXia%26aufirst%3DW.%26atitle%3DPhenotypic%2520analysis%2520of%2520images%2520of%2520zebrafish%2520treated%2520with%2520Alzheimer%25E2%2580%2599s%2520gamma-secretase%2520inhibitors%26jtitle%3DBMC%2520Biotechnol.%26date%3D2010%26volume%3D10%26spage%3D24%26doi%3D10.1186%2F1472-6750-10-24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein recognition of substrates and circumvention through rational drug design</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1021/mp0500871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp0500871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlagu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=3-25&author=T.+J.+Raub&title=P-Glycoprotein+recognition+of+substrates+and+circumvention+through+rational+drug+design&doi=10.1021%2Fmp0500871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">P-Glycoprotein Recognition of Substrates and Circumvention through Rational Drug Design</span></div><div class="casAuthors">Raub, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now well recognized that membrane efflux transporters, esp. P-glycoprotein (P-gp; ABCB1), play a role in detg. the absorption, distribution, metab., excretion, and toxicol. behaviors of some drugs and mols. in development.  An investment in screening structure-activity relation (SAR) is warranted in early discovery when exposure and/or target activity in an in vivo efficacy model is not achieved and P-gp efflux is identified as a rate-limiting factor.  However, the amt. of investment in SAR must be placed into perspective by assessing the risks assocd. with the intended therapeutic target, the potency and margin of safety of the compd., the intended patient population(s), and the market competition.  The task of rationally designing a chem. strategy for circumventing a limiting P-gp interaction can be daunting.  The necessity of retaining biol. potency and metabolic stability places restrictions on what can be done, and the factors for P-gp recognition of substrates are complicated and poorly understood.  The parameters within the assays that affect overall pump efficiency or net efflux, such as passive diffusion, membrane partitioning, and mol. interaction between pump and substrate, should be understood when interpreting data sets assocd. with chem. around a scaffold.  No single, functional group alone is often the cause, but one group can accentuate the recognition points existing within a scaffold.  This can be likened to a rheostat, rather than an on/off switch, where addn. or removal of a key group can increase or decrease the pumping efficiency.  The most practical approach to de-emphasize the limiting effects of P-gp on a particular scaffold is to increase passive diffusion.  Efflux pumping efficiency may be overcome when passive diffusion is fast enough.  Eliminating, or substituting with fewer, groups that solvate in water, or decreasing their hydrogen bonding capacity, and adding halogen groups can increase passive diffusion.  Reducing mol. size, replacing electroneg. atoms, blocking or masking H-bond donors with N-alkylation or bulky flanking groups, introducing constrained conformation, or by promoting intramol. hydrogen bonds are all examples of steps to take.  This review discusses our understanding of how P-gp recognizes and pumps compds. as substrates and describes cases where structural changes were made in a chem. scaffold to circumvent the effects of P-gp interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRbEgPosNnxrVg90H21EOLACvtfcHk0ljwhN0YNyusWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlagu7%252FP&md5=cc89be920dfa0e32edb994be94626aa5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fmp0500871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0500871%26sid%3Dliteratum%253Aachs%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26atitle%3DP-Glycoprotein%2520recognition%2520of%2520substrates%2520and%2520circumvention%2520through%2520rational%2520drug%2520design%26jtitle%3DMol.%2520Pharm.%26date%3D2006%26volume%3D3%26spage%3D3%26epage%3D25%26doi%3D10.1021%2Fmp0500871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deadman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkin, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxendale, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span> <span> </span><span class="NLM_article-title">The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1766</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1039/c2ob27003j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1039%2Fc2ob27003j" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1766-1800&author=B.+J.+Deadmanauthor=M.+D.+Hopkinauthor=I.+R.+Baxendaleauthor=S.+V.+Ley&title=The+synthesis+of+Bcr-Abl+inhibiting+anticancer+pharmaceutical+agents+imatinib%2C+nilotinib+and+dasatinib&doi=10.1039%2Fc2ob27003j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2Fc2ob27003j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob27003j%26sid%3Dliteratum%253Aachs%26aulast%3DDeadman%26aufirst%3DB.%2BJ.%26aulast%3DHopkin%26aufirst%3DM.%2BD.%26aulast%3DBaxendale%26aufirst%3DI.%2BR.%26aulast%3DLey%26aufirst%3DS.%2BV.%26atitle%3DThe%2520synthesis%2520of%2520Bcr-Abl%2520inhibiting%2520anticancer%2520pharmaceutical%2520agents%2520imatinib%252C%2520nilotinib%2520and%2520dasatinib%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D1766%26epage%3D1800%26doi%3D10.1039%2Fc2ob27003j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lgN_ORQWulHgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed Suzuki–Miyaura cross-coupling reactions employing dialkylbiaryl phosphine ligands</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1461</span>– <span class="NLM_lpage">1473</span>, <span class="refDoi"> DOI: 10.1021/ar800036s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar800036s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVejs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=1461-1473&author=R.+Martinauthor=S.+L.+Buchwald&title=Palladium-catalyzed+Suzuki%E2%80%93Miyaura+cross-coupling+reactions+employing+dialkylbiaryl+phosphine+ligands&doi=10.1021%2Far800036s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Suzuki-Miyaura Cross-Coupling Reactions Employing Dialkylbiaryl Phosphine Ligands</span></div><div class="casAuthors">Martin, Ruben; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1461-1473</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review presents the recent advances in palladium-catalyzed Suzuki-Miyaura cross-coupling reactions using dialkylbiaryl phosphine ligands.  The cores of many types of polymers, ligands, natural products, and pharmaceuticals contain biaryl or substituted arom. structures, and efficient methods of synthesizing these structures are crucial to the work of a broad spectrum of org. chemists.  Recently, Pd-catalyzed carbon-carbon bond-forming processes, particularly the Suzuki-Miyaura cross-coupling reaction (SMC), have risen in popularity for this purpose.  The SMC has many advantages over other methods for constructing these moieties, including mild conditions, high tolerance toward functional groups, the com. availability and stability of its reagents, and the ease of handling and sepg. byproducts from its reaction mixts.Until 1998, most catalysts for the SMC employed triarylphosphine ligands.  More recently, new bulky and electron-rich phosphine ligands, which can dramatically improve the efficiency and selectivity of such cross-coupling reactions, have been introduced.  In the course of our studies on carbon-nitrogen bond-forming reactions, we found that the use of electron-rich and bulky phosphines enhanced the rate of both the oxidative addn. and reductive elimination processes; this was the beginning of our development of a new family of ligands, the dialkylbiarylphosphines.  These ligands can be used for a wide variety of palladium-catalyzed carbon-carbon, carbon-nitrogen, and carbon-oxygen bond-forming processes as well as serving as supporting ligands for a no. of other reactions.  The enhanced reactivity of these catalysts has expanded the scope of cross-coupling partners that can be employed in the SMC.  With use of such dialkylbiarylphosphine ligands, the coupling of unactivated aryl chlorides, aryl tosylates, heteroaryl systems, and very hindered substrate combinations have become routine.  The utility of these ligands has been successfully demonstrated in a wide no. of synthetic applications, including industrially relevant processes.  We discuss our studies on the mechanistic framework of the reaction, which have allowed us to rationally modify the ligand structures in order to tune their properties.  We also describe selected applications in the synthesis of natural products and new materials to illustrate the utility of these dialkylbiarylphosphine ligands in various "real-world" synthetic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2cmzKPXhqBbVg90H21EOLACvtfcHk0lgN_ORQWulHgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVejs7c%253D&md5=91dad4ee8d7e21c5fee36b1f10cf054a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Far800036s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far800036s%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-catalyzed%2520Suzuki%25E2%2580%2593Miyaura%2520cross-coupling%2520reactions%2520employing%2520dialkylbiaryl%2520phosphine%2520ligands%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D1461%26epage%3D1473%26doi%3D10.1021%2Far800036s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whelligan, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelder, S.</span></span> <span> </span><span class="NLM_article-title">Two-step synthesis of aza- and diazaindoles from chloroamino-N-heterocycles using ethoxyvinylborolane</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1021/jo902143f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo902143f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=11-15&author=D.+K.+Whelliganauthor=D.+W.+Thomsonauthor=D.+Taylorauthor=S.+Hoelder&title=Two-step+synthesis+of+aza-+and+diazaindoles+from+chloroamino-N-heterocycles+using+ethoxyvinylborolane&doi=10.1021%2Fjo902143f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjo902143f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo902143f%26sid%3Dliteratum%253Aachs%26aulast%3DWhelligan%26aufirst%3DD.%2BK.%26aulast%3DThomson%26aufirst%3DD.%2BW.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DTwo-step%2520synthesis%2520of%2520aza-%2520and%2520diazaindoles%2520from%2520chloroamino-N-heterocycles%2520using%2520ethoxyvinylborolane%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26spage%3D11%26epage%3D15%26doi%3D10.1021%2Fjo902143f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bihorel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camenisch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrmann, J.-M.</span></span> <span> </span><span class="NLM_article-title">Influence of breast cancer resistance protein (Abcg2) and P-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec ) across the mouse blood-brain barrier</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1749</span>– <span class="NLM_lpage">1757</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2007.04808.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1111%2Fj.1471-4159.2007.04808.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=17696988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyksLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2007&pages=1749-1757&author=S.+Bihorelauthor=G.+Camenischauthor=M.+Lemaireauthor=J.-M.+Scherrmann&title=Influence+of+breast+cancer+resistance+protein+%28Abcg2%29+and+P-glycoprotein+%28Abcb1a%29+on+the+transport+of+imatinib+mesylate+%28Gleevec+%29+across+the+mouse+blood-brain+barrier&doi=10.1111%2Fj.1471-4159.2007.04808.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier</span></div><div class="casAuthors">Bihorel, Sebastien; Camenisch, Gian; Lemaire, Michel; Scherrmann, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1749-1757</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib, a protein tyrosine kinase inhibitor, may prevent the growth of glioblastoma cells.  Unfortunately, its brain distribution is restricted by p-glycoprotein (p-gp or multidrug resistance protein Mdr1a), and probably by breast cancer resistance protein (Bcrp1), two efflux pumps expressed at the blood-brain barrier (BBB).  We have used in situ brain perfusion to investigate the mechanisms of imatinib transport across the mouse BBB.  The brain uptake of imatinib in wild-type mice was limited by saturable efflux processes.  The inhibition of p-gp, by valspodar and zosuquidar, increased imatinib uptake (2.5-fold), as did the deficiency of p-gp in Mdr1a/1b(-/-) mice (5.5-fold).  Perfusing imatinib with the p-gp/Bcrp1 inhibitor, elacridar, enhanced the brain uptake of imatinib in wild-type (4.1-fold) and Mdr1a/1b(-/-) mice (1.2-fold).  However, the brain uptake of imatinib was similar in wild-type and Bcrp1(-/-) mice when it was perfused at a non-satg. concn.  The brain uptake of CGP74588, an active metabolite of imatinib, was low.  It was increased by perfusion with elacridar (twofold), but not with valspodar and zosuquidar.  CGP74588 uptake was 1.5 times greater in Bcrp1(-/-) mice than in wild-type mice.  These data suggest that imatinib transport at the mouse BBB is limited by p-gp and probably by Bcrp1, and that CGP74588 transport is restricted by Bcrp1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBJv07PgbrC7Vg90H21EOLACvtfcHk0lgN_ORQWulHgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyksLbN&md5=b3a6dccbdcb2649ac691e1259f0ab8ee</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2007.04808.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2007.04808.x%26sid%3Dliteratum%253Aachs%26aulast%3DBihorel%26aufirst%3DS.%26aulast%3DCamenisch%26aufirst%3DG.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DScherrmann%26aufirst%3DJ.-M.%26atitle%3DInfluence%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528Abcg2%2529%2520and%2520P-glycoprotein%2520%2528Abcb1a%2529%2520on%2520the%2520transport%2520of%2520imatinib%2520mesylate%2520%2528Gleevec%2520%2529%2520across%2520the%2520mouse%2520blood-brain%2520barrier%26jtitle%3DJ.%2520Neurochem.%26date%3D2007%26volume%3D102%26spage%3D1749%26epage%3D1757%26doi%3D10.1111%2Fj.1471-4159.2007.04808.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Netzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flajolet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span> <span> </span><span class="NLM_article-title">Lowering β-amyloid levels rescues learning and memory in a down syndrome mouse model</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e10943</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0010943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1371%2Fjournal.pone.0010943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=20532168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&author=W.+J.+Netzerauthor=C.+Powellauthor=Y.+Nongauthor=J.+Blundellauthor=L.+Wongauthor=K.+Duffauthor=M.+Flajoletauthor=P.+Greengard&title=Lowering+%CE%B2-amyloid+levels+rescues+learning+and+memory+in+a+down+syndrome+mouse+model&doi=10.1371%2Fjournal.pone.0010943"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0010943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0010943%26sid%3Dliteratum%253Aachs%26aulast%3DNetzer%26aufirst%3DW.%2BJ.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DNong%26aufirst%3DY.%26aulast%3DBlundell%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DDuff%26aufirst%3DK.%26aulast%3DFlajolet%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26atitle%3DLowering%2520%25CE%25B2-amyloid%2520levels%2520rescues%2520learning%2520and%2520memory%2520in%2520a%2520down%2520syndrome%2520mouse%2520model%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26doi%3D10.1371%2Fjournal.pone.0010943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaedal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulem, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudbjartsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhangale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenlocher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palotie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span> <span> </span><span class="NLM_article-title">A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1038/nature11283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1038%2Fnature11283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=22801501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=96-99&author=T.+Jonssonauthor=J.+K.+Atwalauthor=S.+Steinbergauthor=J.+Snaedalauthor=P.+V.+Jonssonauthor=S.+Bjornssonauthor=H.+Stefanssonauthor=P.+Sulemauthor=D.+Gudbjartssonauthor=J.+Maloneyauthor=K.+Hoyteauthor=A.+Gustafsonauthor=Y.+Liuauthor=Y.+Luauthor=T.+Bhangaleauthor=R.+R.+Grahamauthor=J.+Huttenlocherauthor=G.+Bjornsdottirauthor=O.+A.+Andreassenauthor=E.+G.+J%C3%B6nssonauthor=A.+Palotieauthor=T.+W.+Behrensauthor=O.+T.+Magnussonauthor=A.+Kongauthor=U.+Thorsteinsdottirauthor=R.+J.+Wattsauthor=K.+Stefansson&title=A+mutation+in+APP+protects+against+Alzheimer%E2%80%99s+disease+and+age-related+cognitive+decline&doi=10.1038%2Fnature11283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in APP protects against Alzheimer's disease and age-related cognitive decline</span></div><div class="casAuthors">Jonsson, Thorlakur; Atwal, Jasvinder K.; Steinberg, Stacy; Snaedal, Jon; Jonsson, Palmi V.; Bjornsson, Sigurbjorn; Stefansson, Hreinn; Sulem, Patrick; Gudbjartsson, Daniel; Maloney, Janice; Hoyte, Kwame; Gustafson, Amy; Liu, Yichin; Lu, Yanmei; Bhangale, Tushar; Graham, Robert R.; Huttenlocher, Johanna; Bjornsdottir, Gyda; Andreassen, Ole A.; Joensson, Erik G.; Palotie, Aarno; Behrens, Timothy W.; Magnusson, Olafur T.; Kong, Augustine; Thorsteinsdottir, Unnur; Watts, Ryan J.; Stefansson, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7409</span>),
    <span class="NLM_cas:pages">96-99</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The prevalence of dementia in the Western world in people over the age of 60 has been estd. to be greater than 5%, about two-thirds of which are due to Alzheimer's disease.  The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3).  Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1795 Icelanders.  We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease.  This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approx. 40% redn. in the formation of amyloidogenic peptides in vitro.  The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease.  Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4AFwQCLRQOLVg90H21EOLACvtfcHk0lj1PnCIHi8e0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M&md5=4db9cb2e3842d5a9d4af4ce102249b70</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnature11283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11283%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DT.%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DSnaedal%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DP.%2BV.%26aulast%3DBjornsson%26aufirst%3DS.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSulem%26aufirst%3DP.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DHoyte%26aufirst%3DK.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBhangale%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DR.%2BR.%26aulast%3DHuttenlocher%26aufirst%3DJ.%26aulast%3DBjornsdottir%26aufirst%3DG.%26aulast%3DAndreassen%26aufirst%3DO.%2BA.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DE.%2BG.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DThorsteinsdottir%26aufirst%3DU.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DA%2520mutation%2520in%2520APP%2520protects%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520age-related%2520cognitive%2520decline%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D96%26epage%3D99%26doi%3D10.1038%2Fnature11283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edward, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuewen JoAnn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youping, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, T. C.</span></span> <span> </span><span class="NLM_article-title">Applications of high throughput microsomal stability assay in drug discovery</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.2174/138620708784911429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.2174%2F138620708784911429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=18673274" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=469-476&author=D.+Liauthor=H.+K.+Edwardauthor=M.+Xuewen+JoAnnauthor=H.+Youpingauthor=T.+C.+Guy&title=Applications+of+high+throughput+microsomal+stability+assay+in+drug+discovery&doi=10.2174%2F138620708784911429"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F138620708784911429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620708784911429%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DEdward%26aufirst%3DH.%2BK.%26aulast%3DXuewen%2BJoAnn%26aufirst%3DM.%26aulast%3DYouping%26aufirst%3DH.%26aulast%3DGuy%26aufirst%3DT.%2BC.%26atitle%3DApplications%2520of%2520high%2520throughput%2520microsomal%2520stability%2520assay%2520in%2520drug%2520discovery%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2008%26volume%3D11%26spage%3D469%26epage%3D476%26doi%3D10.2174%2F138620708784911429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, D. A.</span></span> <span> </span><span class="NLM_article-title">Small molecule quantification by liquid chromatography-mass spectrometry for metabolites of drugs and drug candidates</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2355</span>– <span class="NLM_lpage">2360</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1124%2Fdmd.111.040865" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2355-2360&author=U.+P.+Dahalauthor=J.+P.+Jonesauthor=J.+A.+Davisauthor=D.+A.+Rock&title=Small+molecule+quantification+by+liquid+chromatography-mass+spectrometry+for+metabolites+of+drugs+and+drug+candidates&doi=10.1124%2Fdmd.111.040865"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040865%26sid%3Dliteratum%253Aachs%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DJones%26aufirst%3DJ.%2BP.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DRock%26aufirst%3DD.%2BA.%26atitle%3DSmall%2520molecule%2520quantification%2520by%2520liquid%2520chromatography-mass%2520spectrometry%2520for%2520metabolites%2520of%2520drugs%2520and%2520drug%2520candidates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2355%26epage%3D2360%26doi%3D10.1124%2Fdmd.111.040865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paniagua, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomooka, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, W. H.</span></span> <span> </span><span class="NLM_article-title">Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">2633</span>– <span class="NLM_lpage">2642</span>, <span class="refDoi"> DOI: 10.1172/jci28546.</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1172%2Fjci28546." title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=2633-2642&author=R.+T.+Paniaguaauthor=O.+Sharpeauthor=P.+P.+Hoauthor=S.+M.+Chanauthor=A.+Changauthor=J.+P.+Higginsauthor=B.+H.+Tomookaauthor=F.+M.+Thomasauthor=J.+J.+Songauthor=S.+B.+Goodmanauthor=D.+M.+Leeauthor=M.+C.+Genoveseauthor=P.+J.+Utzauthor=L.+Steinmanauthor=W.+H.+Robinson&title=Selective+tyrosine+kinase+inhibition+by+imatinib+mesylate+for+the+treatment+of+autoimmune+arthritis&doi=10.1172%2Fjci28546."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1172%2Fjci28546.&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci28546.%26sid%3Dliteratum%253Aachs%26aulast%3DPaniagua%26aufirst%3DR.%2BT.%26aulast%3DSharpe%26aufirst%3DO.%26aulast%3DHo%26aufirst%3DP.%2BP.%26aulast%3DChan%26aufirst%3DS.%2BM.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DHiggins%26aufirst%3DJ.%2BP.%26aulast%3DTomooka%26aufirst%3DB.%2BH.%26aulast%3DThomas%26aufirst%3DF.%2BM.%26aulast%3DSong%26aufirst%3DJ.%2BJ.%26aulast%3DGoodman%26aufirst%3DS.%2BB.%26aulast%3DLee%26aufirst%3DD.%2BM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DUtz%26aufirst%3DP.%2BJ.%26aulast%3DSteinman%26aufirst%3DL.%26aulast%3DRobinson%26aufirst%3DW.%2BH.%26atitle%3DSelective%2520tyrosine%2520kinase%2520inhibition%2520by%2520imatinib%2520mesylate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D2633%26epage%3D2642%26doi%3D10.1172%2Fjci28546." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Alloza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Nunes, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betensky, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prada, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacskai, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frosch, M. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2006.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fj.nbd.2006.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=17029828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cmt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=516-524&author=M.+Garcia-Allozaauthor=E.+M.+Robbinsauthor=S.+X.+Zhang-Nunesauthor=S.+M.+Purcellauthor=R.+A.+Betenskyauthor=S.+Rajuauthor=C.+Pradaauthor=S.+M.+Greenbergauthor=B.+J.+Bacskaiauthor=M.+P.+Frosch&title=Characterization+of+amyloid+deposition+in+the+APPswe%2FPS1dE9+mouse+model+of+Alzheimer+disease&doi=10.1016%2Fj.nbd.2006.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease</span></div><div class="casAuthors">Garcia-Alloza, Monica; Robbins, Elissa M.; Zhang-Nunes, Sandy X.; Purcell, Susan M.; Betensky, Rebecca A.; Raju, Susan; Prada, Claudia; Greenberg, Steven M.; Bacskai, Brian J.; Frosch, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">516-524</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Transgenic mice carrying disease-linked forms of genes assocd. with Alzheimer disease often demonstrate deposition of the β-amyloid as senile plaques and cerebral amyloid angiopathy.  We have characterized the natural history of β-amyloid deposition in APPswe/PS1dE9 mice, a particularly aggressive transgenic mouse model generated with mutant transgenes for APP (APPswe: KM594/5NL) and PS1 (dE9: deletion of exon 9).  Ex vivo histochem. showed Aβ deposition by 4 mo with a progressive increase in plaque no. up to 12 mo and a similar increase of Aβ levels.  In vivo multiphoton microscopy at weekly intervals showed increasing β-amyloid deposition as CAA and plaques.  Although first appearing at an early age, CAA progressed at a significantly slower rate than in the Tg2576 mice.  The consistent and early onset of β-amyloid accumulation in the APPswe/PS1dE9 model confirms its utility for studies of biochem. and pathol. mechanisms underlying β-amyloid deposition, as well as exploring new therapeutic treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMkcjJYjASbLVg90H21EOLACvtfcHk0lgqpjLZN8z05w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cmt7rI&md5=14fb7f1d39747a0bb5b132f5f2e90613</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2006.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2006.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Alloza%26aufirst%3DM.%26aulast%3DRobbins%26aufirst%3DE.%2BM.%26aulast%3DZhang-Nunes%26aufirst%3DS.%2BX.%26aulast%3DPurcell%26aufirst%3DS.%2BM.%26aulast%3DBetensky%26aufirst%3DR.%2BA.%26aulast%3DRaju%26aufirst%3DS.%26aulast%3DPrada%26aufirst%3DC.%26aulast%3DGreenberg%26aufirst%3DS.%2BM.%26aulast%3DBacskai%26aufirst%3DB.%2BJ.%26aulast%3DFrosch%26aufirst%3DM.%2BP.%26atitle%3DCharacterization%2520of%2520amyloid%2520deposition%2520in%2520the%2520APPswe%252FPS1dE9%2520mouse%2520model%2520of%2520Alzheimer%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2006%26volume%3D24%26spage%3D516%26epage%3D524%26doi%3D10.1016%2Fj.nbd.2006.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Grijalba, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarasa, M.</span></span> <span> </span><span class="NLM_article-title">Optimized protocol for amyloid-β extraction from the brain</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">839</span>, <span class="refDoi"> DOI: 10.3233/jad-121798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.3233%2Fjad-121798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=23302653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFOhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=835-839&author=M.+Izcoauthor=P.+Pesiniauthor=V.+P%C3%A9rez-Grijalbaauthor=N.+Fandosauthor=M.+Sarasa&title=Optimized+protocol+for+amyloid-%CE%B2+extraction+from+the+brain&doi=10.3233%2Fjad-121798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Protocol for Amyloid-β Extraction from the Brain</span></div><div class="casAuthors">Izco, Maria; Pesini, Pedro; Perez-Grijalba, Virginia; Fandos, Noelia; Sarasa, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">835-839</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Brain levels of amyloid-β (Aβ) are frequently assessed in transgenic mice models of Alzheimer's disease.  The procedure involves tissue sample homogenization using different buffers in a sequential process.  No attempt has been made to assess if these procedures are able to ext. the total amt. of Aβ present in the samples.  Here we present data suggesting that std. protocols can lead to a dramatic underestimation of the Aβ content.  Results show that higher extn. buffer vols. and at least two repetitions of the sol. and membrane-bound extn. steps are necessary for a more accurate estn. of the Aβ content in brain tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_FFoRjzy2kLVg90H21EOLACvtfcHk0lgqpjLZN8z05w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFOhtrc%253D&md5=d0e3833cd714239f8fcbc72501823c68</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3233%2Fjad-121798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252Fjad-121798%26sid%3Dliteratum%253Aachs%26aulast%3DIzco%26aufirst%3DM.%26aulast%3DPesini%26aufirst%3DP.%26aulast%3DP%25C3%25A9rez-Grijalba%26aufirst%3DV.%26aulast%3DFandos%26aufirst%3DN.%26aulast%3DSarasa%26aufirst%3DM.%26atitle%3DOptimized%2520protocol%2520for%2520amyloid-%25CE%25B2%2520extraction%2520from%2520the%2520brain%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2013%26volume%3D34%26spage%3D835%26epage%3D839%26doi%3D10.3233%2Fjad-121798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nebot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crettol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Esposito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tattam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span> <span> </span><span class="NLM_article-title">Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00946.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1111%2Fj.1476-5381.2010.00946.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=20977456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2ms7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=1059-1069&author=N.+Nebotauthor=S.+Crettolauthor=F.+d%E2%80%99Espositoauthor=B.+Tattamauthor=D.+E.+Hibbsauthor=M.+Murray&title=Participation+of+CYP2C8+and+CYP3A4+in+the+N-demethylation+of+imatinib+in+human+hepatic+microsomes&doi=10.1111%2Fj.1476-5381.2010.00946.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes</span></div><div class="casAuthors">Nebot, Noelia; Crettol, Severine; d'Esposito, Fabrizio; Tattam, Bruce; Hibbs, David E.; Murray, Michael</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1059-1069</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Imatinib is a clin. important inhibitor of tyrosine kinases that are dysregulated in chronic myelogenous leukemia and gastrointestinal stromal tumors.  Inter-individual variation in imatinib pharmacokinetics is extensive, and influences drug safety and efficacy.  Hepatic cytochrome P 450 (CYP) 3A4 was implicated in imatinib N-demethylation, but the clearance of imatinib decreases during prolonged therapy.  CYP3A phenotype correlates with imatinib clearance at the commencement of therapy, but not at steady state.  The present study evaluated the possibility that multiple CYPs may contribute to imatinib oxidn. in liver.  Imatinib biotransformation in human liver microsomes (n = 20) and by cDNA-expressed CYPs was detd. by LC-MS.  Relationships between imatinib N-demethylation and other drug metabolizing CYPs were assessed.  N-desmethylimatinib formation was correlated with microsomal oxidn. of the CYP3A4 substrates testosterone (p = 0.60; P < 0.01) and midazolam (p = 0.46; P < 0.05), and the CYP2C8 substrate paclitaxel (p = 0.58; P < 0.01).  CDNA-derived CYPs 2C8, 3A4, 3A5 and 3A7 supported imatinib N-demethylation, but 10 other CYPs were inactive; in kinetic studies, CYP2C8 was a high-affinity enzyme with a catalytic efficiency ∼15-fold greater than those of CYPs 3A4 and 3A5.  The CYP3A inhibitors ketoconazole and troleandomycin, and the CYP2C8 inhibitors quercetin and paclitaxel decreased imatinib oxidn.  From mol. modeling, the imatinib structure could be superimposed on a pharmacophore for CYP2C8 substrates.  CYP2C8 and CYPs 3A contribute to imatinib N-demethylation in human liver.  The involvement of CYP2C8 may account in part for the wide inter-patient variation in imatinib pharmacokinetics obsd. in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq6dSh2LX9GLVg90H21EOLACvtfcHk0liT5O8GAJJVoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2ms7jL&md5=af09256169b40b8fb106e790efac719c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00946.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00946.x%26sid%3Dliteratum%253Aachs%26aulast%3DNebot%26aufirst%3DN.%26aulast%3DCrettol%26aufirst%3DS.%26aulast%3Dd%25E2%2580%2599Esposito%26aufirst%3DF.%26aulast%3DTattam%26aufirst%3DB.%26aulast%3DHibbs%26aufirst%3DD.%2BE.%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DParticipation%2520of%2520CYP2C8%2520and%2520CYP3A4%2520in%2520the%2520N-demethylation%2520of%2520imatinib%2520in%2520human%2520hepatic%2520microsomes%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D1059%26epage%3D1069%26doi%3D10.1111%2Fj.1476-5381.2010.00946.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jack, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiste, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigand, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankratz, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span> <span> </span><span class="NLM_article-title">Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1016/s1474-4422(12)70291-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fs1474-4422%2812%2970291-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=23332364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=207-216&author=C.+R.+Jackauthor=D.+S.+Knopmanauthor=W.+J.+Jagustauthor=R.+C.+Petersenauthor=M.+W.+Weinerauthor=P.+S.+Aisenauthor=L.+M.+Shawauthor=P.+Vemuriauthor=H.+J.+Wisteauthor=S.+D.+Weigandauthor=T.+G.+Lesnickauthor=V.+S.+Pankratzauthor=M.+C.+Donohueauthor=J.+Q.+Trojanowski&title=Tracking+pathophysiological+processes+in+Alzheimer%E2%80%99s+disease%3A+an+updated+hypothetical+model+of+dynamic+biomarkers&doi=10.1016%2Fs1474-4422%2812%2970291-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers</span></div><div class="casAuthors">Jack, Clifford R.; Knopman, David S.; Jagust, William J.; Petersen, Ronald C.; Weiner, Michael W.; Aisen, Paul S.; Shaw, Leslie M.; Vemuri, Prashanthi; Wiste, Heather J.; Weigand, Stephen D.; Lesnick, Timothy G.; Pankratz, Vernon S.; Donohue, Michael C.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In 2010, we put forward a hypothetical model of the major biomarkers of Alzheimer's disease (AD).  The model was received with interest because we described the temporal evolution of AD biomarkers in relation to each other and to the onset and progression of clin. symptoms.  Since then, evidence has accumulated that supports the major assumptions of this model.  Evidence has also appeared that challenges some of our assumptions, which has allowed us to modify our original model.  Refinements to our model include indexing of individuals by time rather than clin. symptom severity; incorporation of interindividual variability in cognitive impairment assocd. with progression of AD pathophysiol.; modifications of the specific temporal ordering of some biomarkers; and recognition that the two major proteinopathies underlying AD biomarker changes, amyloid β (Aβ) and tau, might be initiated independently in sporadic AD, in which we hypothesise that an incident Aβ pathophysiol. can accelerate antecedent limbic and brainstem tauopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgH6Mv-cXkY7Vg90H21EOLACvtfcHk0lhiKv0mxA3qHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCht7o%253D&md5=0f7a94ec086d5287fef9f7a6995981df</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fs1474-4422%2812%2970291-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs1474-4422%252812%252970291-0%26sid%3Dliteratum%253Aachs%26aulast%3DJack%26aufirst%3DC.%2BR.%26aulast%3DKnopman%26aufirst%3DD.%2BS.%26aulast%3DJagust%26aufirst%3DW.%2BJ.%26aulast%3DPetersen%26aufirst%3DR.%2BC.%26aulast%3DWeiner%26aufirst%3DM.%2BW.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DShaw%26aufirst%3DL.%2BM.%26aulast%3DVemuri%26aufirst%3DP.%26aulast%3DWiste%26aufirst%3DH.%2BJ.%26aulast%3DWeigand%26aufirst%3DS.%2BD.%26aulast%3DLesnick%26aufirst%3DT.%2BG.%26aulast%3DPankratz%26aufirst%3DV.%2BS.%26aulast%3DDonohue%26aufirst%3DM.%2BC.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DTracking%2520pathophysiological%2520processes%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520an%2520updated%2520hypothetical%2520model%2520of%2520dynamic%2520biomarkers%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26spage%3D207%26epage%3D216%26doi%3D10.1016%2Fs1474-4422%2812%2970291-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerreiro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bras, J.</span></span> <span> </span><span class="NLM_article-title">The age factor in Alzheimer’s disease</span>. <i>Genome Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">106</span>, <span class="refDoi"> DOI: 10.1186/s13073-015-0232-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1186%2Fs13073-015-0232-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=26482651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SqtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=106&author=R.+Guerreiroauthor=J.+Bras&title=The+age+factor+in+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs13073-015-0232-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The age factor in Alzheimer's disease</span></div><div class="casAuthors">Guerreiro, Rita; Bras, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Genome Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106/1-106/3</span>CODEN:
                <span class="NLM_cas:coden">GMEECG</span>;
        ISSN:<span class="NLM_cas:issn">1756-994X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease is the most common type of dementia, and it is characterized by a decline in memory or other thinking skills.  The greatest risk factor for Alzheimer's disease is advanced age.  A recent genome-wide study identified a locus on chromosome 17 assocd. with the age at onset, and a specific variant in CCL11 is probably responsible for the assocn.  The assocn. of a protective haplotype with a 10-yr delay in the onset of Alzheimer's disease and the identification of a CCL11 variant with possible functional roles in this assocn. might allow the future development of immunomodulators with the potential to halve disease incidence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCXAQavyzR-7Vg90H21EOLACvtfcHk0lhiKv0mxA3qHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SqtLfP&md5=3e493d3eddbd5edbdb0aaafdc7157e1a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2Fs13073-015-0232-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13073-015-0232-5%26sid%3Dliteratum%253Aachs%26aulast%3DGuerreiro%26aufirst%3DR.%26aulast%3DBras%26aufirst%3DJ.%26atitle%3DThe%2520age%2520factor%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DGenome%2520Med.%26date%3D2015%26volume%3D7%26spage%3D106%26doi%3D10.1186%2Fs13073-015-0232-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigue, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devous, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieck, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebrank, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Arrastia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, D. C.</span></span> <span> </span><span class="NLM_article-title">β-Amyloid burden in healthy aging: Regional distribution and cognitive consequences</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1212/wnl.0b013e318245d295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1212%2Fwnl.0b013e318245d295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=22302550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVSlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2012&pages=387-395&author=K.+M.+Rodrigueauthor=K.+M.+Kennedyauthor=M.+D.+Devousauthor=J.+R.+Rieckauthor=A.+C.+Hebrankauthor=R.+Diaz-Arrastiaauthor=D.+Mathewsauthor=D.+C.+Park&title=%CE%B2-Amyloid+burden+in+healthy+aging%3A+Regional+distribution+and+cognitive+consequences&doi=10.1212%2Fwnl.0b013e318245d295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">β-Amyloid burden in healthy aging: Regional distribution and cognitive consequences</span></div><div class="casAuthors">Rodrigue, K. M.; Kennedy, K. M.; Devous, M. D., Sr.; Rieck, J. R.; Hebrank, A. C.; Diaz-Arrastia, R.; Mathews, D.; Park, D. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-395</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: Several lines of evidence suggest that pathol. changes underlying Alzheimer disease (AD) begin years prior to the clin. expression of the disease, underscoring the need for studies of cognitively healthy adults to capture these early changes.  The overall goal of the current study was to map the cortical distribution of β-amyloid (Aβ) in a healthy adult lifespan sample (aged 30-89), and to assess the relationship between elevated amyloid and cognitive performance across multiple domains.  Methods: A total of 137 well-screened and cognitively normal adults underwent Aβ PET imaging with radiotracer F-florbetapir.  Aβ load was estd. from 8 cortical regions.  Participants were genotyped for APOE and tested for processing speed, working memory, fluid reasoning, episodic memory, and verbal ability.  Results: Aβ deposition is distributed differentially across the cortex and progresses at varying rates with age across cortical brain regions.  A subset of cognitively normal adults aged 60 and over show markedly elevated deposition, and also had a higher rate of APOE ε4 (38%) than nonelevated adults (19%).  Aβ burden was linked to poorer cognitive performance on measures of processing speed, working memory, and reasoning.  Conclusions: Even in a highly selected lifespan sample of adults, Aβ deposition is apparent in some adults and is influenced by APOE status.  Greater amyloid burden was related to deleterious effects on cognition, suggesting that subtle cognitive changes accrue as amyloid progresses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYead0UGiYnrVg90H21EOLACvtfcHk0lhiKv0mxA3qHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVSlurc%253D&md5=aea6e7d3051dd39892fdb758d90940dc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1212%2Fwnl.0b013e318245d295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252Fwnl.0b013e318245d295%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigue%26aufirst%3DK.%2BM.%26aulast%3DKennedy%26aufirst%3DK.%2BM.%26aulast%3DDevous%26aufirst%3DM.%2BD.%26aulast%3DRieck%26aufirst%3DJ.%2BR.%26aulast%3DHebrank%26aufirst%3DA.%2BC.%26aulast%3DDiaz-Arrastia%26aufirst%3DR.%26aulast%3DMathews%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DD.%2BC.%26atitle%3D%25CE%25B2-Amyloid%2520burden%2520in%2520healthy%2520aging%253A%2520Regional%2520distribution%2520and%2520cognitive%2520consequences%26jtitle%3DNeurology%26date%3D2012%26volume%3D78%26spage%3D387%26epage%3D395%26doi%3D10.1212%2Fwnl.0b013e318245d295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wekstein, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markesbery, W. R.</span></span> <span> </span><span class="NLM_article-title">Alzheimer neuropathologic alterations in aged cognitively normal subjects</span>. <i>J. Neuropathol. Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1097/00005072-199904000-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1097%2F00005072-199904000-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10218633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADyaK1M3jtlSjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=376-388&author=D.+G.+Davisauthor=F.+A.+Schmittauthor=D.+R.+Weksteinauthor=W.+R.+Markesbery&title=Alzheimer+neuropathologic+alterations+in+aged+cognitively+normal+subjects&doi=10.1097%2F00005072-199904000-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer neuropathologic alterations in aged cognitively normal subjects</span></div><div class="casAuthors">Davis D G; Schmitt F A; Wekstein D R; Markesbery W R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuropathology and experimental neurology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">376-88</span>
        ISSN:<span class="NLM_cas:issn">0022-3069</span>.
    </div><div class="casAbstract">The histopathologic changes distinguishing early Alzheimer disease (AD) from normal or pathologic aging are not clearly defined.  This report describes the autopsy findings of 59 elderly, well-educated, volunteers.  They were examined longitudinally with mental status testing, some for up to 8 years, as part of our normal aging study.  This study reveals that (1) the brains of many subjects who did not show cognitive impairment on neuropsychologic testing contain abundant senile plaques (SP) and/or neurofibrillary tangles (NFT); (2) 29 subjects met Khachaturian criteria for AD, 15 met CERAD and 7 met National Institute on Aging-Reagan Institute guidelines; (3) Braak and Braak staging method included 9 in stage IV subjects, 4 in stage V, and 1 in stage VI; (4) there was a progression of NFT from entorhinal cortex to hippocampus and amygdala as a function of age; (5) 2 subjects met criteria for a diagnosis of dementia with Lewy bodies but were not demented; (6) cerebral amyloid angiopathy was present in leptomeningeal vessels in 75% of subjects and in parenchymal vessels in 62% of subjects; (7) only 10 of 59 subjects (17%) had no or few degenerative brain changes.  Our study demonstrates that the brains of a large percentage of cognitively normal, relatively well-educated individuals contain numerous degenerative changes and only a small percentage are relatively free of these changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRz4lU9mWZDjhgd2Wuil24tfW6udTcc2eboyxWaiOuy-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3jtlSjsw%253D%253D&md5=981d6bc8c95e9cd5abc753d55c8b2f98</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2F00005072-199904000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005072-199904000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DD.%2BG.%26aulast%3DSchmitt%26aufirst%3DF.%2BA.%26aulast%3DWekstein%26aufirst%3DD.%2BR.%26aulast%3DMarkesbery%26aufirst%3DW.%2BR.%26atitle%3DAlzheimer%2520neuropathologic%2520alterations%2520in%2520aged%2520cognitively%2520normal%2520subjects%26jtitle%3DJ.%2520Neuropathol.%2520Exp.%2520Neurol.%26date%3D1999%26volume%3D58%26spage%3D376%26epage%3D388%26doi%3D10.1097%2F00005072-199904000-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvanitakis, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. S.</span></span> <span> </span><span class="NLM_article-title">Neuropathology of older persons without cognitive impairment from two community-based studies</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1837</span>– <span class="NLM_lpage">1844</span>, <span class="refDoi"> DOI: 10.1212/01.wnl.0000219668.47116.e6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1212%2F01.wnl.0000219668.47116.e6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=16801647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BD28zosFKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1837-1844&author=D.+A.+Bennettauthor=J.+A.+Schneiderauthor=Z.+Arvanitakisauthor=J.+F.+Kellyauthor=N.+T.+Aggarwalauthor=R.+C.+Shahauthor=R.+S.+Wilson&title=Neuropathology+of+older+persons+without+cognitive+impairment+from+two+community-based+studies&doi=10.1212%2F01.wnl.0000219668.47116.e6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropathology of older persons without cognitive impairment from two community-based studies</span></div><div class="casAuthors">Bennett D A; Schneider J A; Arvanitakis Z; Kelly J F; Aggarwal N T; Shah R C; Wilson R S</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1837-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine the relation of National Institute on Aging-Reagan (NIA-Reagan) neuropathologic criteria of Alzheimer disease (AD) to level of cognitive function in persons without dementia or mild cognitive impairment (MCI).  METHODS:  More than 2,000 persons without dementia participating in the Religious Orders Study or the Memory and Aging Project agreed to annual detailed clinical evaluation and brain donation.  The studies had 19 neuropsychological performance tests in common that assessed five cognitive domains, including episodic memory, semantic memory, working memory, perceptual speed, and visuospatial ability.  A total of 134 persons without cognitive impairment died and underwent brain autopsy and postmortem assessment for AD pathology using NIA-Reagan neuropathologic criteria for AD, cerebral infarctions, and Lewy bodies.  Linear regression was used to examine the relation of AD pathology to level of cognitive function proximate to death.  RESULTS:  Two (1.5%) persons met NIA-Reagan criteria for high likelihood AD, and 48 (35.8%) met criteria for intermediate likelihood; 29 (21.6%) had cerebral infarctions, and 18 (13.4%) had Lewy bodies.  The mean Mini-Mental State Examination score proximate to death was 28.2 for those meeting high or intermediate likelihood AD by NIA-Reagan criteria and 28.4 for those not meeting criteria.  In linear regression models adjusted for age, sex, and education, persons meeting criteria for intermediate or high likelihood AD scored about a quarter standard unit lower on tests of episodic memory (p = 0.01).  There were no significant differences in any other cognitive domain.  CONCLUSIONS:  Alzheimer disease pathology can be found in the brains of older persons without dementia or mild cognitive impairment and is related to subtle changes in episodic memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZrU4dU_XG5BBrI9DTGjC0fW6udTcc2eboyxWaiOuy-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zosFKjsg%253D%253D&md5=1ddba59fa76644d9e75f4292f626bca3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1212%2F01.wnl.0000219668.47116.e6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252F01.wnl.0000219668.47116.e6%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DD.%2BA.%26aulast%3DSchneider%26aufirst%3DJ.%2BA.%26aulast%3DArvanitakis%26aufirst%3DZ.%26aulast%3DKelly%26aufirst%3DJ.%2BF.%26aulast%3DAggarwal%26aufirst%3DN.%2BT.%26aulast%3DShah%26aufirst%3DR.%2BC.%26aulast%3DWilson%26aufirst%3DR.%2BS.%26atitle%3DNeuropathology%2520of%2520older%2520persons%2520without%2520cognitive%2520impairment%2520from%2520two%2520community-based%2520studies%26jtitle%3DNeurology%26date%3D2006%26volume%3D66%26spage%3D1837%26epage%3D1844%26doi%3D10.1212%2F01.wnl.0000219668.47116.e6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eimerbrink, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chumley, M. J.</span></span> <span> </span><span class="NLM_article-title">Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1016%2Fj.neuroscience.2016.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=27320209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2016&pages=72-77&author=L.+E.+Gardnerauthor=J.+D.+Whiteauthor=M.+J.+Eimerbrinkauthor=G.+W.+Boehmauthor=M.+J.+Chumley&title=Imatinib+methanesulfonate+reduces+hyperphosphorylation+of+tau+following+repeated+peripheral+exposure+to+lipopolysaccharide&doi=10.1016%2Fj.neuroscience.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide</span></div><div class="casAuthors">Gardner, L. E.; White, J. D.; Eimerbrink, M. J.; Boehm, G. W.; Chumley, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-77</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For years, the prevailing hypothesis for Alzheimer's Disease (AD) has proposed a mechanism by which deposition of amyloid-beta (Aβ) in the brain is independent of tau-pathologies and cognitive decline.  However, despite extensive research on the disease, the mechanisms underlying the etiol. of tau-pathol. remain unknown.  Previous research in our lab has shown that imatinib methanesulfonate (IM) blocks the peripheral prodn. of Aβ in response to LPS, thereby preventing the buildup of Aβ in the hippocampus, and rescuing the cognitive dysfunction that normally follows.  The present study aimed to examine the link between Aβ and tau following inflammation, and to expand our understanding of how IM affects AD pathol.  Specifically, we hypothesized that the IM-mediated inhibition of Aβ prodn. following inflammation would successfully protect against the hyperphosphorylation of tau (ptau).  Here we show that 7 days of LPS treatment in male C57BL/6 J mice, which normally produces elevations in peripheral and central Aβ, also produces hyperphosphorylation of tau.  However, just as pre-treatment and concurrent treatment with IM blocks Aβ prodn., it also blocks the phosphorylation of tau.  In addn., 7 days of LPS-induced inflammation and Aβ prodn. also leads to elevated total tau protein expression.  Our results may provide support for the hypothesis that enhanced expression of tau following LPS administration is a protective measure by hippocampal neurons to compensate for the loss of the microtubule-stabilizing protein due to phosphorylation.  More importantly, our results support the hypothesis that blocking the prodn. of Aβ that follows inflammation also leads to reduced tau phosphorylation, lending credence to a model in which Aβ initiates tau phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnS2iTjJeonbVg90H21EOLACvtfcHk0lhbXD2lOHeGDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbvL&md5=b7f91c0d0a2d4aea1772969cfdd54503</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DGardner%26aufirst%3DL.%2BE.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DEimerbrink%26aufirst%3DM.%2BJ.%26aulast%3DBoehm%26aufirst%3DG.%2BW.%26aulast%3DChumley%26aufirst%3DM.%2BJ.%26atitle%3DImatinib%2520methanesulfonate%2520reduces%2520hyperphosphorylation%2520of%2520tau%2520following%2520repeated%2520peripheral%2520exposure%2520to%2520lipopolysaccharide%26jtitle%3DNeuroscience%26date%3D2016%26volume%3D331%26spage%3D72%26epage%3D77%26doi%3D10.1016%2Fj.neuroscience.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cancino, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yévenes, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inestrosa, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A. R.</span></span> <span> </span><span class="NLM_article-title">STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer’s β-amyloid deposits</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2425</span>– <span class="NLM_lpage">2442</span>, <span class="refDoi"> DOI: 10.1093/brain/awn125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1093%2Fbrain%2Fawn125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=18559370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BD1crksVWlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2008&pages=2425-2442&author=G.+I.+Cancinoauthor=E.+M.+Toledoauthor=N.+R.+Lealauthor=D.+E.+Hernandezauthor=L.+F.+Y%C3%A9venesauthor=N.+C.+Inestrosaauthor=A.+R.+Alvarez&title=STI571+prevents+apoptosis%2C+tau+phosphorylation+and+behavioural+impairments+induced+by+Alzheimer%E2%80%99s+%CE%B2-amyloid+deposits&doi=10.1093%2Fbrain%2Fawn125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits</span></div><div class="casAuthors">Cancino Gonzalo I; Toledo Enrique M; Leal Nancy R; Hernandez Diego E; Yevenes L Fernanda; Inestrosa Nibaldo C; Alvarez Alejandra R</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">Pt 9</span>),
    <span class="NLM_cas:pages">2425-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is evidence that amyloid beta-protein (Abeta) deposits or Abeta intermediates trigger pathogenic factors in Alzheimer's disease patients.  We have previously reported that c-Abl kinase activation involved in cell signalling regulates the neuronal death response to Abeta fibrils (Abeta(f)).  In the present study we investigated the therapeutic potential of the selective c-Abl inhibitor STI571 on both the intrahippocampal injection of Abeta(f) and APPsw/PSEN1DeltaE9 transgenic mice Alzheimer's disease models.  Injection of Abeta(f) induced an increase in the numbers of p73 and c-Abl immunoreactive cells in the hippocampal area near to the lesion.  Chronic intraperitoneal administration of STI571 reduced the rat behavioural deficit induced by Abeta(f), as well as apoptosis and tau phosphorylation.  Our in vitro studies suggest that inhibition of the c-Abl/p73 signalling pathway is the mechanism underlying of the effects of STI571 on Abeta-induced apoptosis for the following reasons: (i) Abeta(f) induces p73 phosphorylation, the TAp73 isoform levels increase so as to enhance its proapoptotic function, and all these effects where reduced by STI571; (ii) c-Abl kinase activity is required for neuronal apoptosis and (iii) STI571 prevents the Abeta-induced increase in the expression of apoptotic genes.  Furthermore, in the Abeta-injected area there was a huge increase in phosphorylated p73 and a larger number of TAp73-positive cells, with these changes being prevented by STI571 coinjection.  Moreover, the intraperitoneal administration of STI571 rescued the cognitive decline in APPsw/PSEN1DeltaE9 mice, p73 phosphorylation, tau phosphorylation and caspase-3 activation in neurons around Abeta deposits.  Besides, we observed a decrease in the number and size of Abeta deposits in the APPsw/PSEN1DeltaE9-STI571-treated mice.  These results are consistent with the role of the c-Abl/p73 signalling pathway in Abeta neurodegeneration, and suggest that STI571-like compounds would be effective in therapeutic treatments of Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuTiFgI2X54Hqj_yg7twvpfW6udTcc2eYQm_nTvUfYmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crksVWlsA%253D%253D&md5=1fbaf5b5383cddea70d39fd4fcf2796d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawn125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawn125%26sid%3Dliteratum%253Aachs%26aulast%3DCancino%26aufirst%3DG.%2BI.%26aulast%3DToledo%26aufirst%3DE.%2BM.%26aulast%3DLeal%26aufirst%3DN.%2BR.%26aulast%3DHernandez%26aufirst%3DD.%2BE.%26aulast%3DY%25C3%25A9venes%26aufirst%3DL.%2BF.%26aulast%3DInestrosa%26aufirst%3DN.%2BC.%26aulast%3DAlvarez%26aufirst%3DA.%2BR.%26atitle%3DSTI571%2520prevents%2520apoptosis%252C%2520tau%2520phosphorylation%2520and%2520behavioural%2520impairments%2520induced%2520by%2520Alzheimer%25E2%2580%2599s%2520%25CE%25B2-amyloid%2520deposits%26jtitle%3DBrain%26date%3D2008%26volume%3D131%26spage%3D2425%26epage%3D2442%26doi%3D10.1093%2Fbrain%2Fawn125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.1186/s13195-014-0089-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.1186%2Fs13195-014-0089-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=25621019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVCqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=89&author=R.+Vassar&title=BACE1+inhibitor+drugs+in+clinical+trials+for+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs13195-014-0089-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 inhibitor drugs in clinical trials for Alzheimer's disease</span></div><div class="casAuthors">Vassar, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">89/1-89/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for the prodn. of the neurotoxic β-amyloid (Aβ) peptide that is widely considered to have a crucial early role in the etiol. of Alzheimer's disease (AD).  As a result, BACE1 has emerged as a prime drug target for reducing the levels of Aβ in the AD brain, and the development of BACE1 inhibitors as therapeutic agents is being vigorously pursued.  It has proven difficult for the pharmaceutical industry to design BACE1 inhibitor drugs that pass the blood-brain barrier, however this challenge has recently been met and BACE1 inhibitors are now in human clin. trials to test for safety and efficacy in AD patients and individuals with pre-symptomatic AD.  Initial results suggest that some of these BACE1 inhibitor drugs are well tolerated, although others have dropped out because of toxicity and it is still too early to know whether any will be effective for the prevention or treatment of AD.  Addnl., based on newly identified BACE1 substrates and phenotypes of mice that lack BACE1, concerns have emerged about potential mechanism-based side effects of BACE1 inhibitor drugs with chronic administration.  It is hoped that a therapeutic window can be achieved that balances safety and efficacy.  This review summarizes the current state of progress in the development of BACE1 inhibitor drugs and the evaluation of their therapeutic potential for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-BPlLZzu7rVg90H21EOLACvtfcHk0lj3bBJG-f7Urg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVCqtL4%253D&md5=a9ec66c8f0254986406323efa56c6f5a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs13195-014-0089-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-014-0089-7%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DBACE1%2520inhibitor%2520drugs%2520in%2520clinical%2520trials%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D89%26doi%3D10.1186%2Fs13195-014-0089-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span> <span> </span><span class="NLM_article-title">Physiological functions of the beta-site amyloid precursor protein cleaving enzyme 1 and 2</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">97</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2017.00097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=10.3389%2Ffnmol.2017.00097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=28469554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=97&author=R.+Yan&title=Physiological+functions+of+the+beta-site+amyloid+precursor+protein+cleaving+enzyme+1+and+2&doi=10.3389%2Ffnmol.2017.00097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2</span></div><div class="casAuthors">Yan Riqiang</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in molecular neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97</span>
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    </div><div class="casAbstract">BACE1 was discovered as the β-secretase for initiating the cleavage of amyloid precursor protein (APP) at the β-secretase site, while its close homology BACE2 cleaves APP within the β-amyloid (Aβ) domain region and shows distinct cleavage preferences in vivo.  Inhibition of BACE1 proteolytic activity has been confirmed to decrease Aβ generation and amyloid deposition, and thus specific inhibition of BACE1 by small molecules is a current focus for Alzheimer's disease therapy.  While BACE1 inhibitors are being tested in advanced clinical trials, knowledge regarding the properties and physiological functions of BACE is highly important and this review summarizes advancements in BACE1 research over the past several years.  We and others have shown that BACE1 is not only a critical enzyme for testing the "Amyloid Hypothesis" associated with Alzheimer's pathogenesis, but also important for various functions such as axon growth and pathfinding, astrogenesis, neurogenesis, hyperexcitation, and synaptic plasticity.  BACE2 appears to play different roles such as glucose homeostasis and pigmentation.  This knowledge regarding BACE1 functions is critical for monitoring the safe use of BACE1 inhibitors in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbYoN5Bm7IDcScOqQTSkOffW6udTcc2eYQm_nTvUfYmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D&md5=b8e9ffa2007cebb2ae68c0074b7dea06</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2017.00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2017.00097%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26atitle%3DPhysiological%2520functions%2520of%2520the%2520beta-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520and%25202%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2017%26volume%3D10%26spage%3D97%26doi%3D10.3389%2Ffnmol.2017.00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jester, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, I.</span></span> <span> </span><span class="NLM_article-title">A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">11727</span>– <span class="NLM_lpage">11735</span>, <span class="refDoi"> DOI: 10.1021/ja104491h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja104491h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=11727-11735&author=B.+W.+Jesterauthor=K.+J.+Coxauthor=A.+Gajauthor=C.+D.+Shominauthor=J.+R.+Porterauthor=I.+Ghosh&title=A+coiled-coil+enabled+split-luciferase+three-hybrid+system%3A+applied+toward+profiling+inhibitors+of+protein+kinases&doi=10.1021%2Fja104491h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A Coiled-Coil Enabled Split-Luciferase Three-Hybrid System: Applied Toward Profiling Inhibitors of Protein Kinases</span></div><div class="casAuthors">Jester, Benjamin W.; Cox, Kurt J.; Gaj, Alicia; Shomin, Carolyn D.; Porter, Jason R.; Ghosh, Indraneel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">11727-11735</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 518 protein kinases encoded in the human genome are exquisitely regulated and their aberrant function(s) are often assocd. with human disease.  Thus, to advance therapeutics and to probe signal transduction cascades, there is considerable interest in the development of inhibitors that can selectively target protein kinases.  However, identifying specific compds. against such a large array of protein kinases is difficult to routinely achieve using traditional activity assays, where purified protein kinases are necessary.  Toward a simple, rapid, and practical method for identifying specific inhibitors, the authors describe the development and application of a split-protein methodol. using a coiled-coil-assisted three-hybrid system.  In this approach, a protein kinase of interest is attached to the C-terminal fragment of split-firefly luciferase and the coiled-coil Fos, which is specific for the coiled-coil Jun, is attached to the N-terminal fragment.  Upon addn. of Jun conjugated to a pan-kinase inhibitor such as staurosporine, a three-hybrid complex was established with concomitant reassembly of the split-luciferase enzyme.  An inhibitor can be potentially identified by the commensurate loss in split-luciferase activity by displacement of the modified staurosporine.  This new three-hybrid approach is potentially general by testing protein kinases from the different kinase families.  To interrogate whether this method allows for screening inhibitors, the authors tested six different protein kinases against a library of 80 known protein kinase inhibitors.  Finally, this three-hybrid system can potentially provide a rapid method for structure/function anal. as well as aid in the identification of allosteric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2HlzU6VW-HbVg90H21EOLACvtfcHk0lj3bBJG-f7Urg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtL0%253D&md5=b6b422ada61cbc678e0156eeb07ed9a9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fja104491h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja104491h%26sid%3Dliteratum%253Aachs%26aulast%3DJester%26aufirst%3DB.%2BW.%26aulast%3DCox%26aufirst%3DK.%2BJ.%26aulast%3DGaj%26aufirst%3DA.%26aulast%3DShomin%26aufirst%3DC.%2BD.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DGhosh%26aufirst%3DI.%26atitle%3DA%2520coiled-coil%2520enabled%2520split-luciferase%2520three-hybrid%2520system%253A%2520applied%2520toward%2520profiling%2520inhibitors%2520of%2520protein%2520kinases%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D11727%26epage%3D11735%26doi%3D10.1021%2Fja104491h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i35"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b02007">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_26067"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b02007">10.1021/acs.jmedchem.8b02007</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">General synthetic procedures and characterization of synthesized compounds including <sup>1</sup>H NMR spectra and MS data, truncated Gleevec analogues containing 3 or 4 rings, Gleevec analogues containing 4 or 5 rings and ABC rings identical to 1a and different from 1a, and figures showing screening data of all synthetic analogues and evaluation of selected compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES data for compounds <b>1a–l</b>, <b>2a–j</b>, <b>3a–i</b>, <b>4a–h</b>, <b>5</b>, <b>6a–g</b>, <b>7a–b</b>, <b>8a–q</b>, and <b>9a–u</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_001.pdf">jm8b02007_si_001.pdf (1.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02007/suppl_file/jm8b02007_si_002.csv">jm8b02007_si_002.csv (7.0 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b02007&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b02007%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-6%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b02007" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679906a2bc443d18","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
